BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 2018;362:eaar3593. [PMID: 30309915 DOI: 10.1126/science.aar3593] [Cited by in Crossref: 1035] [Cited by in F6Publishing: 1063] [Article Influence: 207.0] [Reference Citation Analysis]
Number Citing Articles
1 Su S, You S, Wang Y, Tamukong P, Quist MJ, Grasso CS, Kim HL. PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration. Cancer Lett 2023;555:216034. [PMID: 36509363 DOI: 10.1016/j.canlet.2022.216034] [Reference Citation Analysis]
2 Li Z, Zhang XJ, Sun CY, Fei H, Li ZF, Zhao DB. CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment. World J Clin Cases 2023; 11(4): 738-755 [DOI: 10.12998/wjcc.v11.i4.738] [Reference Citation Analysis]
3 Jensen S, Serrano-chávez E, Halldórsdóttir H, Engel T, Jørgensen J, Kostrikov S, Scheeper M, Ringgaard L, Bruun L, Stavnsbjerg C, Jæhger D, Christensen E, Bak M, Thuroczy J, Balogh L, Jensen A, Melander F, Kjaer A, Henriksen J, Hansen A, Andresen T. CarboCell combinatorial immunotherapy orchestrates curative anticancer immune activation of the tumor microenvironment.. [DOI: 10.21203/rs.3.rs-2511064/v1] [Reference Citation Analysis]
4 Ishino T, Kawashima S, Tanji E, Ueno T, Ueda Y, Ogasawara S, Sato K, Mano H, Ishihara S, Kato N, Kawazu M, Togashi Y. Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens. Br J Cancer 2023. [PMID: 36732592 DOI: 10.1038/s41416-023-02165-6] [Reference Citation Analysis]
5 Zhou Y, Chen Y, Shi Y, Wu L, Tan Y, Li T, Chen Y, Xia J, Hu R. FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1/NRF2 signaling pathway. J Clin Invest 2023;133:e158705. [PMID: 36719368 DOI: 10.1172/JCI158705] [Reference Citation Analysis]
6 Mortezaee K, Majidpoor J, Najafi S, Tasa D. Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies. Biomed Pharmacother 2023;158:114150. [PMID: 36577330 DOI: 10.1016/j.biopha.2022.114150] [Reference Citation Analysis]
7 Bao Y, Zhai J, Chen H, Wong CC, Liang C, Ding Y, Huang D, Gou H, Chen D, Pan Y, Kang W, To KF, Yu J. Targeting m(6)A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut 2023:gutjnl-2022-328845. [PMID: 36717220 DOI: 10.1136/gutjnl-2022-328845] [Reference Citation Analysis]
8 Zheng L, Xiong A, Wang S, Xu J, Shen Y, Zhong R, Lu J, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1094378] [Reference Citation Analysis]
9 Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, Wang XW. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2023. [PMID: 36697706 DOI: 10.1038/s41575-022-00741-4] [Reference Citation Analysis]
10 Mok TSK, Lopes G, Cho BC, Kowalski DM, Kasahara K, Wu YL, de Castro G Jr, Turna HZ, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza MC, Piperdi B, Herbst RS. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC. Ann Oncol 2023:S0923-7534(23)00049-2. [PMID: 36709038 DOI: 10.1016/j.annonc.2023.01.011] [Reference Citation Analysis]
11 Zhou JG, Liang R, Wang HT, Jin SH, Hu W, Frey B, Fietkau R, Hecht M, Ma H, Gaipl US. Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients - Knowledge from two independent international studies. Neoplasia 2023;37:100877. [PMID: 36696838 DOI: 10.1016/j.neo.2023.100877] [Reference Citation Analysis]
12 Zhang Q, Feng X, Zhang M, Sun W, Zhai Y, Qing S, Liu Y, Zhao H, Zhang Y, Ma Z, Sun J. Clinical Plasma Cells-related Genes to Aid Therapy in Colon Cancer.. [DOI: 10.21203/rs.3.rs-2483973/v1] [Reference Citation Analysis]
13 Paulino E, de Melo AC, de Andrade DAP, de Almeida MS. Systemic therapy for advanced cervical cancer: Leveraging the historical threshold of overall survival. Crit Rev Oncol Hematol 2023;183:103925. [PMID: 36696932 DOI: 10.1016/j.critrevonc.2023.103925] [Reference Citation Analysis]
14 Wu RY, Wang BC, Wang K, Xia F, Zhang ZY, Wan JF, Zhang Z. Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis. Front Oncol 2022;12:994276. [PMID: 36741738 DOI: 10.3389/fonc.2022.994276] [Reference Citation Analysis]
15 Li Q, Pan H, Gao Z, Li W, Zhang L, Zhao J, Fang L, Chu Y, Yuan W, Shi J. High-expression of the innate-immune related gene UNC93B1 predicts inferior outcomes in acute myeloid leukemia. Front Genet 2023;14:1063227. [PMID: 36741319 DOI: 10.3389/fgene.2023.1063227] [Reference Citation Analysis]
16 Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AM. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest 2023;133. [PMID: 36647828 DOI: 10.1172/JCI163447] [Reference Citation Analysis]
17 Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nat Rev Clin Oncol 2023. [PMID: 36639452 DOI: 10.1038/s41571-022-00718-x] [Reference Citation Analysis]
18 Imamura T, Ashida R, Ohshima K, Uesaka K, Sugiura T, Ohgi K, Yamada M, Otsuka S, Hatakeyama K, Nagashima T, Sugino T, Urakami K, Akiyama Y, Yamaguchi K. Characterization of Pancreatic Cancer with Ultra-low Tumor Mutational Burden.. [DOI: 10.21203/rs.3.rs-2449003/v1] [Reference Citation Analysis]
19 Mortezaee K, Majidpoor J. Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated. J Cell Mol Med 2023;27:311-21. [PMID: 36625080 DOI: 10.1111/jcmm.17666] [Reference Citation Analysis]
20 Zhang H, Chen S, Kong W, Luo D, Zhao X, Deng B, Xie Y, Pan Z, Qiu Y. Construction of a Cuproptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response in Cervical Cancer.. [DOI: 10.21203/rs.3.rs-2439058/v1] [Reference Citation Analysis]
21 Luo J, Chen C, Liu Z, Wang X. The mutation in splicing factor genes correlates with unfavorable prognosis, genomic instability, anti-tumor immunosuppression and increased immunotherapy response in pan-cancer. Front Cell Dev Biol 2022;10:1045130. [PMID: 36684432 DOI: 10.3389/fcell.2022.1045130] [Reference Citation Analysis]
22 Yu W, Miao Z, Ainiwaer J, Qiao B, Jumai K, Sheyhidin I. Integrative Identification of Angiogenesis-Related Genes for Predicting Immune Interaction and Prognosis in LUAD.. [DOI: 10.21203/rs.3.rs-2417491/v1] [Reference Citation Analysis]
23 Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, Liu LF, Li Y, Gupta V, Li C, Rishipathak D, Peng J, Şenbabaoǧlu Y, Modrusan Z, Keerthivasan S, Madireddi S, Chen YJ, Fraser EJ, Leng N, Hamidi H, Koeppen H, Ziai J, Hashimoto K, Fassò M, Williams P, McDermott DF, Rosenberg JE, Powles T, Emens LA, Hegde PS, Mellman I, Turley SJ, Wilson MS, Mariathasan S, Molinero L, Merchant M, West NR. CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med 2023;4:100878. [PMID: 36599350 DOI: 10.1016/j.xcrm.2022.100878] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Li H, Luo Q, Zhang H, Ma X, Gu Z, Gong Q, Luo K. Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. Chem Soc Rev 2023;52:47-96. [PMID: 36427082 DOI: 10.1039/d2cs00437b] [Reference Citation Analysis]
25 Posner A, Sivakumaran T, Pattison A, Etemadmoghadam D, Thio N, Wood C, Fisher K, Webb S, DeFazio A, Wilcken N, Gao B, Karapetis CS, Singh M, Collins IM, Richardson G, Steer C, Warren M, Karanth N, Fellowes A, Fox SB, Hicks RJ, Schofield P, Bowtell D, Prall OWJ, Tothill RW, Mileshkin L. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. J Immunother Cancer 2023;11:e005809. [PMID: 36720497 DOI: 10.1136/jitc-2022-005809] [Reference Citation Analysis]
26 Saw SPL, Ng WP, Zhou S, Lai GGY, Tan AC, Ang MK, Lim WT, Kanesvaran R, Ng QS, Jain A, Tan WL, Rajasekaran T, Chan JWK, Teh YL, Pang M, Yeo JC, Takano A, Ong BH, Tan EH, Tan SH, Skanderup AJ, Tan DSW. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer. Eur J Cancer 2023;178:139-49. [PMID: 36436331 DOI: 10.1016/j.ejca.2022.10.012] [Reference Citation Analysis]
27 Wei C, Wang M, Gao Q, Yuan S, Deng W, Bie L, Ma Y, Zhang C, Li S, Luo S, Li N. Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors. Cancer Immunol Immunother 2023;72:23-37. [PMID: 35661905 DOI: 10.1007/s00262-022-03221-5] [Reference Citation Analysis]
28 Wolf J, Lapp T, Reinhard T, Agostini H, Schlunck G, Lange C. Web-based gene expression analysis-paving the way to decode healthy and diseased ocular tissue. Ophthalmologie 2023;120:59-65. [PMID: 36098765 DOI: 10.1007/s00347-022-01721-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Feng J, Tang X, Song L, Zhou Z, Jiang Y, Huang Y. A telomerase regulation-related lncRNA signature predicts prognosis and immunotherapy response for gastric cancer. J Cancer Res Clin Oncol 2023;149:135-46. [PMID: 36333566 DOI: 10.1007/s00432-022-04456-6] [Reference Citation Analysis]
30 Kang SY, Heo YJ, Kwon GY, Lee J, Park SH, Kim KM. Five-gene signature for the prediction of response to immune checkpoint inhibitors in patients with gastric and urothelial carcinomas. Pathol Res Pract 2023;241:154233. [PMID: 36455365 DOI: 10.1016/j.prp.2022.154233] [Reference Citation Analysis]
31 Ángeles Vaz M, del Barco S, Luque R, Villamayor M, Manuel Sepúlveda Sánchez J, Vieito M. Systemic Treatment in Glioblastoma. Glioblastoma - Current Evidences [Working Title] 2022. [DOI: 10.5772/intechopen.109243] [Reference Citation Analysis]
32 Peleg Hasson S, Hershkovitz D, Adar L, Brezis M, Shachar E, Aks R, Galmor L, Raviv Y, Ben Neriah S, Merimsky O, Sabo E, Wolf I, Safra T. Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis. Cancers (Basel) 2022;15. [PMID: 36612212 DOI: 10.3390/cancers15010218] [Reference Citation Analysis]
33 Tilsed CM, Principe N, Kidman J, Chin WL, Orozco Morales ML, Zemek RM, Chee J, Islam R, Fear VS, Forbes C, Aston WJ, Jansen M, Chopra A, Lassmann T, Nowak AK, Fisher SA, Lake RA, Lesterhuis WJ. CD4(+) T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy. Cell Rep 2022;41:111874. [PMID: 36577370 DOI: 10.1016/j.celrep.2022.111874] [Reference Citation Analysis]
34 Qiu J, Li X, He Y, Wang Q, Li J, Wu J, Jiang Y, Han J. Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy. J Transl Med 2022;20:613. [PMID: 36564823 DOI: 10.1186/s12967-022-03836-3] [Reference Citation Analysis]
35 Song Z, Zou K, Zou L. Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data. Front Oncol 2022;12:1045481. [PMID: 36644634 DOI: 10.3389/fonc.2022.1045481] [Reference Citation Analysis]
36 Élez E, Mulet-Margalef N, Sanso M, Ruiz-Pace F, Mancuso FM, Comas R, Ros J, Argilés G, Martini G, Sanz-Garcia E, Baraibar I, Salvà F, Noguerido A, Cuadra-Urteaga JL, Fasani R, Garcia A, Jimenez J, Aguilar S, Landolfi S, Hernández-Losa J, Braña I, Nuciforo P, Dienstmann R, Tabernero J, Salazar R, Vivancos A. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy. Int J Mol Sci 2022;24. [PMID: 36613564 DOI: 10.3390/ijms24010118] [Reference Citation Analysis]
37 Wengang Zhang, Xiaoling Shang, Ni Liu, Xinchun Ma, Rui Yang, Handai Xia, Yuqing Zhang, Qi Zheng, Xiuwen Wang, Yanguo Liu. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. BMC Pulm Med 2022;22:483. [PMID: 36539782 DOI: 10.1186/s12890-022-02279-2] [Reference Citation Analysis]
38 Seyhan AA, Carini C. Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. Int J Mol Sci 2022;24. [PMID: 36613491 DOI: 10.3390/ijms24010041] [Reference Citation Analysis]
39 Lin X, Chen X, Long X, Zeng C, Zhang Z, Fang W, Xu P. New Biomarkers Exploration and Nomogram Construction of Prognostic and Immune-Related Adverse Events of Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.. [DOI: 10.21203/rs.3.rs-2378554/v1] [Reference Citation Analysis]
40 Ioannis A. Vathiotis, Leonidas Salichos, Sandra Martinez-Morilla, Niki Gavrielatou, Thazin Nwe Aung, Saba Shafi, Pok Fai Wong, Shlomit Jessel, Harriet M. Kluger, Konstantinos N. Syrigos, Sarah Warren, Mark Gerstein, David L. Rimm. Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade. NPJ Precis Oncol 2022;6:92. [PMID: 36522538 DOI: 10.1038/s41698-022-00330-3] [Reference Citation Analysis]
41 Liu Q, Yang X, Yin Y, Zhang H, Yin F, Guo P, Zhang X, Sun C, Li S, Han Y, Yang Z. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer. Oxid Med Cell Longev 2022;2022:6575534. [PMID: 36561981 DOI: 10.1155/2022/6575534] [Reference Citation Analysis]
42 Tarantino G, Ricker CA, Wang A, Ge W, Aprati TJ, Huang AY, Madha S, Chen J, Shi Y, Glettig M, Frederick DT, Freeman S, Holovatska MM, Manos MP, Zimmer L, Rösch A, Zaremba A, Reardon B, Park J, Elmarakeby HA, Schilling B, Giobbie-hurder A, Vokes NI, Buchbinder EI, Flaherty KT, Haq R, Wu CJ, Boland GM, Hodi FS, Van Allen EM, Schadendorf D, Liu D. Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.. [DOI: 10.1101/2022.12.11.519808] [Reference Citation Analysis]
43 Huang J, Xu Z, Yuan Z, Teh BM, Zhou C, Shen Y. Identification of a cuproptosis-related lncRNA signature to predict the prognosis and immune landscape of head and neck squamous cell carcinoma. Front Oncol 2022;12:983956. [PMID: 36568234 DOI: 10.3389/fonc.2022.983956] [Reference Citation Analysis]
44 Mason M, Lapuente-santana Ó, Halkola AS, Wang W, Mall R, Xiao X, Kaufman J, Fu J, Pfeil J, Banerjee J, Chung V, Chang H, Chasalow SD, Lin HY, Chai R, Yu T, Finotello F, Mirtti T, Mäyränpää MI, Bao J, Verschuren EW, Ahmed EI, Ceccarelli M, Miller LD, Monaco G, Hendrickx WR, Sherif S, Yang L, Tang M, Gu SS, Zhang W, Zhang Y, Zeng Z, Sahu AD, Liu Y, Yang W, Bedognetti D, Tang J, Eduati F, Laajala TD, Geese WJ, Guinney J, Szustakowski JD, Carbone DP, Vincent BG. A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.. [DOI: 10.1101/2022.12.05.518667] [Reference Citation Analysis]
45 Pfister DG, Haddad RI, Worden FP, Weiss J, Mehra R, Chow LQM, Liu SV, Kang H, Saba NF, Wirth LJ, Sukari A, Massarelli E, Ayers M, Albright A, Webber AL, Mogg R, Lunceford J, Huang L, Cristescu R, Cheng J, Seiwert TY, Bauml JM. Biomarkers predictive of response to pembrolizumab in head and neck cancer. Cancer Medicine 2022. [DOI: 10.1002/cam4.5434] [Reference Citation Analysis]
46 Qiao DR, Shan GY, Wang S, Cheng JY, Yan WQ, Li HJ. The mononuclear phagocyte system in hepatocellular carcinoma. World J Gastroenterol 2022; 28(45): 6345-6355 [DOI: 10.3748/wjg.v28.i45.6345] [Reference Citation Analysis]
47 Thol K, Pawlik P, McGranahan N. Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. Genome Med 2022;14:137. [PMID: 36476325 DOI: 10.1186/s13073-022-01138-3] [Reference Citation Analysis]
48 Meliante PG, Barbato C, Zoccali F, Ralli M, Greco A, de Vincentiis M, Colizza A, Petrella C, Ferraguti G, Minni A, Fiore M. Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies. Int J Mol Sci 2022;23. [PMID: 36499710 DOI: 10.3390/ijms232315384] [Reference Citation Analysis]
49 Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O'Donnell PH. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol 2022:S0923-7534(22)04760-3. [PMID: 36494006 DOI: 10.1016/j.annonc.2022.11.012] [Reference Citation Analysis]
50 Chen J, Wang R, Liu Z, Fan J, Liu S, Tan S, Li X, Li B, Yang X. Unbalanced Glutamine Partitioning between CD8T Cells and Cancer Cells Accompanied by Immune Cell Dysfunction in Hepatocellular Carcinoma. Cells 2022;11. [PMID: 36497182 DOI: 10.3390/cells11233924] [Reference Citation Analysis]
51 Tan TG, Zybina Y, Mckenna C, Olow A, Rukmini SJ, Wong MT, Sadekova S, Chackerian A, Bauché D. SPATA2 and CYLD inhibit T cell infiltration into colorectal cancer via regulation of IFN-γ/STAT1 axis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1016307] [Reference Citation Analysis]
52 Sun N, Luo Y, Zheng B, Zhang Z, Zhang C, Zhang Z, Zhang G, Tan F, Xue Q, Gao S, He J. A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03520-6] [Reference Citation Analysis]
53 Sherif S, Roelands J, Mifsud W, Ahmed EI, Raynaud CM, Rinchai D, Sathappan A, Maaz A, Saleh A, Ozer E, Fakhro KA, Mifsud B, Thorsson V, Bedognetti D, Hendrickx WRL. The immune landscape of solid pediatric tumors. J Exp Clin Cancer Res 2022;41:199. [DOI: 10.1186/s13046-022-02397-z] [Reference Citation Analysis]
54 He R, Yuan X, Chen Z, Zheng Y. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. International Immunopharmacology 2022;113:109444. [DOI: 10.1016/j.intimp.2022.109444] [Reference Citation Analysis]
55 Kagawa H, Hatakeyama K, Shiomi A, Hino H, Manabe S, Yamaoka Y, Nagashima T, Ohshima K, Urakami K, Yamaguchi K. Consensus molecular subtyping improves the clinical usefulness of canonical tumor markers for colorectal cancer. Biomed Res 2022;43:201-9. [PMID: 36517022 DOI: 10.2220/biomedres.43.201] [Reference Citation Analysis]
56 Pan J, Gu X, Luo J, Qian X, Gao Q, Li T, Ye L, Li C. Characteristics of Adenosine-to-Inosine RNA editing-based subtypes and novel risk score for the prognosis and drug sensitivity in stomach adenocarcinoma. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.1073688] [Reference Citation Analysis]
57 Saw SP, Ang MK, Tan DS. Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions. Curr Treat Options Oncol 2022;23:1721-31. [PMID: 36451063 DOI: 10.1007/s11864-022-01034-3] [Reference Citation Analysis]
58 Ho J, Fiocco C, Spencer K. Treating Biliary Tract Cancers: New Targets and Therapies. Drugs 2022. [DOI: 10.1007/s40265-022-01808-x] [Reference Citation Analysis]
59 Wen S, Zeng H, An K, Wu S, Huang X, Shao Z, Bai J, Yin T. PRKCB is a novel and potential biomarker in colon cancer and shapes an inflamed tumor immune microenvironment.. [DOI: 10.21203/rs.3.rs-2296058/v1] [Reference Citation Analysis]
60 Kawashima S, Togashi Y. Resistance to immune checkpoint inhibitors and the tumor microenvironment. Exp Dermatol 2022. [PMID: 36437644 DOI: 10.1111/exd.14716] [Reference Citation Analysis]
61 Zhang Y, Yang Y, Chen Y, Lin W, Chen X, Liu J, Huang Y, Wang H, Teng L. PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer. Front Immunol 2022;13:1060497. [PMID: 36505487 DOI: 10.3389/fimmu.2022.1060497] [Reference Citation Analysis]
62 Berner M, Hartmann A, Erber R. Role of Surgical Pathologist for Detection of Predictive Immuno-oncological Factors in Breast Cancer. Advances in Anatomic Pathology 2022;Publish Ahead of Print. [DOI: 10.1097/pap.0000000000000382] [Reference Citation Analysis]
63 Gabryś HS, Basler L, Burgermeister S, Hogan S, Ahmadsei M, Pavic M, Bogowicz M, Vuong D, Tanadini-Lang S, Förster R, Kudura K, Huellner M, Dummer R, Levesque MP, Guckenberger M. PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors. Front Oncol 2022;12:977822. [PMID: 36505821 DOI: 10.3389/fonc.2022.977822] [Reference Citation Analysis]
64 Liu T, Cai L, Hua H, Jiang X, Xu X, Zhang T, Huang W, Qian L, Bai H, Duan J. Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/9772208] [Reference Citation Analysis]
65 Li K, Cao L, Li C, Wu J, Chen B, Zhang G, Li X, Wen L, Jia M, Wei G, Lin J, Li Y, Zhang Y, Mok H, Ren C, Wang Y, Qi X, Guo L, Che Y, Liao N. Genomic alteration profile and PD‐L1 expression among different breast cancer subtypes in Chinese population and their correlations. Cancer Medicine 2022. [DOI: 10.1002/cam4.5314] [Reference Citation Analysis]
66 Yang Y, Wang F. Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.983892] [Reference Citation Analysis]
67 Kurose K, Sakaeda K, Fukuda M, Sakai Y, Yamaguchi H, Takemoto S, Shimizu K, Masuda T, Nakatomi K, Kawase S, Tanaka R, Suetsugu T, Mizuno K, Hasegawa T, Atarashi Y, Irino Y, Sato T, Inoue H, Hattori N, Kanda E, Nakata M, Mukae H, Oga T, Oka M. Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. Adv Clin Chem 2023;112:155-204. [PMID: 36642483 DOI: 10.1016/bs.acc.2022.09.004] [Reference Citation Analysis]
68 Lopes-Brás R, Lopez-Presa D, Esperança-Martins M, Melo-Alvim C, Gallego L, Costa L, Fernandes I. Genomic Profiling of Sarcomas: A Promising Weapon in the Therapeutic Arsenal. Int J Mol Sci 2022;23. [PMID: 36430703 DOI: 10.3390/ijms232214227] [Reference Citation Analysis]
69 Kibriya MG, Raza M, Quinn A, Kamal M, Ahsan H, Jasmine F. A Transcriptome and Methylome Study Comparing Tissues of Early and Late Onset Colorectal Carcinoma. Int J Mol Sci 2022;23. [PMID: 36430738 DOI: 10.3390/ijms232214261] [Reference Citation Analysis]
70 Tan S, Yu J, Huang Q, Zhou N, Gou H. PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1006075] [Reference Citation Analysis]
71 Gan T, Wang Y, Xie M, Wang Q, Zhao S, Wang P, Shi Q, Qian X, Miao F, Shen Z, Nie E. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma. Cancer Res 2022;82:4234-46. [PMID: 36112059 DOI: 10.1158/0008-5472.CAN-22-2036] [Reference Citation Analysis]
72 Qiangwei Wang, Weiwei Lin, Tianjian Liu, Jue Hu, Yongjian Zhu. Immunological classification of glioblastoma and its prognostic implications. Am J Transl Res 2022;14. [PMID: 36505340] [Reference Citation Analysis]
73 Xu X, Zhang L, Qian Y, Fang Q, Xiao Y, Chen G, Cai G, Abula A, Wang Z, Zhai E, Chen J, Cai S, Wu H. A SERPINE1-Based Immune Gene Signature Predicts Prognosis and Immunotherapy Response in Gastric Cancer. Pharmaceuticals 2022;15:1401. [DOI: 10.3390/ph15111401] [Reference Citation Analysis]
74 Choi J, Kim JS, Sung HJ, Chen YW, Chen Z, Wen W, Shu XO, Guo X. Polygenic Risk Scores Associated with Tumor Immune Infiltration in Common Cancers. Cancers (Basel) 2022;14. [PMID: 36428664 DOI: 10.3390/cancers14225571] [Reference Citation Analysis]
75 Wang Q, Zhao Y, Wang F, Tan G. A novel immune signature predicts immunotherapy responsiveness and reveals the landscape of the tumor immune microenvironment in head and neck squamous cell carcinoma. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.1051051] [Reference Citation Analysis]
76 Zhou X, Zou B, Wang J, Wu L, Tan Q, Ji C. Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.946848] [Reference Citation Analysis]
77 Esposito Abate R, Cheetham MH, Fairley JA, Pasquale R, Sacco A, Nicola W, Deans ZC, Patton SJ, Normanno N. External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme. Virchows Arch 2022. [DOI: 10.1007/s00428-022-03444-y] [Reference Citation Analysis]
78 Wang J, Qiu Q, Zheng Q, Zhao Y, Xu Y, Zhang T, Wang S, Wang Q, Jin Q, Ye Y, Li P, Xie J, Lin J, Lu J, Chen Q, Cao L, Yang Y, Zheng C, Huang C. Tumor immunophenotyping-derived signature identifies prognosis and neoadjuvant immunotherapeutic responsiveness in gastric cancer.. [DOI: 10.21203/rs.3.rs-2248043/v1] [Reference Citation Analysis]
79 Anagnostou V, Landon BV, Medina JE, Forde P, Velculescu VE. Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Sci Transl Med 2022;14:eabo3958. [PMID: 36350985 DOI: 10.1126/scitranslmed.abo3958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Yin H, Harrison TA, Thomas SS, Sather CL, Koehne AL, Malen RC, Reedy AM, Wurscher MA, Hsu L, Phipps AI, Zaidi SHE, Newcomb PA, Peters U, Huyghe JR. T cell-inflamed gene expression profile is associated with favorable disease-specific survival in non-hypermutated microsatellite-stable colorectal cancer patients. Cancer Med 2022. [PMID: 36341526 DOI: 10.1002/cam4.5429] [Reference Citation Analysis]
81 Li Z, Pu Z, Yang Z, Zhu Y, Deng Y, Li N, Peng F. Pan-cancer analysis of trophinin-associated protein with potential implications in clinical significance, prognosis, and tumor microenvironment in human cancers. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.971618] [Reference Citation Analysis]
82 Peng J, Zhang J, Zou D, Xiao L, Ma H, Zhang X, Li Y, Han L, Xie B. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.960459] [Reference Citation Analysis]
83 Wu F, Jiang T, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J, Bai X, Ren S, Zhou C; CameL Study Group. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy. Cancer Commun (Lond) 2022;42:1331-46. [PMID: 36331328 DOI: 10.1002/cac2.12383] [Reference Citation Analysis]
84 Liou L, Hornburg M, Robertson DS. Global FDR control across multiple RNAseq experiments. Bioinformatics 2023;39. [PMID: 36326442 DOI: 10.1093/bioinformatics/btac718] [Reference Citation Analysis]
85 Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, Hu Q, Liang K, Zhang Z, Ye Y, Huang LA, Nguyen TK, Egranov SD, Zhao Z, Wu A, Xi Y, Yao J, Hung MC, Calin GA, Cheng J, Lim B, Lehmann LH, Salem JE, Johnson DB, Curran MA, Yu D, Han L, Darabi R, Yang L, Moslehi JJ, Lin C. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med 2022;14:eabo1981. [PMID: 36322628 DOI: 10.1126/scitranslmed.abo1981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Kunimasa K, Sugimoto N, Kawamura T, Yamasaki T, Honma K, Nagata S, Kukita Y, Fujisawa F, Inoue T, Yamaguchi Y, Kitasaka M, Wakamatsu T, Yamai T, Yamamoto S, Hayashi T, Inoue T, Tamiya M, Imamura F, Nishimura K, Nishino K. Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single-center retrospective study. Thorac Cancer 2022;13:2970-7. [PMID: 36100256 DOI: 10.1111/1759-7714.14643] [Reference Citation Analysis]
87 Deng J, Yang J, Hou L, Wu J, He Y, Zhao M, Ni B, Wei D, Pfister H, Zhou C, Jiang T, She Y, Wu C, Chen C. Genopathomic profiling identifies signatures for immunotherapy response of lung adenocarcinoma via confounder-aware representation learning. iScience 2022;25:105382. [DOI: 10.1016/j.isci.2022.105382] [Reference Citation Analysis]
88 Fathi M, Razavi SM, Sojoodi M, Ahmadi A, Ebrahimi F, Namdar A, Hojjat-Farsangi M, Gholamin S, Jadidi-Niaragh F. Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions. Expert Opin Ther Targets 2022;26:949-61. [PMID: 36527817 DOI: 10.1080/14728222.2022.2160703] [Reference Citation Analysis]
89 Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-gabry EA, Elvin J, Gajewski TF, Mcshane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precision Oncology 2022. [DOI: 10.1200/po.22.00454] [Reference Citation Analysis]
90 Chi H, Peng G, Wang R, Yang F, Xie X, Zhang J, Xu K, Gu T, Yang X, Tian G. Cuprotosis Programmed-Cell-Death-Related lncRNA Signature Predicts Prognosis and Immune Landscape in PAAD Patients. Cells 2022;11:3436. [DOI: 10.3390/cells11213436] [Reference Citation Analysis]
91 Escors D, Bocanegra A, Chocarro L, Blanco E, Piñeiro-hermida S, Garnica M, Fernandez-rubio L, Vera R, Arasanz H, Kochan G. Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. IJMS 2022;23:13241. [DOI: 10.3390/ijms232113241] [Reference Citation Analysis]
92 Fujita M, Chen MM, Siwak DR, Sasagawa S, Oosawa-Tatsuguchi A, Arihiro K, Ono A, Miura R, Maejima K, Aikata H, Ueno M, Hayami S, Yamaue H, Chayama K, Lee JS, Lu Y, Mills GB, Liang H, Nishizuka SS, Nakagawa H. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. Nat Commun 2022;13:6481. [PMID: 36309506 DOI: 10.1038/s41467-022-34249-x] [Reference Citation Analysis]
93 Georgoulias G, Zaravinos A. Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1006665] [Reference Citation Analysis]
94 Lu T, Park S, Han Y, Wang Y, Hubert SM, Futreal PA, Wistuba I, Heymach JV, Reuben A, Zhang J, Wang T. Netie: inferring the evolution of neoantigen–T cell interactions in tumors. Nat Methods 2022. [DOI: 10.1038/s41592-022-01644-7] [Reference Citation Analysis]
95 Elshora H, El-hadidi M. Supervised ML for Identifiying Biomarkers Driving the Response to ICBs in Melanoma patients. 2022 4th Novel Intelligent and Leading Emerging Sciences Conference (NILES) 2022. [DOI: 10.1109/niles56402.2022.9942398] [Reference Citation Analysis]
96 Sharma P, Anandhan S, Siddiqui BA, Goswami S, Subudhi SK, Gao J, Peggs K, Quezada S, Allison JP. Cancer Immunotherapy. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm068.pub2] [Reference Citation Analysis]
97 Moss DY, McCann C, Kerr EM. Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers. Sci Signal 2022;15:eabj3490. [PMID: 36256706 DOI: 10.1126/scisignal.abj3490] [Reference Citation Analysis]
98 Davar D, Zarour HM. Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. Clin Cancer Res 2022;28:4370-84. [PMID: 35748749 DOI: 10.1158/1078-0432.CCR-21-1129] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Mabrouk N, Tran T, Sam I, Pourmir I, Gruel N, Granier C, Pineau J, Gey A, Kobold S, Fabre E, Tartour E. CXCR6 expressing T cells: Functions and role in the control of tumors. Front Immunol 2022;13:1022136. [DOI: 10.3389/fimmu.2022.1022136] [Reference Citation Analysis]
100 Zhou Y, Xu S, Sun Q, Dong Y, Belluzzi E. An Analysis of BMP1 Associated with m6A Modification and Immune Infiltration in Pancancer. Disease Markers 2022;2022:1-28. [DOI: 10.1155/2022/7899961] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Murayama M, Hosonuma M, Kuramasu A, Yoshimura K. Current Status of Immune Checkpoint Inhibitors in the Broncho-Esophagological Field. The Journal of the Japan Broncho-esophagological Society 2022;73:308-317. [DOI: 10.2468/jbes.73.308] [Reference Citation Analysis]
102 Lai G, Zhong X, Liu H, Deng J, Li K, Xie B. Development of a Hallmark Pathway-Related Gene Signature Associated with Immune Response for Lower Grade Gliomas. Int J Mol Sci 2022;23:11971. [PMID: 36233273 DOI: 10.3390/ijms231911971] [Reference Citation Analysis]
103 Galizia D, Minei S, Maldi E, Chilà G, Polidori A, Merlano MC. How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy. Biomedicines 2022;10:2498. [PMID: 36289760 DOI: 10.3390/biomedicines10102498] [Reference Citation Analysis]
104 Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Gavilá J, López-González A, Cejalvo JM, Izarzugaza Y, Amillano K, Corbacho JG, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesía R, Cervantes A, Tabernero J. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future Oncol 2022. [PMID: 36200668 DOI: 10.2217/fon-2022-0660] [Reference Citation Analysis]
105 Indini A, Lombardo M, Sidoni A, Gianatti A, Mandalà M, Massi D. Pathology of Immunotherapy-induced Responses in Cutaneous Melanoma: Current Evidences and Future Perspectives. Advances in Anatomic Pathology 2022;Publish Ahead of Print. [DOI: 10.1097/pap.0000000000000375] [Reference Citation Analysis]
106 Cao T, Dong J, Huang J, Tang Z, Shen H. Identification of fatty acid signature to predict prognosis and guide clinical therapy in patients with ovarian cancer. Front Oncol 2022;12:979565. [DOI: 10.3389/fonc.2022.979565] [Reference Citation Analysis]
107 Xiaoyan Li, Di Lu, Zhibo Zhang, Yuning Zhang, Jinliang Wang, Yi Hu. Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study. J Thorac Dis 2022;14. [PMID: 36389301 DOI: 10.21037/jtd-22-1363] [Reference Citation Analysis]
108 Coutzac C, Funk-debleds P, Cattey-javouhey A, Desseigne F, Guibert P, Marolleau P, Rochefort P, de la Fouchardière C. Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new? Bulletin du Cancer 2022. [DOI: 10.1016/j.bulcan.2022.08.013] [Reference Citation Analysis]
109 Taverna C, Franchi A. Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors in Head and Neck Cancer. Adv Anat Pathol 2022. [PMID: 36175939 DOI: 10.1097/PAP.0000000000000374] [Reference Citation Analysis]
110 Wu G, Chen B, Jiang J, Chen Y, Chen Y, Wang H. Identification of a pyroptosis-based model for predicting clinical outcomes from immunotherapy in patients with metastatic melanoma. Cancer Med 2022. [PMID: 36151761 DOI: 10.1002/cam4.5178] [Reference Citation Analysis]
111 Wei F, Guo R, Yan Y, Lin R, Chen J, Lin Z. Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study. Front Immunol 2022;13:990224. [DOI: 10.3389/fimmu.2022.990224] [Reference Citation Analysis]
112 Jaén M, Martín-Regalado Á, Bartolomé RA, Robles J, Casal JI. Interleukin 13 receptor alpha 2 (IL13Rα2): Expression, signaling pathways and therapeutic applications in cancer. Biochim Biophys Acta Rev Cancer 2022;1877:188802. [PMID: 36152905 DOI: 10.1016/j.bbcan.2022.188802] [Reference Citation Analysis]
113 Song G, Luo J, Zou S, Lou F, Zhang T, Zhu X, Yang J, Wang X. Molecular classification of human papillomavirus-positive cervical cancers based on immune signature enrichment. Front Public Health 2022;10:979933. [PMID: 36203656 DOI: 10.3389/fpubh.2022.979933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Huang L, Zhang J, Gong F, Han Y, Huang X, Luo W, Cai H, Zhang F. Identification and validation of ferroptosis-related lncRNA signatures as a novel prognostic model for glioma. Front Genet 2022;13:927142. [DOI: 10.3389/fgene.2022.927142] [Reference Citation Analysis]
115 Chera A, Stancu AL, Bucur O. Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol 2022;13:1010279. [DOI: 10.3389/fendo.2022.1010279] [Reference Citation Analysis]
116 Mayoh C, Gifford AJ, Terry R, Lau LM, Wong M, Rao P, Shai-hee T, Saletta F, Khuong-quang D, Qin V, Mateos M, Meyran D, Miller KE, Yuksel A, Mould EV, Bowen-james R, Govender D, Senapati A, Zhukova N, Omer N, Dholaria H, Alvaro F, Tapp H, Diamond Y, Pozza LD, Moore AS, Nicholls W, Gottardo NG, Mccowage G, Hansford JR, Khaw S, Wood PJ, Catchpoole D, Cottrell CE, Mardis ER, Marshall GM, Tyrrell V, Haber M, Ziegler DS, Vittorio O, Trapani JA, Cowley MJ, Neeson PJ, Ekert PG. A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer.. [DOI: 10.1101/2022.09.16.508179] [Reference Citation Analysis]
117 Jiang Y, Huang S, Zhu X, Cheng L, Liu W, Chen Q, Yang D, Du X. Artificial Intelligence Meets Whole Slide Images: Deep Learning Model Shapes an Immune-Hot Tumor and Guides Precision Therapy in Bladder Cancer. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/8213321] [Reference Citation Analysis]
118 Wang Y, Lai X, Wang J, Xu Y, Zhang X, Zhu X, Liu Y, Shao Y, Zhang L, Fang W. TMBcat: A multi-endpoint p-value criterion on different discrepancy metrics for superiorly inferring tumor mutation burden thresholds. Front Immunol 2022;13:995180. [DOI: 10.3389/fimmu.2022.995180] [Reference Citation Analysis]
119 Jiang S, Geng S, Luo X, Zhang C, Yu Y, Cheng M, Zhang S, Shi N, Dong M. Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors. Front Immunol 2022;13:995785. [DOI: 10.3389/fimmu.2022.995785] [Reference Citation Analysis]
120 Zhao Z, Yang Y, Liu Z, Chen H, Guan X, Jiang Z, Yang M, Liu H, Chen T, Gao Y, Zou S, Wang X. Prognostic and immunotherapeutic significance of mannose receptor C type II in 33 cancers: An integrated analysis. Front Mol Biosci 2022;9:951636. [DOI: 10.3389/fmolb.2022.951636] [Reference Citation Analysis]
121 Quigley M, Meyer MJ, Katlinski K. Modeling Resistance to Immune Checkpoint Blockade. Animal Models for the Development of Cancer Immunotherapy 2022. [DOI: 10.1002/9781119535331.ch4] [Reference Citation Analysis]
122 Wang J, Gu X, Cao L, Ouyang Y, Qi X, Wang Z, Wang J. A novel prognostic biomarker CD3G that correlates with the tumor microenvironment in cervical cancer. Front Oncol 2022;12:979226. [DOI: 10.3389/fonc.2022.979226] [Reference Citation Analysis]
123 Salomé B, Sfakianos JP, Ranti D, Daza J, Bieber C, Charap A, Hammer C, Banchereau R, Farkas AM, Ruan DF, Izadmehr S, Geanon D, Kelly G, de Real RM, Lee B, Beaumont KG, Shroff S, Wang YA, Wang YC, Thin TH, Garcia-Barros M, Hegewisch-Solloa E, Mace EM, Wang L, O'Donnell T, Chowell D, Fernandez-Rodriguez R, Skobe M, Taylor N, Kim-Schulze S, Sebra RP, Palmer D, Clancy-Thompson E, Hammond S, Kamphorst AO, Malmberg KJ, Marcenaro E, Romero P, Brody R, Viard M, Yuki Y, Martin M, Carrington M, Mehrazin R, Wiklund P, Mellman I, Mariathasan S, Zhu J, Galsky MD, Bhardwaj N, Horowitz A. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell 2022;40:1027-1043.e9. [PMID: 36099881 DOI: 10.1016/j.ccell.2022.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Snyder A, McGranahan N. The importance of ancestry to understanding tumor mutation burden in cancer. Cancer Cell 2022:S1535-6108(22)00433-0. [PMID: 36179683 DOI: 10.1016/j.ccell.2022.09.004] [Reference Citation Analysis]
125 Español-rego M, Fernández-martos C, Elez E, Foguet C, Pedrosa L, Rodríguez N, Ruiz-casado A, Pineda E, Cid J, Cabezón R, Oliveres H, Lozano M, Ginés A, García-criado A, Ayuso JR, Pagés M, Cuatrecasas M, Torres F, Thomson T, Cascante M, Benítez-ribas D, Maurel J. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03283-5] [Reference Citation Analysis]
126 Pan S, Li S, Zhan Y, Chen X, Sun M, Liu X, Wu B, Li Z, Liu B. Immune status for monitoring and treatment of bladder cancer. Front Immunol 2022;13:963877. [DOI: 10.3389/fimmu.2022.963877] [Reference Citation Analysis]
127 Zheng J, Xie Z, Niu L, Zheng G, Li R, Dan H, Duan L, Wu H, Ren G, Dou X, Feng F, Zhang J. SPP1+ macrophages: A malignant macrophage subset in the colorectal cancer microenvironment revealed by single-cell sequencing.. [DOI: 10.21203/rs.3.rs-1984416/v1] [Reference Citation Analysis]
128 Titmuss E, Corbett RD, Davidson S, Abbasi S, Williamson LM, Pleasance ED, Shlien A, Renouf DJ, Jones SJM, Laskin J, Marra MA. TMBur: a distributable tumor mutation burden approach for whole genome sequencing. BMC Med Genomics 2022;15:190. [PMID: 36071521 DOI: 10.1186/s12920-022-01348-z] [Reference Citation Analysis]
129 Wu Z, Zhang F, Wang Y, Lu Z, Lin C. Identification and Validation of the lncRNA MYOSLID as a Regulating Factor of Necroptosis and Immune Cell Infiltration in Colorectal Cancer following Necroptosis-Related LncRNA Model Establishment. Cancers 2022;14:4364. [DOI: 10.3390/cancers14184364] [Reference Citation Analysis]
130 Wang Y, Chen X, Jiang F, Shen Y, Fang F, Li Q, Yang C, Dong Y, Shen X. A prognostic signature of pyroptosis-related lncRNAs verified in gastric cancer samples to predict the immunotherapy and chemotherapy drug sensitivity. Front Genet 2022;13:939439. [DOI: 10.3389/fgene.2022.939439] [Reference Citation Analysis]
131 Zhang C, Wang K, Lin J, Wang H. Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor. Future Oncol 2022. [PMID: 36065989 DOI: 10.2217/fon-2022-0295] [Reference Citation Analysis]
132 Pedrosa L, Foguet C, Oliveres H, Archilla I, de Herreros MG, Rodríguez A, Postigo A, Benítez-ribas D, Camps J, Cuatrecasas M, Castells A, Prat A, Thomson TM, Maurel J, Cascante M. A novel gene signature unveils three distinct immune-metabolic rewiring patterns conserved across diverse tumor types and associated with outcomes. Front Immunol 2022;13:926304. [DOI: 10.3389/fimmu.2022.926304] [Reference Citation Analysis]
133 Reiter FP, Ben Khaled N, Ye L, Zhang C, Seidensticker M, Op den Winkel M, Denk G, Geier A, De Toni EN. Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review. Dig Dis 2022;40:565-80. [PMID: 34644705 DOI: 10.1159/000520095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
134 Yigit A, Kuscu B, Kirik A, Ozcaglayan R, Afsar CU. New Biomarkers and Immunotherapy Decision. Biomarkers in Medicine 2022. [DOI: 10.2174/9789815040463122010003] [Reference Citation Analysis]
135 Tang H, Shan J, Liu J, Wang X, Wang F, Han S, Zhao X, Wang J. Molecular subtypes, clinical significance, and tumor immune landscape of angiogenesis-related genes in ovarian cancer. Front Oncol 2022;12:995929. [DOI: 10.3389/fonc.2022.995929] [Reference Citation Analysis]
136 Xu X, Zhou N, Lan H, Yang F, Dong B, Zhang X. The Ferroptosis Molecular Subtype Reveals Characteristics of the Tumor Microenvironment, Immunotherapeutic Response, and Prognosis in Gastric Cancer. IJMS 2022;23:9767. [DOI: 10.3390/ijms23179767] [Reference Citation Analysis]
137 Yu L, Gong C. Pancancer analysis of a potential gene mutation model in the prediction of immunotherapy outcomes. Front Genet 2022;13:917118. [DOI: 10.3389/fgene.2022.917118] [Reference Citation Analysis]
138 Xiao Y, Dong Y, Yu T, Wang R, Gao Y, Li S, Nong S, Li W. Characterization of the immune related lncRNAs in bladder cancer to aid immunotherapy. Front Immunol 2022;13:941189. [DOI: 10.3389/fimmu.2022.941189] [Reference Citation Analysis]
139 Yang Y, Lin Z, Cai Z, Huang K, Li M, Wang X, Lin Y, Chen S, Yang Z. A composite score based on immune-related gene prognostic index and m6A risk score of head and neck squamous cell carcinoma.. [DOI: 10.21203/rs.3.rs-1987322/v1] [Reference Citation Analysis]
140 Zeng C, Liu Y, He R, Lu X, Dai Y, Qi G, Liu J, Deng J, Lu W, Jin J, Liu Q. Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma. Front Genet 2022;13:935056. [DOI: 10.3389/fgene.2022.935056] [Reference Citation Analysis]
141 Zahid KR, Raza U, Tumbath S, Jiang L, Xu W, Huang X. Neutrophils: Musketeers against immunotherapy. Front Oncol 2022;12:975981. [DOI: 10.3389/fonc.2022.975981] [Reference Citation Analysis]
142 Yang L, Chen Z, Liu Y, Wang X, Li J, Ye Q. Immunization Combined with Ferroptosis Related Genes to Construct a New Prognostic Model for Head and Neck Squamous Cell Carcinoma. Cancers 2022;14:4099. [DOI: 10.3390/cancers14174099] [Reference Citation Analysis]
143 Song C, Lin W, Meng H, Li N, Geng Q. Integrated Analysis Reveals the Potential Significance of HDAC Family Genes in Lung Adenocarcinoma. Front Genet 2022;13:862977. [DOI: 10.3389/fgene.2022.862977] [Reference Citation Analysis]
144 Shan J, Geng R, Zhang Y, Wei J, Liu J, Bai J. Identification of cuproptosis-related subtypes, establishment of a prognostic model and tumor immune landscape in endometrial carcinoma. Comput Biol Med 2022;149:105988. [PMID: 36007289 DOI: 10.1016/j.compbiomed.2022.105988] [Reference Citation Analysis]
145 Rizzo M, Varnier L, Pezzicoli G, Pirovano M, Cosmai L, Porta C. IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma. Front Oncol 2022;12:990568. [DOI: 10.3389/fonc.2022.990568] [Reference Citation Analysis]
146 Kim H, Kim J, Sa JK, Ryu BK, Park KJ, Kim J, Ha H, Park Y, Shin MH, Kim J, Lee H, Kim D, Lee K, Jang B, Lee KM, Kang SH. Calcipotriol, a synthetic Vitamin D analog, promotes antitumor immunity via CD4+T-dependent CTL/NK cell activation. Biomed Pharmacother 2022;154:113553. [PMID: 35994815 DOI: 10.1016/j.biopha.2022.113553] [Reference Citation Analysis]
147 Ng S, Lim S, Sim ACN, Mangadu R, Lau A, Zhang C, Martinez SB, Chandramohan A, Lim UM, Ho SSW, Chang SC, Gopal P, Hong LZ, Schwaid A, Fernandis AZ, Loboda A, Li C, Phan U, Henry B, Partridge AW. STUB1 is an intracellular checkpoint for interferon gamma sensing. Sci Rep 2022;12:14087. [PMID: 35982220 DOI: 10.1038/s41598-022-18404-4] [Reference Citation Analysis]
148 Zhu Z, Turner NC, Loi S, André F, Martin M, Diéras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. NPJ Precis Oncol 2022;6:56. [PMID: 35974168 DOI: 10.1038/s41698-022-00297-1] [Reference Citation Analysis]
149 Gong Y, Yao Y, Cheng W, Duan C, Li D, Wang Z, Xiang Y. Highly Sensitive Detection of the Immune Checkpoint PD-L1-Positive Circulating Tumor Cells Based on Steric Hindrance. Anal Chem 2022. [PMID: 35972912 DOI: 10.1021/acs.analchem.2c01762] [Reference Citation Analysis]
150 Shi D, Zhong W, Liu D, Sun X, Hao S, Yang Y, Ao L, Zhou J, Xia Y, Zhou Y, Yu H, Xia H. Computational identification of immune-related lncRNA signature for predicting the prognosis and immune landscape of human glioblastoma multiforme. Front Immunol 2022;13:932938. [DOI: 10.3389/fimmu.2022.932938] [Reference Citation Analysis]
151 Zheng G, Lu Y, Yang Z, Chen H, Liang Q, Zhu Q, Li Y, Xiao X, He Z, Zhu Y, Li B, Huang L, Dong N, Hu S, Pan Y, Zhang C, Zhu C. Typing the tumor immune signatures in patients of Lynch syndrome facilitates predicting the responsiveness of immune checkpoint inhibition.. [DOI: 10.21203/rs.3.rs-1932907/v1] [Reference Citation Analysis]
152 Pinilla K, Drewett LM, Lucey R, Abraham JE. Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. Front Oncol 2022;12:866889. [DOI: 10.3389/fonc.2022.866889] [Reference Citation Analysis]
153 Giotta Lucifero A, Luzzi S. Emerging immune-based technologies for high-grade gliomas. Expert Rev Anticancer Ther 2022. [PMID: 35924820 DOI: 10.1080/14737140.2022.2110072] [Reference Citation Analysis]
154 Sokač M, Ahrenfeldt J, Litchfield K, Watkins TB, Knudsen M, Dyrskjøt L, Jakobsen MR, Birkbak NJ. Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer. Cancer Research Communications 2022;2:762-771. [DOI: 10.1158/2767-9764.crc-22-0047] [Reference Citation Analysis]
155 Wang Y, Lai X, Wang J, Xu Y, Zhang X, Zhu X, Liu Y, Shao Y, Zhang L, Fang W. A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold. Front Genet 2022;13:915839. [DOI: 10.3389/fgene.2022.915839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Ahmed KM, Veeramachaneni R, Deng D, Putluri N, Putluri V, Cardenas MF, Wheeler DA, Decker WK, Frederick AI, Kazi S, Sikora AG, Sandulache VC, Frederick MJ. Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response. J Immunother Cancer 2022;10:e004752. [PMID: 36002187 DOI: 10.1136/jitc-2022-004752] [Reference Citation Analysis]
157 Yin Z, Chen D, Liang S, Li X. . JHC 2022;Volume 9:929-46. [DOI: 10.2147/jhc.s357313] [Reference Citation Analysis]
158 Ritterhouse LL, Gogakos T. Molecular Biomarkers of Response to Cancer Immunotherapy. Clinics in Laboratory Medicine 2022. [DOI: 10.1016/j.cll.2022.05.004] [Reference Citation Analysis]
159 Kanemura H, Hayashi H, Tomida S, Tanizaki J, Suzuki S, Kawanaka Y, Tsuya A, Fukuda Y, Kaneda H, Kudo K, Takahama T, Imai R, Haratani K, Chiba Y, Otani T, Ito A, Sakai K, Nishio K, Nakagawa K. The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC. JTO Clinical and Research Reports 2022;3:100373. [DOI: 10.1016/j.jtocrr.2022.100373] [Reference Citation Analysis]
160 Liu P, Ye M, Wu Y, Wu L, Lan K, Wu Z. Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes. Cancer Medicine. [DOI: 10.1002/cam4.5085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol 2022;12:960317. [DOI: 10.3389/fonc.2022.960317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Xu M, Mu J, Wang J, Zhou Q, Wang J. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. Front Oncol 2022;12:961213. [DOI: 10.3389/fonc.2022.961213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
163 Damato A, Rotolo M, Caputo F, Borghi E, Iachetta F, Pinto C. New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. Life (Basel) 2022;12:1137. [PMID: 36013315 DOI: 10.3390/life12081137] [Reference Citation Analysis]
164 Zhao Z, Chen Z, Yu B, Xiao B, Liu L, Xia Y, Li A, Wang P, Xiang C, Liu C, Yang H, Li H, Xiao T. Characterization of the immune cell infiltration landscape in myxofibrosarcoma to aid immunotherapy. Front Immunol 2022;13:916915. [DOI: 10.3389/fimmu.2022.916915] [Reference Citation Analysis]
165 Wang W, Dong D, Chen L, Wang H, Bi B, Liu T. Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules. Front Genet 2022;13:893380. [DOI: 10.3389/fgene.2022.893380] [Reference Citation Analysis]
166 Jiang M, Zhang C, Hu Y, Li T, Yang G, Wang G, Zhu J, Shao C, Hou H, Zhou N, Liu K, Zhang X. Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma. Oncologist 2022;27:e856-69. [PMID: 35857405 DOI: 10.1093/oncolo/oyac136] [Reference Citation Analysis]
167 Xu JL. Wilms Tumor 1-Associated Protein Expression Is Linked to a T-Cell-Inflamed Phenotype in Pancreatic Cancer. Dig Dis Sci 2022. [PMID: 35859262 DOI: 10.1007/s10620-022-07620-7] [Reference Citation Analysis]
168 Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Bhagia P, Cao ZA, Lunceford J, Suryawanshi S, Ayers M, J Marton M, Kato K. T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future Oncol 2022. [PMID: 35852104 DOI: 10.2217/fon-2021-1134] [Reference Citation Analysis]
169 de Sousa LG, Jovanovic K, Ferrarotto R. Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments. Curr Treat Options Oncol 2022. [PMID: 35854180 DOI: 10.1007/s11864-022-01001-y] [Reference Citation Analysis]
170 Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam MHC, Ma ESK, Poon DMC. Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. Front Oncol 2022;12:962958. [DOI: 10.3389/fonc.2022.962958] [Reference Citation Analysis]
171 Lee JY, Kannan B, Lim BY, Li Z, Lim AH, Loh JW, Ko TK, Ng CC, Chan JY. The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. Int J Mol Sci 2022;23:7839. [PMID: 35887186 DOI: 10.3390/ijms23147839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
172 Gong X, Chen H, Zhang L, Chen D, Li W, Chen D, Xu J, Zhou H, Zhao L, Song Y, Xiao M, Deng W, Qi C, Wang X, Chen X. NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer. Front Immunol 2022;13:920253. [DOI: 10.3389/fimmu.2022.920253] [Reference Citation Analysis]
173 Boukhaled GM, Gadalla R, Elsaesser HJ, Abd-Rabbo D, Quevedo R, Yang SYC, Guo M, Wang BX, Noamani B, Gray D, Lau SCM, Taylor K, Aung K, Spreafico A, Hansen AR, Saibil SD, Hirano N, Guidos C, Pugh TJ, McGaha TL, Ohashi PS, Sacher AG, Butler MO, Brooks DG. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nat Immunol 2022. [PMID: 35835962 DOI: 10.1038/s41590-022-01262-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
174 Lau D, Khare S, Stein MM, Jain P, Gao Y, BenTaieb A, Rand TA, Salahudeen AA, Khan AA. Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer. Nat Commun 2022;13:4053. [PMID: 35831288 DOI: 10.1038/s41467-022-31769-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Geng R, Song J, Zhong Z, Ni S, Liu W, He Z, Gan S, Huang Q, Yu H, Bai J, Liu J. Crosstalk of Redox-Related Subtypes, Establishment of a Prognostic Model and Immune Responses in Endometrial Carcinoma. Cancers 2022;14:3383. [DOI: 10.3390/cancers14143383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 Yu J, Fan Z, Zhou Z, Zhang P, Bai J, Li X, Tang M, Fan N, Wu X, Nie X, Chen X, Ma D, Chen X, Cui L, Xia X, Yang L, Yi X, Li L. TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy. Cancers 2022;14:3382. [DOI: 10.3390/cancers14143382] [Reference Citation Analysis]
177 Wang Z, Liu Y, Zhan X, Wang X, Zhang C, Qin L, Liu L, Qin S. A novel prognostic signature of metastasis-associated genes and personalized therapeutic strategy for lung adenocarcinoma patients. Aging (Albany NY) 2022;14. [PMID: 35830566 DOI: 10.18632/aging.204169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Rao S, Anandappa G, Capdevila J, Dahan L, Evesque L, Kim S, Saunders MP, Gilbert DC, Jensen LH, Samalin E, Spindler KL, Tamberi S, Demols A, Guren MG, Arnold D, Fakih M, Kayyal T, Cornfeld M, Tian C, Catlett M, Smith M, Spano JP. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022;7:100529. [PMID: 35816951 DOI: 10.1016/j.esmoop.2022.100529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Makaranka S, Scutt F, Frixou M, Wensley KE, Sharma R, Greenhowe J. The gut microbiome and melanoma: A review. Exp Dermatol 2022. [PMID: 35793428 DOI: 10.1111/exd.14639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Liu J, Lin J, Wang X, Zheng X, Gao X, Huang Y, Chen G, Xiong J, Lan B, Chen C, Si L, Chen Y. CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. Front Immunol 2022;13:725679. [DOI: 10.3389/fimmu.2022.725679] [Reference Citation Analysis]
181 Cheng G, Zhang F, Xing Y, Hu X, Zhang H, Chen S, Li M, Peng C, Ding G, Zhang D, Chen P, Xia Q, Wu M. Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer. Front Immunol 2022;13:893198. [DOI: 10.3389/fimmu.2022.893198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
182 Takamatsu S, Hamanishi J, Brown JB, Yamaguchi K, Yamanoi K, Murakami K, Gotoh O, Mori S, Mandai M, Matsumura N. Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy. J Immunother Cancer 2022;10:e004831. [PMID: 35868660 DOI: 10.1136/jitc-2022-004831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Shui IM, Liu XQ, Zhao Q, Kim ST, Sun Y, Yearley JH, Choudhury T, Webber AL, Krepler C, Cristescu R, Lee J. Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. J Immunother Cancer 2022;10:e004879. [PMID: 35793874 DOI: 10.1136/jitc-2022-004879] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
184 Miao K, Zhang X, Wang H, Si X, Ni J, Zhong W, Zhao J, Xu Y, Chen M, Pan R, Wang M, Zhang L. Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Front Immunol 2022;13:912180. [PMID: 35844502 DOI: 10.3389/fimmu.2022.912180] [Reference Citation Analysis]
185 Wang H, Li Z, Ou S, Song Y, Luo K, Guan Z, Zhao L, Huang R, Yu S. Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts. Front Mol Biosci 2022;9:884839. [DOI: 10.3389/fmolb.2022.884839] [Reference Citation Analysis]
186 Ruan L, Chen W, Zhao X, Fang N, Li T, Pan J. Predictive Potentials of ZEB1-AS1 in Colorectal Cancer Prognosis and Their Correlation with Immunotherapy. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/1084555] [Reference Citation Analysis]
187 Gould AL, Baumgartner R, Zhao A. Bayesian screening for feature selection. J Biopharm Stat 2022;:1-26. [PMID: 35736220 DOI: 10.1080/10543406.2022.2033760] [Reference Citation Analysis]
188 Wang F, Gao X, Wang P, He H, Chen P, Liu Z, Chen Y, Zhou H, Chen W, Yi X, Xia X, Liu S. Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications. Front Immunol 2022;13:877896. [PMID: 35720373 DOI: 10.3389/fimmu.2022.877896] [Reference Citation Analysis]
189 Shi Y, Ma X, Shen W, Liu T, Liang L, Liu S, Shen Z, Zhang Y, Zhang P. Evaluation of the EdgeSeq Precision Immuno-Oncology Panel for Gene Expression Profiling From Clinical Formalin-Fixed Paraffin-Embedded Tumor Specimens. Front Cell Dev Biol 2022;10:899353. [PMID: 35712667 DOI: 10.3389/fcell.2022.899353] [Reference Citation Analysis]
190 Wan RJ, Bai L, Jiang J, Hu CP, Chen Q, Zhao BR, Zhang Y, Li YY. N6-methyladenosine (m6A) regulator expression pattern correlates with the immune landscape in lung adenocarcinoma. Gene 2022;836:146639. [PMID: 35700805 DOI: 10.1016/j.gene.2022.146639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Rad HS, Shiravand Y, Radfar P, Ladwa R, Perry C, Han X, Warkiani ME, Adams MN, Hughes BG, O'Byrne K, Kulasinghe A. Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clin Transl Immunology 2022;11:e1397. [PMID: 35686027 DOI: 10.1002/cti2.1397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Vo DHT, Mcgleave G, Overton IM. Immune Cell Networks Uncover Candidate Biomarkers of Melanoma Immunotherapy Response. JPM 2022;12:958. [DOI: 10.3390/jpm12060958] [Reference Citation Analysis]
193 Takahashi N, Hatakeyama K, Nagashima T, Ohshima K, Urakami K, Yamaguchi K, Hirashima Y. Characterization of rare histological subtypes of ovarian cancer based on molecular profiling. Cancer Med 2023;12:387-95. [PMID: 35676859 DOI: 10.1002/cam4.4927] [Reference Citation Analysis]
194 Hwang M, Canzoniero JV, Rosner S, Zhang G, White JR, Belcaid Z, Cherry C, Balan A, Pereira G, Curry A, Niknafs N, Zhang J, Smith KN, Sivapalan L, Chaft JE, Reuss JE, Marrone K, Murray JC, Li QK, Lam V, Levy BP, Hann C, Velculescu VE, Brahmer JR, Forde PM, Seiwert T, Anagnostou V. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer 2022;10:e004688. [PMID: 35688557 DOI: 10.1136/jitc-2022-004688] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
195 Jin Z, Sinicrope FA. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. J Clin Oncol 2022;:JCO2102691. [PMID: 35649217 DOI: 10.1200/JCO.21.02691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
196 Mody K, Jain P, El-Refai SM, Azad NS, Zabransky DJ, Baretti M, Shroff RT, Kelley RK, El-Khouiery AB, Hockenberry AJ, Lau D, Lesinski GB, Yarchoan M. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precis Oncol 2022;6:e2100510. [PMID: 35675577 DOI: 10.1200/PO.21.00510] [Reference Citation Analysis]
197 Chen J, Lin D, Yang J, Cai X, Wei G, Cao P. Advances in the synergistic and toxic attenuating effect of traditional Chinese medicine in cancer treatment. Sci Sin -Vitae 2022;52:920-934. [DOI: 10.1360/ssv-2021-0389] [Reference Citation Analysis]
198 Tawbi HA, Robert C, Brase JC, Gusenleitner D, Gasal E, Garrett J, Savchenko A, Görgün G, Flaherty KT, Ribas A, Dummer R, Schadendorf D, Long GV, Nathan PD, Ascierto PA. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J Immunother Cancer 2022;10:e004226. [PMID: 35728875 DOI: 10.1136/jitc-2021-004226] [Reference Citation Analysis]
199 Wei B, Kang J, Kibukawa M, Arreaza G, Maguire M, Chen L, Qiu P, Lang L, Aurora-Garg D, Cristescu R, Levitan D. Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab. J Mol Diagn 2022;24:600-8. [PMID: 35218944 DOI: 10.1016/j.jmoldx.2022.01.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
200 Rijnders M, Nakauma-gonzález JA, Robbrecht DG, Gil-jimenez A, Aarts MJ, Boormans JL, Hamberg P, van der Heijden MS, Szabados BE, van Leenders GJ, Mehra N, Voortman J, Westgeest HM, de Wit R, van der Veldt AA, Debets R, Lolkema MP. T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancer.. [DOI: 10.1101/2022.05.30.493997] [Reference Citation Analysis]
201 Kovács SA, Győrffy B. Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review. J Transl Med 2022;20:249. [PMID: 35641998 DOI: 10.1186/s12967-022-03409-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
202 Yang J, Tian Z, Gao H, Xiong F, Cao C, Yu J, Shi W, Zhan Q, Yang C. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer. BMC Cancer 2022;22:584. [PMID: 35624419 DOI: 10.1186/s12885-022-09639-5] [Reference Citation Analysis]
203 Oitabén A, Fonseca P, Villanueva MJ, García-Benito C, López-López A, Garrido-Fernández A, González-Ojea C, Juaneda-Magdalena L, Lázaro ME, Martínez-Fernández M. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. Cancers (Basel) 2022;14:2626. [PMID: 35681606 DOI: 10.3390/cancers14112626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
204 Rha SY, Ku GY, Kim HS, Chung HC, Amlashi FG, Maru DM, Fein CA, Tang LH, Zhou W, Wu T, Peter SA, Kelsen DP, Ajani JA. PD-L1 expression and overall survival in Asian and western patients with gastric cancer. Future Oncol 2022. [PMID: 35616013 DOI: 10.2217/fon-2022-0103] [Reference Citation Analysis]
205 Ye Z, Zeng D, Zhou R, Shi M, Liao W. Tumor Microenvironment Evaluation for Gastrointestinal Cancer in the Era of Immunotherapy and Machine Learning. Front Immunol 2022;13:819807. [PMID: 35603201 DOI: 10.3389/fimmu.2022.819807] [Reference Citation Analysis]
206 Zhang J, Huang D, Saw PE, Song E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol 2022:S1471-4906(22)00096-5. [PMID: 35624021 DOI: 10.1016/j.it.2022.04.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
207 Peng J, Xiao L, Zou D, Han L. A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer. Front Med (Lausanne) 2022;9:808378. [PMID: 35592856 DOI: 10.3389/fmed.2022.808378] [Reference Citation Analysis]
208 Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
209 Yan H, Li Y, Wang X, Qian J, Xu M, Peng J, Huang D. The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry. Front Oncol 2022;12:867658. [DOI: 10.3389/fonc.2022.867658] [Reference Citation Analysis]
210 Weir WH, Mucha PJ, Kim WY. A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response. Cell Rep Med 2022;3:100602. [PMID: 35584624 DOI: 10.1016/j.xcrm.2022.100602] [Reference Citation Analysis]
211 Weiner AB, Yu CY, Kini M, Liu Y, Davicioni E, Mitrofanova A, Lotan TL, Schaeffer EM. High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. Prostate Cancer Prostatic Dis 2022. [PMID: 35568781 DOI: 10.1038/s41391-022-00547-0] [Reference Citation Analysis]
212 Sun S, Wang Y, Li M, Wu J. Identification of TRP-Related Subtypes, Development of a Prognostic Model, and Characterization of Tumor Microenvironment Infiltration in Lung Adenocarcinoma. Front Mol Biosci 2022;9:861380. [DOI: 10.3389/fmolb.2022.861380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Zhang SL, Han B, Mao YQ, Zhang ZY, Li ZM, Kong CY, Wu Y, Chen GQ, Wang LS. Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice. Gut Microbes 2022;14:2046246. [PMID: 35259052 DOI: 10.1080/19490976.2022.2046246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
214 Jee B, Seo E, Park K, Kim YR, Byeon SJ, Lee SM, Chung JH, Song W, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Park SH, Park WY, Kang M. Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2022;14:2354. [PMID: 35625960 DOI: 10.3390/cancers14102354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Lee YJ, Woo HY, Kim Y, Park J, Nam EJ, Kim SW, Kim S, Kim YT, Park E, Joung J, Lee J. Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer. Cancers 2022;14:2308. [DOI: 10.3390/cancers14092308] [Reference Citation Analysis]
216 Nie W, Wang ZJ, Zhang K, Li B, Cai YR, Wen FC, Zhang D, Bai YZ, Zhang XY, Wang SY, Cheng L, Zhong H, Liu L, Wang J, Han BH. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. BMC Med 2022;20:170. [PMID: 35509036 DOI: 10.1186/s12916-022-02360-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Cappello F, Angerilli V, Munari G, Ceccon C, Sabbadin M, Pagni F, Fusco N, Malapelle U, Fassan M. FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. JPM 2022;12:750. [DOI: 10.3390/jpm12050750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Wang Y, Liu Y, Li X, Li W, Xue Z, He X, Xiong W, He L, Bai Y. TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC. Front Pharmacol 2022;13:875149. [DOI: 10.3389/fphar.2022.875149] [Reference Citation Analysis]
219 Wang J, Ma X, Ma Z, Ma Y, Wang J, Cao B. Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers. Front Immunol 2022;13:810539. [PMID: 35493526 DOI: 10.3389/fimmu.2022.810539] [Reference Citation Analysis]
220 Gao Y, Zhang Z, Li Y, Chen S, Lu J, Wu L, Ma Z, Hu Y, Zhang G. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy. Front Oncol 2022;12:834564. [PMID: 35494073 DOI: 10.3389/fonc.2022.834564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Sung MT, Wang YH, Li CF. Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB. Int J Mol Sci 2022;23:5097. [PMID: 35563486 DOI: 10.3390/ijms23095097] [Reference Citation Analysis]
222 Zeng H, Tong F, Bin Y, Peng L, Gao X, Xia X, Yi X, Dong X. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer. Front Immunol 2022;13:834142. [PMID: 35242138 DOI: 10.3389/fimmu.2022.834142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
223 Qing X, Xu W, Liu S, Chen Z, Ye C, Zhang Y. Molecular Characteristics, Clinical Significance, and Cancer Immune Interactions of Angiogenesis-Associated Genes in Gastric Cancer. Front Immunol 2022;13:843077. [PMID: 35273618 DOI: 10.3389/fimmu.2022.843077] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
224 Karamitopoulou E, Andreou A, Wenning AS, Gloor B, Perren A. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Eur J Cancer 2022;169:64-73. [PMID: 35512587 DOI: 10.1016/j.ejca.2022.03.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Ranti D, Bieber C, Wang Y, Sfakianos JP, Horowitz A. Natural killer cells: unlocking new treatments for bladder cancer. Trends in Cancer 2022. [DOI: 10.1016/j.trecan.2022.03.007] [Reference Citation Analysis]
226 Chen Y, Zheng X, Lin J, Gao X, Xiong J, Liu J, Fei Z, Chen C. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients. Oral Oncology 2022;128:105860. [DOI: 10.1016/j.oraloncology.2022.105860] [Reference Citation Analysis]
227 Mukherji R, Weinberg BA, Pedersen KS. Immunotherapy for Colorectal Cancer. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2022.02.010] [Reference Citation Analysis]
228 Lai G, Li K, Deng J, Liu H, Xie B, Zhong X, Srinivasan K. Identification and Validation of a Gene Signature for Lower-Grade Gliomas Based on Pyroptosis-Related Genes to Predict Survival and Response to Immune Checkpoint Inhibitors. Journal of Healthcare Engineering 2022;2022:1-17. [DOI: 10.1155/2022/8704127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
229 Nowroozi A, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N. Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms. Expert Opin Biol Ther 2022. [PMID: 35477305 DOI: 10.1080/14712598.2022.2072206] [Reference Citation Analysis]
230 He J, Jiang Z, Lei J, Zhou W, Cui Y, Luo B, Zhang M. Prognostic Value and Therapeutic Perspectives of CXCR Members in the Glioma Microenvironment. Front Genet 2022;13:787141. [DOI: 10.3389/fgene.2022.787141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Fromme JE, Zigrino P. The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance. Front Mol Biosci 2022;9:864302. [DOI: 10.3389/fmolb.2022.864302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
232 Mudassar F, Shen H, Cook KM, Hau E. Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. J Med Imag Rad Onc. [DOI: 10.1111/1754-9485.13416] [Reference Citation Analysis]
233 Best SA, Gubser PM, Sethumadhavan S, Kersbergen A, Negrón Abril YL, Goldford J, Sellers K, Abeysekera W, Garnham AL, McDonald JA, Weeden CE, Anderson D, Pirman D, Roddy TP, Creek DJ, Kallies A, Kingsbury G, Sutherland KD. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. Cell Metab 2022:S1550-4131(22)00130-9. [PMID: 35504291 DOI: 10.1016/j.cmet.2022.04.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
234 Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, Sawchyn B, Gjoerup O, Meng W, Skoletsky J, Concepcion AD, Tang Y, Bai X, Dewal N, Ma P, Bailey ST, Thornton J, Pavlick DC, Frampton GM, Lieber D, White J, Burns C, Vietz C. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLoS One 2022;17:e0264138. [PMID: 35294956 DOI: 10.1371/journal.pone.0264138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
235 Li X, Dai Z, Wu X, Zhang N, Zhang H, Wang Z, Zhang X, Liang X, Luo P, Zhang J, Liu Z, Zhou Y, Cheng Q, Chang R. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma. Front Immunol 2022;13:749241. [DOI: 10.3389/fimmu.2022.749241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
236 Ascierto PA, Butterfield LH, Finn OJ, Futreal A, Hamid O, LaVallee T, Postow MA, Puzanov I, Sosman J, Fox BA, Hwu P. The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021. J Transl Med 2022;20:179. [PMID: 35449104 DOI: 10.1186/s12967-022-03384-w] [Reference Citation Analysis]
237 Tzoras E, Zerdes I, Tsiknakis N, Manikis GC, Mezheyeuski A, Bergh J, Matikas A, Foukakis T. Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. Cancers 2022;14:1999. [DOI: 10.3390/cancers14081999] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Wang X, Cao H, Zhai Y, Deng S, Chao M, Hu Y, Mou Y, Guo S, Zhao W, Li C, Jiao Y, Xue G, Han L, Zhang H, Wang L. Immune Gene Signatures and Immunotypes in Immune Microenvironment Are Associated With Glioma Prognose. Front Immunol 2022;13:823910. [DOI: 10.3389/fimmu.2022.823910] [Reference Citation Analysis]
239 Hou J, Li H, Ma S, He Z, Yang S, Hao L, Zhou H, Zhang Z, Han J, Wang L, Wang Q. EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives. Biomark Res 2022;10:21. [PMID: 35418149 DOI: 10.1186/s40364-022-00372-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
240 Hu J, Mao F, Li L, Wang X, Cai D, He L, Wu Q, Wang C, Zhang N, Ma Y, Wu X, Qu K, Wang X. Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. J Oncol 2022;2022:1087399. [PMID: 35401750 DOI: 10.1155/2022/1087399] [Reference Citation Analysis]
241 Paschen A, Melero I, Ribas A. Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade. Annu Rev Cancer Biol 2022;6:85-102. [DOI: 10.1146/annurev-cancerbio-070220-111016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
242 Holm JS, Funt SA, Borch A, Munk KK, Bjerregaard A, Reading JL, Maher C, Regazzi A, Wong P, Al-ahmadie H, Iyer G, Tamhane T, Bentzen AK, Herschend NO, De Wolf S, Snyder A, Merghoub T, Wolchok JD, Nielsen M, Rosenberg JE, Bajorin DF, Hadrup SR. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-29342-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
243 Salem RA, Nabegh LM, Abu-zeid RM, Abd Raboh NM, El-rashedy M. Evaluation of Programmed Death Ligand-1 Immunohistochemical Expression and Tumor-Infiltrating Lymphocytes in Different Types of Endometrial Carcinoma. Open Access Maced J Med Sci 2022;10:702-8. [DOI: 10.3889/oamjms.2022.9195] [Reference Citation Analysis]
244 Wotman M, Gold B, Takahashi M, Draper L, Posner M. Treatment of Recurrent and Metastatic HPV-Associated Squamous Cell Carcinoma. Curr Otorhinolaryngol Rep. [DOI: 10.1007/s40136-022-00402-9] [Reference Citation Analysis]
245 Wang H, Zhou Y, Zhang Y, Fang S, Zhang M, Li H, Xu F, Liu L, Liu J, Zhao Q, Wang F. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target. J Immunother Cancer 2022;10:e004302. [PMID: 35383115 DOI: 10.1136/jitc-2021-004302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Chen A, Shah T, Brown A, Akrami H, Swiston A, Vajdi A, Krishnan R, Cristescu R. Prediction of tumor mutation burden from H&E whole-slide images: a comparison of training strategies with convolutional neural networks. Medical Imaging 2022: Digital and Computational Pathology 2022. [DOI: 10.1117/12.2613196] [Reference Citation Analysis]
247 Hoch T, Schulz D, Eling N, Gómez JM, Levesque MP, Bodenmiller B. Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. Sci Immunol 2022;7:eabk1692. [PMID: 35363540 DOI: 10.1126/sciimmunol.abk1692] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
248 Lu C, Zhang YC, Chen ZH, Zhou Q, Wu YL. Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. Front Oncol 2022;12:836891. [PMID: 35359372 DOI: 10.3389/fonc.2022.836891] [Reference Citation Analysis]
249 Ning B, Liu Y, Wang M, Li Y, Xu T, Wei Y. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis. Front Pharmacol 2022;13:748674. [PMID: 35355708 DOI: 10.3389/fphar.2022.748674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
250 Graham LS, Schweizer MT. Mismatch repair deficiency and clinical implications in prostate cancer. Prostate 2022. [PMID: 35358351 DOI: 10.1002/pros.24343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Wu SY, Xu Y, Chen L, Fan L, Ma XY, Zhao S, Song XQ, Hu X, Yang WT, Chai WJ, Guo XM, Chen XZ, Xu YH, Zhu XY, Zou JJ, Wang ZH, Jiang YZ, Shao ZM. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol Cancer 2022;21:84. [PMID: 35337339 DOI: 10.1186/s12943-022-01536-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
252 Cao J, Yang X, Chen S, Wang J, Fan X, Fu S, Yang L. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis. Transl Oncol 2022;20:101375. [PMID: 35339028 DOI: 10.1016/j.tranon.2022.101375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
253 Ravi A, Gainor JF, Arniella MB, Holton M, Freeman SS, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Hellmann MD. Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer.. [DOI: 10.1101/2022.03.21.485199] [Reference Citation Analysis]
254 Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry MB, Ross-Macdonald P, Wind-Rotolo M. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer 2022;10:e004316. [PMID: 35304405 DOI: 10.1136/jitc-2021-004316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
255 Wang A, Yuan Y, Chu H, Gao Y, Jin Z, Jia Q, Zhu B. Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment. Pathol Oncol Res 2022;28:1610196. [PMID: 35264912 DOI: 10.3389/pore.2022.1610196] [Reference Citation Analysis]
256 Darabi S, Elliott A, Braxton DR, Zeng J, Hodges K, Poorman K, Swensen J, Shanthappa BU, Hinton JP, Gibney GT, Moser J, Phung T, Atkins MB, In GK, Korn WM, Eisenberg BL, Demeure MJ. Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. Cancers (Basel) 2022;14:1505. [PMID: 35326655 DOI: 10.3390/cancers14061505] [Reference Citation Analysis]
257 Huang Z, Yang J, Qiu W, Huang J, Chen Z, Han Y, Ye C. HAUS5 Is A Potential Prognostic Biomarker With Functional Significance in Breast Cancer. Front Oncol 2022;12:829777. [PMID: 35280773 DOI: 10.3389/fonc.2022.829777] [Reference Citation Analysis]
258 Brastianos PK, Kim AE, Giobbie-hurder A, Lee EQ, Wang N, Eichler AF, Chukwueke U, Forst DA, Arrillaga-romany IC, Dietrich J, Corbin Z, Moliterno J, Baehring J, White M, Lou KW, Larson J, de Sauvage MA, Evancic K, Mora J, Nayyar N, Loeffler J, Oh K, Shih HA, Curry WT, Cahill DP, Barker FG, Gerstner ER, Santagata S. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-29052-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
259 Dervovic D, Chen EL, Malik A, Afiuni-zadeh S, Boucher J, Berman JM, Teng K, Ayyaz A, Lü Y, Narimatsu M, Mbamalu G, Loganathan S, Martinez S, Tsai R, Lee JB, Zhang L, Wrana J, Roux PP, Jackson HW, Schramek D. In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.. [DOI: 10.1101/2022.03.13.484176] [Reference Citation Analysis]
260 Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, Chevrier S, Joubert P, Routy B, Truntzer C, Ghiringhelli F. MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. J Immunother Cancer 2022;10:e004241. [DOI: 10.1136/jitc-2021-004241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
261 Wang L, Cao H, Zhong Y, Ji P, Chen F. The Role of m6A Regulator-Mediated Methylation Modification and Tumor Microenvironment Infiltration in Glioblastoma Multiforme. Front Cell Dev Biol 2022;10:842835. [PMID: 35265626 DOI: 10.3389/fcell.2022.842835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
262 Liu Y, Zhang Q, Xing B, Luo N, Gao R, Yu K, Hu X, Bu Z, Peng J, Ren X, Zhang Z. Immune phenotypic linkage between colorectal cancer and liver metastasis. Cancer Cell 2022:S1535-6108(22)00065-4. [PMID: 35303421 DOI: 10.1016/j.ccell.2022.02.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
263 Xu X, Gu H, Li H, Gao S, Shi X, Shen J, Li B, Wang H, Zheng K, Shao Z, Cheng P, Cha Z, Peng S, Nie Y, Li Z, Guo S, Qian B, Jin G. Large-cohort humanized NPI mice reconstituted with CD34+ hematopoietic stem cells are feasible for evaluating preclinical cancer immunotherapy. FASEB J 2022;36:e22244. [PMID: 35262964 DOI: 10.1096/fj.202101548RR] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Xu J, Gao Z, Liu K, Fan Y, Zhang Z, Xue H, Guo X, Zhang P, Deng L, Wang S, Wang H, Wang Q, Zhao R, Li G. The Non-N6-Methyladenosine Epitranscriptome Patterns and Characteristics of Tumor Microenvironment Infiltration and Mesenchymal Transition in Glioblastoma. Front Immunol 2021;12:809808. [PMID: 35154083 DOI: 10.3389/fimmu.2021.809808] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
265 Loo K, Smithy JW, Postow MA, Betof Warner A. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. Front Immunol 2021;12:810388. [PMID: 35087529 DOI: 10.3389/fimmu.2021.810388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
266 Ranti D, Wang Y, Daza J, Bieber C, Salomé B, Merritt E, Cavallo J, Hegewisch-solloa E, Mace E, Farkas A, Shroff S, Patel F, Tran M, Strandgaard T, Lindskrog SV, Dyrskjøt L, Qi J, Patel M, Geanon D, Kelly G, de Real R, Lee B, Kim-schulze S, Thin T, Garcia-barros M, Beaumont K, Ravichandran H, Hu Y, Wang Y, Wang L, Laroche D, lee Y, Sebra R, Brody R, Elemento O, Tocheva A, Hopkins BD, Wiklund P, Zhu J, Galsky M, Bhardwaj N, Sfakianos J, Horowitz A. Elevated HLA-E and NKG2A as a Consequence of Chronic Immune Activation Defines Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.. [DOI: 10.1101/2022.03.06.483198] [Reference Citation Analysis]
267 Dhakad GG, Shirsat SP, Tambe KP. Review on Immuno-Oncology Agents for Cancer Therapy. RJPPD 2022. [DOI: 10.52711/2321-5836.2022.00008] [Reference Citation Analysis]
268 Dhakad GG, Shirsat SP, Tambe KP, Kairnar V, Jain RS. Review on Immuno-Oncology agents for Cancer Therapy. AJPR 2022. [DOI: 10.52711/2231-5691.2022.00017] [Reference Citation Analysis]
269 Yu T, Tan H, Liu C, Nie W, Wang Y, Zhou K, Shi H. Integratively Genomic Analysis Reveals the Prognostic and Immunological Characteristics of Pyroptosis and Ferroptosis in Pancreatic Cancer for Precision Immunotherapy. Front Cell Dev Biol 2022;10:826879. [PMID: 35242763 DOI: 10.3389/fcell.2022.826879] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
270 Salomé B, Sfakianos JP, Daza J, Charap A, Hammer C, Banchereau R, Farkas AM, Geanon D, Kelly G, de Real RM, Lee B, Beaumont KG, Shroff S, Wang YSA, Wang Y, Thin TH, Garcia-barros M, Hegewisch-solloa E, Mace EM, Wang L, O’donnell T, Chowell D, Fernandez-rodriguez R, Skobe M, Taylor N, Kim-schulze S, Sebra RP, Palmer D, Clancy-thompson E, Hammond S, Kamphorst AO, Malmberg K, Marcenaro E, Romero P, Brody R, Viard M, Yuki Y, Martin M, Carrington M, Mehrazin R, Wiklund P, Mellman I, Mariathasan S, Zhu J, Galsky MD, Bhardwaj N, Horowitz A. NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer.. [DOI: 10.1101/2022.03.04.482960] [Reference Citation Analysis]
271 Mac QD, Sivakumar A, Phuengkham H, Xu C, Bowen JR, Su FY, Stentz SZ, Sim H, Harris AM, Li TT, Qiu P, Kwong GA. Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors. Nat Biomed Eng 2022. [PMID: 35241815 DOI: 10.1038/s41551-022-00852-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
272 Ye T, Zhang JY, Liu XY, Zhou YH, Yuan SY, Yang MM, Xie WZ, Gao C, Chen YX, Huang ML, Ye CZ, Chen J. The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma. Front Immunol 2021;12:785526. [PMID: 35069558 DOI: 10.3389/fimmu.2021.785526] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
273 Zhu Y, Chang X, Zhou R, Chen Y, Ma H, Xiao Z, Qu X, Liu Y, Liu L, Li Y, Yu Y, Zhang H. Bone Metastasis Attenuates Efficacy of Immune Checkpoint Inhibitors and Displays “Cold” Immune Characteristics in Non-small Cell Lung Cancer. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
274 Zhang X, Mao T, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Ge W, Li S, Yue M, Ma J, Yao J, Wang Y, Wang Y, Shentu D, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L, Wang L. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. EBioMedicine 2022;77:103897. [PMID: 35231699 DOI: 10.1016/j.ebiom.2022.103897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
275 Bie F, Tian H, Sun N, Zang R, Zhang M, Song P, Liu L, Peng Y, Bai G, Zhou B, Gao S. Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC. Front Oncol 2022;12:769124. [PMID: 35223466 DOI: 10.3389/fonc.2022.769124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
276 Ladányi A, Rásó E, Barbai T, Vízkeleti L, Puskás LG, Kovács SA, Győrffy B, Tímár J. Identification of a Tumor Cell Associated Type I IFN Resistance Gene Expression Signature of Human Melanoma, the Components of Which Have a Predictive Potential for Immunotherapy. Int J Mol Sci 2022;23:2704. [PMID: 35269844 DOI: 10.3390/ijms23052704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
277 Schöffski P, Tan DSW, Martín M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T, Prawira A, Akerley W, De Braud F, Hui R, Zhang T, Soo RA, Maur M, Weickhardt A, Krauss J, Deschler-Baier B, Lau A, Samant TS, Longmire T, Chowdhury NR, Sabatos-Peyton CA, Patel N, Ramesh R, Hu T, Carion A, Gusenleitner D, Yerramilli-Rao P, Askoxylakis V, Kwak EL, Hong DS. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer 2022;10:e003776. [PMID: 35217575 DOI: 10.1136/jitc-2021-003776] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
278 Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer 2022;10:e003026. [PMID: 35217573 DOI: 10.1136/jitc-2021-003026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
279 Wu Z, Lu Z, Li L, Ma M, Long F, Wu R, Huang L, Chou J, Yang K, Zhang Y, Li X, Hu G, Zhang Y, Lin C. Identification and Validation of Ferroptosis-Related LncRNA Signatures as a Novel Prognostic Model for Colon Cancer. Front Immunol 2021;12:783362. [PMID: 35154072 DOI: 10.3389/fimmu.2021.783362] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
280 Wang Y, Xu Y, Chen H, Zhang J, He W. Novel insights based on the plasticity of γδ T cells in the tumor microenvironment. Explor Immunol 2022. [DOI: 10.37349/ei.2022.00039] [Reference Citation Analysis]
281 Voutsadakis IA. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies. Current Oncology 2022;29:1390-407. [DOI: 10.3390/curroncol29030117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
282 Zhou X, Ji Q, Li Q, Wang P, Hu G, Xiao F, Ye M, Lin L, Luo M, Guo Y, Wu W, Huang K, Guo H. HSPA6 is Correlated With the Malignant Progression and Immune Microenvironment of Gliomas. Front Cell Dev Biol 2022;10:833938. [DOI: 10.3389/fcell.2022.833938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
283 Roh W, Geffen Y, Miller M, Anand S, Kim J, Heiman D, Gainor JF, Laird PW, Cherniack AD, Getz G, National Cancer Institute Center for Cancer Genomics Tumor Molecular Pathology (TMP) Analysis Working Group. High-resolution lung adenocarcinoma expression subtypes identify tumors with dependencies on MET, CDK4, CDK6, and PD-L1.. [DOI: 10.1101/2022.02.20.481157] [Reference Citation Analysis]
284 Kaufman HL, Shalhout SZ, Iodice G. Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class. Front Mol Biosci 2022;9:834841. [DOI: 10.3389/fmolb.2022.834841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
285 Wolf J, Lapp T, Reinhard T, Agostini H, Schlunck G, Lange C. [Web-based gene expression analysis-paving the way to decode healthy and diseased ocular tissue]. Ophthalmologe 2022. [PMID: 35194679 DOI: 10.1007/s00347-022-01592-9] [Reference Citation Analysis]
286 Sturgill EG, Misch A, Jones CC, Luckett D, Fu X, Schlauch D, Jones SF, Burris HA, Spigel DR, Mckenzie AJ. Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings. The Oncologist 2022. [DOI: 10.1093/oncolo/oyab064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
287 Wilde DC, Castro PD, Bera K, Lai S, Madabhushi A, Corredor G, Koyuncu C, Lewis JS, Lu C, Frederick MJ, Frederick AM, Haugen AE, Zevallos JP, Sturgis EM, Shi J, Huang AT, Hernandez DJ, Skinner HD, Kemnade JO, Yu W, Sikora AG, Sandulache VC. Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration. Mod Pathol. [DOI: 10.1038/s41379-022-01024-8] [Reference Citation Analysis]
288 Wang X, Li L, Yang Y, Fan L, Ma Y, Mao F. Reveal the Heterogeneity in the Tumor Microenvironment of Pancreatic Cancer and Analyze the Differences in Prognosis and Immunotherapy Responses of Distinct Immune Subtypes. Front Oncol 2022;12:832715. [DOI: 10.3389/fonc.2022.832715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
289 Imamura T, Okamura Y, Ohshima K, Uesaka K, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Otsuka S, Ohnami S, Nagashima T, Hatakeyama K, Kakuda Y, Sugino T, Urakami K, Akiyama Y, Yamaguchi K. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation. Cancer Med 2022. [PMID: 35174643 DOI: 10.1002/cam4.4571] [Reference Citation Analysis]
290 Zhang AZ, Yuan X, Liang WH, Zhang HJ, Li Y, Xie YF, Li JF, Jiang CH, Li FP, Shen XH, Pang LJ, Zou H, Zhou WH, Li F, Hu JM. Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance. Front Cell Dev Biol 2022;9:762029. [DOI: 10.3389/fcell.2021.762029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
291 Freeman SS, Sade-Feldman M, Kim J, Stewart C, Gonye ALK, Ravi A, Arniella MB, Gushterova I, LaSalle TJ, Blaum EM, Yizhak K, Frederick DT, Sharova T, Leshchiner I, Elagina L, Spiro OG, Livitz D, Rosebrock D, Aguet F, Carrot-Zhang J, Ha G, Lin Z, Chen JH, Barzily-Rokni M, Hammond MR, Vitzthum von Eckstaedt HC, Blackmon SM, Jiao YJ, Gabriel S, Lawrence DP, Duncan LM, Stemmer-Rachamimov AO, Wargo JA, Flaherty KT, Sullivan RJ, Boland GM, Meyerson M, Getz G, Hacohen N. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Rep Med 2022;3:100500. [PMID: 35243413 DOI: 10.1016/j.xcrm.2021.100500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
292 Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer 2022;10:e004089. [PMID: 35135866 DOI: 10.1136/jitc-2021-004089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
293 Lv J, Ren J, Zheng J, Zhang F, Han M, Zhang Y. Prognosis of Tumor Microenvironment in Luminal B-Type Breast Cancer. Disease Markers 2022;2022:1-21. [DOI: 10.1155/2022/5621441] [Reference Citation Analysis]
294 Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, McDermott DF, Stephen Hodi F, Choueiri TK, Freeman GJ. Soluble PD-L1 as an early marker of progressive disease on nivolumab. J Immunother Cancer 2022;10:e003527. [PMID: 35131863 DOI: 10.1136/jitc-2021-003527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
295 Wolpaw AJ, Grossmann LD, Dessau JL, Dong MM, Aaron BJ, Brafford PA, Volgina D, Pascual-Pasto G, Rodriguez-Garcia A, Uzun Y, Arsenian-Henriksson M, Powell DJ Jr, Bosse KR, Kossenkov A, Tan K, Hogarty MD, Maris JM, Dang CV. Epigenetic state determines inflammatory sensing in neuroblastoma. Proc Natl Acad Sci U S A 2022;119:e2102358119. [PMID: 35121657 DOI: 10.1073/pnas.2102358119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
296 Costa G, Younes H, Kourie HR, Kattan J. The rapidly evolving landscape of advanced gastric cancer therapy. Future Oncol 2022. [PMID: 35129395 DOI: 10.2217/fon-2021-1499] [Reference Citation Analysis]
297 Cristescu R, Aurora-Garg D, Albright A, Xu L, Liu XQ, Loboda A, Lang L, Jin F, Rubin EH, Snyder A, Lunceford J. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer 2022;10:e003091. [PMID: 35101941 DOI: 10.1136/jitc-2021-003091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
298 Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W, Yin W, Fang W. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer 2022;10:e003133. [PMID: 35101942 DOI: 10.1136/jitc-2021-003133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
299 Zhang L, Jiang Y, Xue C, Chen H, Zhang Y. Camrelizumab for the treatment of advanced cervical adenocarcinoma: a case report and literature review. Ann Transl Med 2022;10:239. [PMID: 35280424 DOI: 10.21037/atm-22-67] [Reference Citation Analysis]
300 Robert C, Lewis K, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira R, Eigentler T, Rutkowski P, Demidov L, Caro I, Forbes H, Shah K, Yan Y, Li H, Mcarthur G, Ascierto P. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.01.076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
301 Palmeri M, Mehnert J, Silk A, Jabbour S, Ganesan S, Popli P, Riedlinger G, Stephenson R, de Meritens A, Leiser A, Mayer T, Chan N, Spencer K, Girda E, Malhotra J, Chan T, Subbiah V, Groisberg R. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open 2022;7:100336. [DOI: 10.1016/j.esmoop.2021.100336] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
302 Fischer S, Hamed M, Emmert S, Wolkenhauer O, Fuellen G, Thiem A. The Prognostic and Predictive Role of Xeroderma Pigmentosum Gene Expression in Melanoma. Front Oncol 2022;12:810058. [PMID: 35174087 DOI: 10.3389/fonc.2022.810058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
303 Weidhaas J, Marco N, Scheffler AW, Kalbasi A, Wilenius K, Rietdorf E, Gill J, Heilig M, Desler C, Chin RK, Kaprealian T, McCloskey S, Raldow A, Raja NP, Kesari S, Carrillo J, Drakaki A, Scholz M, Telesca D. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. J Immunother Cancer 2022;10. [PMID: 35115362 DOI: 10.1136/jitc-2021-003625] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
304 Ti W, Wang J, Cheng Y. The Interaction Between Long Non-Coding RNAs and Cancer-Associated Fibroblasts in Lung Cancer. Front Cell Dev Biol 2021;9:714125. [PMID: 35087824 DOI: 10.3389/fcell.2021.714125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
305 Ye Y, Zhang Y, Yang N, Gao Q, Ding X, Kuang X, Bao R, Zhang Z, Sun C, Zhou B, Wang L, Hu Q, Lin C, Gao J, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Profiling of immune features to predict immunotherapy efficacy. Innovation (N Y) 2022;3:100194. [PMID: 34977836 DOI: 10.1016/j.xinn.2021.100194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
306 Li C, Pan J, Jiang Y, Yu Y, Jin Z, Chen X. Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy. Front Genet 2021;12:793628. [PMID: 35069691 DOI: 10.3389/fgene.2021.793628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
307 Santos V, Freitas C, Fernandes MG, Sousa C, Reboredo C, Cruz-martins N, Mosquera J, Hespanhol V, Campelo R. Liquid biopsy: the value of different bodily fluids. Biomarkers in Medicine. [DOI: 10.2217/bmm-2021-0370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
308 Wang D, Peng L, Hua L, Li J, Liu Y, Zhou Y. Mapk14 is a Prognostic Biomarker and Correlates with the Clinicopathological Features and Immune Infiltration of Colorectal Cancer. Front Cell Dev Biol 2022;10:817800. [DOI: 10.3389/fcell.2022.817800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
309 Tai J, Wang L, Guo H, Yan Z, Liu J. Prognostic implications of N6-methyladenosine RNA regulators in breast cancer. Sci Rep 2022;12:1222. [PMID: 35075167 DOI: 10.1038/s41598-022-05125-x] [Reference Citation Analysis]
310 Robertson C, Sebastian A, Hinckley A, Rios-Arce ND, Hynes WF, Edwards SA, He W, Hum NR, Wheeler EK, Loots GG, Coleman MA, Moya ML. Extracellular matrix modulates T cell clearance of malignant cells in vitro. Biomaterials 2022;282:121378. [PMID: 35121359 DOI: 10.1016/j.biomaterials.2022.121378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
311 Huang Y, Huang J, Tseng L, Yu P, Chen S, Lin C. High Expression of Interferon Pathway Genes CXCL10 and STAT2 Is Associated with Activated T-Cell Signature and Better Outcome of Oral Cancer Patients. JPM 2022;12:140. [DOI: 10.3390/jpm12020140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
312 Peng Y, Song Y, Wang H. Systematic Elucidation of the Aneuploidy Landscape and Identification of Aneuploidy Driver Genes in Prostate Cancer. Front Cell Dev Biol 2022;9:723466. [DOI: 10.3389/fcell.2021.723466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Roalsø MTT, Hald ØH, Alexeeva M, Søreide K. Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma. Cancers 2022;14:546. [DOI: 10.3390/cancers14030546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
314 Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol 2022. [PMID: 35039679 DOI: 10.1038/s41571-021-00597-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
315 Singh V, Khurana A, Allawadhi P, Banothu AK, Bharani KK, Weiskirchen R. Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Front Pharmacol 2021;12:790963. [PMID: 35002724 DOI: 10.3389/fphar.2021.790963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
316 Wu CC, Wang YA, Livingston JA, Zhang J, Futreal PA. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. Nat Commun 2022;13:42. [PMID: 35013211 DOI: 10.1038/s41467-021-27651-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
317 Qi Z, Xu Z, Zhang L, Zou Y, Li J, Yan W, Li C, Liu N, Wu H. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment. Nat Commun 2022;13:182. [PMID: 35013322 DOI: 10.1038/s41467-021-27833-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
318 Robert C, Gautheret D. Multi-omics prediction in melanoma immunotherapy: A new brick in the wall. Cancer Cell 2022;40:14-6. [PMID: 35016026 DOI: 10.1016/j.ccell.2021.12.008] [Reference Citation Analysis]
319 Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC, Kang TW, Rhim H, Lee SJ, Cristescu R, Lee J, Paik YH, Lim HY. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med 2022;14:1. [PMID: 34986867 DOI: 10.1186/s13073-021-00995-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
320 Kuang C, Park Y, Augustin RC, Lin Y, Hartman DJ, Seigh L, Pai RK, Sun W, Bahary N, Ohr J, Rhee JC, Marks SM, Beasley HS, Shuai Y, Herman JG, Zarour HM, Chu E, Lee JJ, Krishnamurthy A. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. Clin Epigenetics 2022;14:3. [PMID: 34991708 DOI: 10.1186/s13148-021-01226-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
321 Jiang Y, Lin L, Lv H, Zhang H, Jiang L, Ma F, Wang Q, Ma X, Yu S. . MBE 2022;19:7178-200. [DOI: 10.3934/mbe.2022339] [Reference Citation Analysis]
322 Anisman H, Kusnecov AW. Immunotherapies and their moderation. Cancer 2022. [DOI: 10.1016/b978-0-323-91904-3.00006-9] [Reference Citation Analysis]
323 Kirtane K, Chung CH. Development of Predictive Biomarkers to Immunotherapy in Head and Neck Cancer. Cancer Immunotherapy 2022. [DOI: 10.1007/13905_2022_34] [Reference Citation Analysis]
324 den bossche VV, Zaryouh H, Vara-messler M, Vignau J, Machiels J, Wouters A, Schmitz S, Corbet C. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. Drug Resistance Updates 2022. [DOI: 10.1016/j.drup.2022.100806] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
325 Kumar A, Weller KP, Vilgelm AE. Personalized cancer immunotherapy. Engineering Technologies and Clinical Translation 2022. [DOI: 10.1016/b978-0-323-90949-5.00012-7] [Reference Citation Analysis]
326 Liu G, Bolkov MA, Shinwari K, Tuzankina IA, Chereshnev VA. Prognostic and immunotherapeutic significance of tumor- infiltrating M2 macrophages in muscle-invasive bladder cancer. AIP Conference Proceedings 2022. [DOI: 10.1063/5.0069183] [Reference Citation Analysis]
327 Wu X, Jiang D, Liu H, Lu X, Lv D, Liang L. CD8+ T Cell-Based Molecular Classification With Heterogeneous Immunogenomic Landscapes and Clinical Significance of Clear Cell Renal Cell Carcinoma. Front Immunol 2021;12:745945. [PMID: 34970257 DOI: 10.3389/fimmu.2021.745945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
328 Wai K, Kang H. Epidemiology and Genomics of Head and Neck Squamous Cell Carcinoma. Multidisciplinary Management of Head and Neck Cancer 2022. [DOI: 10.1007/978-3-031-05973-5_8] [Reference Citation Analysis]
329 Mir MA, Aisha S, Nisar S, Qayoom H, Mehraj U. Immuno-onco-metabolism and Therapeutic Resistance. Immuno-Oncology Crosstalk and Metabolism 2022. [DOI: 10.1007/978-981-16-6226-3_3] [Reference Citation Analysis]
330 Stefanou DT, Souliotis VL, Zakopoulou R, Liontos M, Bamias A. DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer? Biomedicines 2022;10:82. [DOI: 10.3390/biomedicines10010082] [Reference Citation Analysis]
331 Tanaka I, Morise M. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations. Int J Mol Sci 2021;23:245. [PMID: 35008669 DOI: 10.3390/ijms23010245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
332 Tan AT, Bertoletti A. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunotherapy Advances 2022;2:ltab026. [DOI: 10.1093/immadv/ltab026] [Reference Citation Analysis]
333 Westaby D, Jimenez-Vacas JM, Padilha A, Varkaris A, Balk SP, de Bono JS, Sharp A. Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. Cancers (Basel) 2021;14:51. [PMID: 35008216 DOI: 10.3390/cancers14010051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
334 Brandish PE, Palmieri A, Ayanoglu G, Baker J, Bueno R, Byford A, Caniga M, Chappell C, Cherwinski H, Cua DJ, Du X, Fayadat-dilman L, Hall BE, Issafras H, Joyce-shaikh B, Juan V, Levy RD, Loboda A, Lunceford J, Mieczkowski C, Meehl M, Qu Y, Rosenzweig M, Singh L, Stivers P, Tramontozzi PJ, Vermilya K, Vroom K, Wilson DC, Zhang C, Zhang-hoover J. Antibodies to ILT3 abrogate myeloid immunosuppression and enable tumor killing.. [DOI: 10.1101/2021.12.18.472552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
335 Williamson LM, Rive CM, Di Francesco D, Titmuss E, Chun HE, Brown SD, Milne K, Pleasance E, Lee AF, Yip S, Rosenbaum DG, Hasselblatt M, Johann PD, Kool M, Harvey M, Dix D, Renouf DJ, Holt RA, Nelson BH, Hirst M, Jones SJM, Laskin J, Rassekh SR, Deyell RJ, Marra MA. Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury. npj Precis Onc 2021;5. [DOI: 10.1038/s41698-021-00238-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
336 Zhai Y, Ma Y, Pang B, Zhang J, Li Y, Rui Y, Xu T, Zhao Y, Qian Z, Gu Y, Li S. A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy. J Nanobiotechnology 2021;19:434. [PMID: 34930285 DOI: 10.1186/s12951-021-01193-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
337 Takada K, Takamori S, Shimokawa M, Toyokawa G, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy. ESMO Open 2021;7:100348. [PMID: 34942439 DOI: 10.1016/j.esmoop.2021.100348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
338 Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther 2021;6:424. [PMID: 34924562 DOI: 10.1038/s41392-021-00827-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
339 Zhang M, Zhang YY, Chen Y, Wang J, Wang Q, Lu H. TGF-β Signaling and Resistance to Cancer Therapy. Front Cell Dev Biol 2021;9:786728. [PMID: 34917620 DOI: 10.3389/fcell.2021.786728] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
340 Baltussen JC, Welters MJP, Verdegaal EME, Kapiteijn E, Schrader AMR, Slingerland M, Liefers G, van der Burg SH, Portielje JEA, de Glas NA. Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. Cancers 2021;13:6366. [DOI: 10.3390/cancers13246366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
341 Yang S, Cheng Y, Wang X, Wei P, Wang H, Tan S. Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy. Front Genet 2021;12:777931. [PMID: 34899862 DOI: 10.3389/fgene.2021.777931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
342 Goulart MR, Stasinos K, Fincham REA, Delvecchio FR, Kocher HM. T cells in pancreatic cancer stroma. World J Gastroenterol 2021; 27(46): 7956-7968 [DOI: 10.3748/wjg.v27.i46.7956] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
343 Leader AM, Grout JA, Maier BB, Nabet BY, Park MD, Tabachnikova A, Chang C, Walker L, Lansky A, Le Berichel J, Troncoso L, Malissen N, Davila M, Martin JC, Magri G, Tuballes K, Zhao Z, Petralia F, Samstein R, D'Amore NR, Thurston G, Kamphorst AO, Wolf A, Flores R, Wang P, Müller S, Mellman I, Beasley MB, Salmon H, Rahman AH, Marron TU, Kenigsberg E, Merad M. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 2021;39:1594-1609.e12. [PMID: 34767762 DOI: 10.1016/j.ccell.2021.10.009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 27.0] [Reference Citation Analysis]
344 Pullikuth AK, Routh ED, Zimmerman KD, Chifman J, Chou JW, Soike MH, Jin G, Su J, Song Q, Black MA, Print C, Bedognetti D, Howard-mcnatt M, O’neill SS, Thomas A, Langefeld CD, Sigalov AB, Lu Y, Miller LD. Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes. Front Oncol 2021;11:734959. [DOI: 10.3389/fonc.2021.734959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
345 Zheng X, Liu Z, Mi M, Wen Q, Wu G, Zhang L. Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer. Front Oncol 2021;11:734853. [PMID: 34858816 DOI: 10.3389/fonc.2021.734853] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
346 Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RP, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell 2021. [DOI: 10.1016/j.ccell.2021.11.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
347 Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, Yuan J, Zhao W, Ling X, Burks JK, Laffleur B, Amidei C, Bruce JN, Lukas RV, Yamaguchi JT, Cieremans D, Rothschild G, Basu U, McCord M, Brat DJ, Zhang H, Cooper LAD, Zhang B, Sims P, Cloughesy TF, Prins R, Canoll P, Stupp R, Heimberger AB, Horbinski C, Iwamoto FM, Rabadan R, Sonabend AM. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer 2021;2:1372-86. [PMID: 35121903 DOI: 10.1038/s43018-021-00260-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
348 Marzio A, Kurz E, Sahni JM, Di Feo G, Puccini J, Jiang S, Hirsch CA, Arbini AA, Wu WL, Pass HI, Bar-sagi D, Papagiannakopoulos T, Pagano M. EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion. Cell 2021. [DOI: 10.1016/j.cell.2021.12.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
349 Wu J, Li C, Gensheimer M, Padda S, Kato F, Shirato H, Wei Y, Schönlieb CB, Price SJ, Jaffray D, Heymach J, Neal JW, Loo BW Jr, Wakelee H, Diehn M, Li R. Radiological tumor classification across imaging modality and histology. Nat Mach Intell 2021;3:787-98. [PMID: 34841195 DOI: 10.1038/s42256-021-00377-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
350 Machiraju D, Schäfer S, Hassel JC. Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma. Life (Basel) 2021;11:1318. [PMID: 34947849 DOI: 10.3390/life11121318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
351 Ledys F, Kalfeist L, Galland L, Limagne E, Ladoire S. Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. Cancers (Basel) 2021;13:5999. [PMID: 34885109 DOI: 10.3390/cancers13235999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
352 Jiang J, Ding Y, Chen Y, Lu J, Chen Y, Wu G, Xu N, Wang H, Teng L. Pan-cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors. Cancer Med 2021. [PMID: 34841742 DOI: 10.1002/cam4.4456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
353 Zhang X, Mao T, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Li S, Yue M, Ma J, Yao J, Wang Y, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L, Wang L. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Cancer Commun (Lond) 2021. [PMID: 34821074 DOI: 10.1002/cac2.12238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
354 Zhang Y, Gao C, Cao F, Wu Y, Chen S, Han X, Mo J, Qiu Z, Fan W, Zhou P, Shen L. Pan-Cancer Analysis of IGF-1 and IGF-1R as Potential Prognostic Biomarkers and Immunotherapy Targets. Front Oncol 2021;11:755341. [PMID: 34804946 DOI: 10.3389/fonc.2021.755341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
355 Golota AS. HLA AND CANCER. Physical and rehabilitation medicine, medical rehabilitation 2021. [DOI: 10.36425/rehab79387] [Reference Citation Analysis]
356 Huang C, Yang X. [Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:777-83. [PMID: 34802209 DOI: 10.3779/j.issn.1009-3419.2021.102.40] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
357 Porter RL, Matulonis UA. Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer. J Clin Oncol 2021;39:3651-5. [PMID: 34529504 DOI: 10.1200/JCO.21.01886] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
358 Ding H, Chen Z, Wu K, Huang SM, Wu WL, LeBoeuf SE, Pillai RG, Rabinowitz JD, Papagiannakopoulos T. Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition. Sci Adv 2021;7:eabk1023. [PMID: 34788087 DOI: 10.1126/sciadv.abk1023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
359 Kamakura D, Asano R, Yasunaga M. T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals (Basel) 2021;14:1172. [PMID: 34832954 DOI: 10.3390/ph14111172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
360 Wu H, Zhu JQ, Xu XF, Xing H, Wang MD, Liang L, Li C, Jia HD, Shen F, Huang DS, Yang T. Biointerfacing Antagonizing T-Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy. Small 2021;:e2105237. [PMID: 34791793 DOI: 10.1002/smll.202105237] [Reference Citation Analysis]
361 Liu J, Chen C, Wang Y, Qian C, Wei J, Xing Y, Bai J. Comprehensive of N1-Methyladenosine Modifications Patterns and Immunological Characteristics in Ovarian Cancer. Front Immunol 2021;12:746647. [PMID: 34777359 DOI: 10.3389/fimmu.2021.746647] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
362 Zhou C, Wang S, Shen Z, Shen Y, Li Q, Shen Y, Huang J, Deng H, Ye D, Zhan G, Li J. Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma. J Clin Lab Anal 2021;:e24113. [PMID: 34783061 DOI: 10.1002/jcla.24113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
363 Lee D, Kim NW, Kim JY, Lee JH, Noh JH, Lee H, Jeong JW, Lee S, Kang J. Sarcopenia's Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:5329. [PMID: 34830611 DOI: 10.3390/jcm10225329] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
364 Burcher KM, Lantz JW, Gavrila E, Abreu A, Burcher JT, Faucheux AT, Xie A, Jackson C, Song AH, Hughes RT, Lycan T Jr, Bunch PM, Furdui CM, Topaloglu U, D'Agostino RB Jr, Zhang W, Porosnicu M. Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5733. [PMID: 34830888 DOI: 10.3390/cancers13225733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
365 Yan Y, Zheng L, Du Q, Geller DA. Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC). Oncotarget 2021;12:2316-7. [PMID: 34786183 DOI: 10.18632/oncotarget.27995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
366 Wen XM, Xu ZJ, Jin Y, Xia PH, Ma JC, Qian W, Lin J, Qian J. Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia. Front Immunol 2021;12:717527. [PMID: 34745095 DOI: 10.3389/fimmu.2021.717527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
367 Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol 2021. [PMID: 34754128 DOI: 10.1038/s41571-021-00565-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 81] [Article Influence: 33.5] [Reference Citation Analysis]
368 Meng J, Huang X, Qiu Y, Zheng X, Huang J, Wen Z, Yao J. Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy. Aging (Albany NY) 2021;13:24379-401. [PMID: 34753832 DOI: 10.18632/aging.203687] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
369 Liu J, Wang Y, Yuan S, Wei J, Bai J. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients. Front Immunol 2021;12:751594. [PMID: 34745124 DOI: 10.3389/fimmu.2021.751594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
370 Tang X, Liu M, Luo X, Zhu M, Huang S, Pan X. The Prognostic Value of a Tumor Microenvironment-Based Immune Cell Infiltration Score Model in Colon Cancer. Front Oncol 2021;11:728842. [PMID: 34737949 DOI: 10.3389/fonc.2021.728842] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
371 Jarvis EM, Collings S, Authier-Hall A, Dasyam N, Luey B, Nacey J, Painter GF, Delahunt B, Hermans IF, Weinkove R. Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy. Front Immunol 2021;12:748741. [PMID: 34737749 DOI: 10.3389/fimmu.2021.748741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
372 Su S, Lin A, Luo P, Zou J, Huang Z, Wang X, Zeng Y, Cen W, Zhang X, Huang H, Hu J, Zhang J. Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. Ann Transl Med 2021;9:1475. [PMID: 34734027 DOI: 10.21037/atm-21-4543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
373 Zhang H, Sang S, Xu H, Piao L, Liu X. Lovastatin suppresses bacterial therapy-induced neutrophil recruitment to the tumor by promoting neutrophil apoptosis. Journal of Functional Foods 2021;86:104693. [DOI: 10.1016/j.jff.2021.104693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
374 Roudi R, D'Angelo A, Sirico M, Sobhani N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int Immunopharmacol 2021;101:108322. [PMID: 34735916 DOI: 10.1016/j.intimp.2021.108322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
375 Dousset L, Poizeau F, Robert C, Mansard S, Mortier L, Caumont C, Routier É, Dupuy A, Rouanet J, Battistella M, Greliak A, Cappellen D, Galibert M, Allayous C, Lespagnol A, Gerard É, Kerneuzet I, Roy S, Dutriaux C, Merlio J, Vergier B, Schrock AB, Lee J, Ali SM, Kammerer-jacquet S, Lebbé C, Beylot-barry M, Boussemart L. Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy. JCO Precision Oncology 2021. [DOI: 10.1200/po.21.00084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
376 Xu Q, Chen S, Hu Y, Huang W. Clinical M2 macrophages-related genes to aid therapy in pancreatic ductal adenocarcinoma. Cancer Cell Int 2021;21:582. [PMID: 34717651 DOI: 10.1186/s12935-021-02289-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
377 Liu SM, Sun H, Zhou JY, Zhang JT, Yin K, Chen ZH, Su J, Zhang XC, Yang JJ, Zhou Q, Tu HY, Wu YL. Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score. Transl Oncol 2022;15:101254. [PMID: 34715621 DOI: 10.1016/j.tranon.2021.101254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
378 Horton BL, Morgan DM, Momin N, Zagorulya M, Torres-Mejia E, Bhandarkar V, Wittrup KD, Love JC, Spranger S. Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Sci Immunol 2021;6:eabi8800. [PMID: 34714687 DOI: 10.1126/sciimmunol.abi8800] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
379 Zhai W, Lai H, Kaya NA, Chen J, Yang H, Lu B, Lim JQ, Ma S, Chew SC, Chua KP, Alvarez JJS, Chen PJ, Chang MM, Wu L, Goh BKP, Chung AY, Chan CY, Cheow PC, Lee SY, Kam JH, Kow AW, Ganpathi IS, Chanwat R, Thammasiri J, Yoong BK, Ong DB, de Villa VH, Dela Cruz RD, Loh TJ, Wan WK, Zeng Z, Skanderup AJ, Pang YH, Madhavan K, Lim TK, Bonney G, Leow WQ, Chew V, Dan YY, Tam WL, Toh HC, Foo RS, Chow PK. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. Natl Sci Rev 2022;9:nwab192. [PMID: 35382356 DOI: 10.1093/nsr/nwab192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
380 McGrail DJ, Pilié PG, Dai H, Lam TNA, Liang Y, Voorwerk L, Kok M, Zhang XH, Rosen JM, Heimberger AB, Peterson CB, Jonasch E, Lin SY. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci Transl Med 2021;13:eabe6201. [PMID: 34705519 DOI: 10.1126/scitranslmed.abe6201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
381 Hu-Lieskovan S, Braiteh F, Grilley-Olson JE, Wang X, Forgie A, Bonato V, Jacobs IA, Chou J, Johnson ML. Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration. Target Oncol 2021;16:773-87. [PMID: 34694529 DOI: 10.1007/s11523-021-00833-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
382 Li Y, Luo Y. Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation. Sci Rep 2021;11:21072. [PMID: 34702927 DOI: 10.1038/s41598-021-00626-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
383 Steiniche T, Rha SY, Chung HC, Georgsen JB, Ladekarl M, Nordsmark M, Jespersen ML, Kim HS, Kim H, Fein C, Tang LH, Wu T, Marton MJ, Peter S, Kelsen DP, Ku G. Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer. Cancer Med 2021. [PMID: 34693652 DOI: 10.1002/cam4.4333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
384 Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci 2021;17:3837-49. [PMID: 34671202 DOI: 10.7150/ijbs.64077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
385 Zhou W, Zhou Y, Yi C, Shu X, Wei G, Chen X, Shen X, Qiu M. Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody. Front Immunol 2021;12:749204. [PMID: 34659249 DOI: 10.3389/fimmu.2021.749204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
386 Li Y, Ma Y, Wu Z, Zeng F, Song B, Zhang Y, Li J, Lui S, Wu M. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:751407. [PMID: 34659255 DOI: 10.3389/fimmu.2021.751407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
387 Kalloger SE, Karasinska JM, Warren C, Renouf DJ, Schaeffer DF. Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue. Biomark Insights 2021;16:11772719211049852. [PMID: 34658620 DOI: 10.1177/11772719211049852] [Reference Citation Analysis]
388 Jin X, Yan J, Chen C, Chen Y, Huang WK. Integrated Analysis of Copy Number Variation, Microsatellite Instability, and Tumor Mutation Burden Identifies an 11-Gene Signature Predicting Survival in Breast Cancer. Front Cell Dev Biol 2021;9:721505. [PMID: 34650974 DOI: 10.3389/fcell.2021.721505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
389 Du K, Wei S, Wei Z, Frederick DT, Miao B, Moll T, Tian T, Sugarman E, Gabrilovich DI, Sullivan RJ, Liu L, Flaherty KT, Boland GM, Herlyn M, Zhang G. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nat Commun 2021;12:6023. [PMID: 34654806 DOI: 10.1038/s41467-021-26299-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
390 Luca BA, Steen CB, Matusiak M, Azizi A, Varma S, Zhu C, Przybyl J, Espín-Pérez A, Diehn M, Alizadeh AA, van de Rijn M, Gentles AJ, Newman AM. Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell 2021;184:5482-5496.e28. [PMID: 34597583 DOI: 10.1016/j.cell.2021.09.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
391 Roudko V, Cimen Bozkus C, Greenbaum B, Lucas A, Samstein R, Bhardwaj N. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. Front Immunol 2021;12:757804. [PMID: 34630437 DOI: 10.3389/fimmu.2021.757804] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
392 Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C. Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Front Oncol 2021;11:756365. [PMID: 34631593 DOI: 10.3389/fonc.2021.756365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
393 Bronger H. Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects. Geburtshilfe Frauenheilkd 2021;81:1128-44. [PMID: 34629492 DOI: 10.1055/a-1475-4335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
394 Yang C, Zhang Z, Tang X, Zhang X, Chen Y, Hu T, Zhang H, Guan M, Zhang X, Wu Z. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders. Hum Cell 2021. [PMID: 34628623 DOI: 10.1007/s13577-021-00630-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
395 Meng L, Xu J, Ye Y, Wang Y, Luo S, Gong X. The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients. Front Immunol 2021;12:723609. [PMID: 34621270 DOI: 10.3389/fimmu.2021.723609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
396 Hernando-Calvo A, Cescon DW, Bedard PL. Novel classes of immunotherapy for breast cancer. Breast Cancer Res Treat 2021. [PMID: 34623509 DOI: 10.1007/s10549-021-06405-2] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
397 Brasó-Maristany F, Sansó M, Chic N, Martínez D, González-Farré B, Sanfeliu E, Ghiglione L, Carcelero E, Garcia-Corbacho J, Sánchez M, Soy D, Jares P, Peg V, Saura C, Muñoz M, Prat A, Vivancos A. Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. Front Oncol 2021;11:710596. [PMID: 34616675 DOI: 10.3389/fonc.2021.710596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
398 Chen Z, Chen C, Li L, Zhang T, Wang X. Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity. Front Cell Dev Biol 2021;9:729927. [PMID: 34616736 DOI: 10.3389/fcell.2021.729927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
399 Wu W, Liu Y, Zeng S, Han Y, Shen H. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes. J Hematol Oncol 2021;14:160. [PMID: 34620200 DOI: 10.1186/s13045-021-01166-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
400 Hwang HS, Kim D, Choi J. Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors. J Immunother Cancer 2021;9:e002797. [PMID: 34607897 DOI: 10.1136/jitc-2021-002797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
401 Zeng Z, Jiang X, Pan Z, Zhou R, Lin Z, Tang Y, Cui Y, Zhang E, Cao Z. Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma. Aging (Albany NY) 2021;13:22802-29. [PMID: 34607313 DOI: 10.18632/aging.203574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
402 Takamatsu S, Hamanishi J, Brown J, Yamaguchi K, Yamanoi K, Murakami K, Gotoh O, Mori S, Mandai M, Matsumura N. Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.. [DOI: 10.1101/2021.10.03.21264330] [Reference Citation Analysis]
403 Wang Z, Ran L, Chen C, Shi R, Dong Y, Li Y, Zhou X, Qi Y, Zhu P, Gao Y, Wu Y. Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma. Vaccines (Basel) 2021;9:1118. [PMID: 34696226 DOI: 10.3390/vaccines9101118] [Reference Citation Analysis]
404 Xu Q, Chen S, Hu Y, Huang W. Prognostic Role of ceRNA Network in Immune Infiltration of Hepatocellular Carcinoma. Front Genet 2021;12:739975. [PMID: 34589117 DOI: 10.3389/fgene.2021.739975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
405 Chen HZ, Bonneville R, Paruchuri A, Reeser JW, Wing MR, Samorodnitsky E, Krook MA, Smith AM, Dao T, Miya J, Wang W, Yu L, Freud AG, Allenby P, Cole S, Otterson G, Shields P, Carbone DP, Roychowdhury S. Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy. JTO Clin Res Rep 2021;2:100164. [PMID: 34590014 DOI: 10.1016/j.jtocrr.2021.100164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
406 Chen X, Chen H, Yao H, Zhao K, Zhang Y, He D, Zhu Y, Cheng Y, Liu R, Xu R, Cao K. Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer. Oncogene 2021;40:6381-93. [PMID: 34588621 DOI: 10.1038/s41388-021-02024-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 11.5] [Reference Citation Analysis]
407 Kinoshita T, Terai H, Yaguchi T. Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. Life (Basel) 2021;11:1029. [PMID: 34685400 DOI: 10.3390/life11101029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
408 Lu Y, Jin J, Du Q, Hu M, Wei Y, Wang M, Li H, Li Q. Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib. Front Cell Dev Biol 2021;9:730240. [PMID: 34568339 DOI: 10.3389/fcell.2021.730240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
409 Zhang A, Zhong G, Wang L, Cai R, Han R, Xu C, Chen S, Sun P, Chen H. Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma. Cancer Cell Int 2021;21:518. [PMID: 34583688 DOI: 10.1186/s12935-021-02217-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
410 Shibata H, Saito S, Uppaluri R. Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. Front Oncol 2021;11:727433. [PMID: 34552878 DOI: 10.3389/fonc.2021.727433] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
411 Zhang R, Wan Y, Lv H, Li F, Lee CS. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy. J Mater Chem B 2021;9:7544-56. [PMID: 34551052 DOI: 10.1039/d1tb00269d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
412 Hijazo-Pechero S, Alay A, Marín R, Vilariño N, Muñoz-Pinedo C, Villanueva A, Santamaría D, Nadal E, Solé X. Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:4734. [PMID: 34638221 DOI: 10.3390/cancers13194734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
413 Winkler C, King M, Berthe J, Ferraioli D, Garuti A, Grillo F, Rodriguez-Canales J, Ferrando L, Chopin N, Ray-Coquard I, Delpuech O, Rinchai D, Bedognetti D, Ballestrero A, Leo E, Zoppoli G. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer. JCI Insight 2021;6:e146098. [PMID: 34549724 DOI: 10.1172/jci.insight.146098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
414 Yu S, Li X, Zhang J, Wu S. Development of a Novel Immune Infiltration-Based Gene Signature to Predict Prognosis and Immunotherapy Response of Patients With Cervical Cancer. Front Immunol 2021;12:709493. [PMID: 34539641 DOI: 10.3389/fimmu.2021.709493] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
415 Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun 2021;12:5563. [PMID: 34548479 DOI: 10.1038/s41467-021-25769-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
416 Mahadik N, Bhattacharya D, Padmanabhan A, Sakhare K, Narayan KP, Banerjee R. Targeting steroid hormone receptors for anti-cancer therapy-A review on small molecules and nanotherapeutic approaches. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1755. [PMID: 34541822 DOI: 10.1002/wnan.1755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
417 Zheng C, Sun L, Zhou B, Wang A. Identification and validation of a metabolism-related model and associated with tumor-infiltrating lymphocytes in p53 mutant lung adenocarcinoma patients. Ann Transl Med 2021;9:1312. [PMID: 34532449 DOI: 10.21037/atm-21-3234] [Reference Citation Analysis]
418 Shu C, Jin R, Niu Q, Cicka D, Doyle S, Wahafu A, Fan D, Zheng X, Du Y, Ivanov AA, Doxie DB, Dhodapkar KM, Carlisle J, Owonikoko T, Ramalingam S, Sica G, Dhodapkar MV, Zhou W, Mo X, Fu H. Pharmacological rescue of tumor intrinsic STING expression and immune response in LKB1-mutant lung cancer via the IAP-JAK regulatory axis.. [DOI: 10.1101/2021.09.17.460294] [Reference Citation Analysis]
419 Xu Q, Chen S, Hu Y, Huang W. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer. Front Immunol 2021;12:711433. [PMID: 34512634 DOI: 10.3389/fimmu.2021.711433] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
420 Tan GF, Chan JY. Towards precision oncology in angiosarcomas using next generation "omic" technologies. Oncotarget 2021;12:1953-5. [PMID: 34548911 DOI: 10.18632/oncotarget.27996] [Reference Citation Analysis]
421 Cimen Bozkus C, Bhardwaj N. Tumor organoid-originated biomarkers predict immune response to PD-1 blockade. Cancer Cell 2021;39:1187-9. [PMID: 34478641 DOI: 10.1016/j.ccell.2021.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
422 Bruce WJ, Koljonen JL, Romanelli MR, Khan AU, Neumeister MW. Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma. Clin Plast Surg 2021;48:651-8. [PMID: 34503725 DOI: 10.1016/j.cps.2021.06.001] [Reference Citation Analysis]
423 Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet 2021;398:1002-14. [PMID: 34509219 DOI: 10.1016/S0140-6736(21)01206-X] [Cited by in Crossref: 90] [Cited by in F6Publishing: 70] [Article Influence: 45.0] [Reference Citation Analysis]
424 Di Federico A, De Giglio A, Parisi C, Gelsomino F. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? Eur J Cancer 2021;157:108-13. [PMID: 34500370 DOI: 10.1016/j.ejca.2021.08.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
425 Wu J, Zeng D, Zhi S, Ye Z, Qiu W, Huang N, Sun L, Wang C, Wu Z, Bin J, Liao Y, Shi M, Liao W. Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response. J Transl Med 2021;19:381. [PMID: 34496872 DOI: 10.1186/s12967-021-03053-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
426 Lu Z, Chen H, Jiao X, Zhou W, Han W, Li S, Liu C, Gong J, Li J, Zhang X, Wang X, Peng Z, Qi C, Wang Z, Li Y, Li J, Li Y, Brock M, Zhang H, Shen L. Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. J Immunother Cancer 2020;8:e000631. [PMID: 32792359 DOI: 10.1136/jitc-2020-000631] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
427 Lu Z, Chen H, Li S, Gong J, Li J, Zou J, Wu L, Yu J, Han W, Sun H, Jiao X, Zhang X, Peng Z, Lu M, Wang Z, Zhang H, Shen L. Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. J Immunother Cancer 2020;8:e000374. [PMID: 32792358 DOI: 10.1136/jitc-2019-000374] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
428 McAuliffe J, Chan HF, Noblecourt L, Ramirez-Valdez RA, Pereira-Almeida V, Zhou Y, Pollock E, Cappuccini F, Redchenko I, Hill AV, Leung CSK, Van den Eynde BJ. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. J Immunother Cancer 2021;9:e003218. [PMID: 34479921 DOI: 10.1136/jitc-2021-003218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
429 Hu X, Zhu H, Zhang X, He X, Xu X. Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker. Cancer Med 2021;10:6897-916. [PMID: 34472711 DOI: 10.1002/cam4.4203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
430 Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). J Clin Oncol 2021;:JCO2100334. [PMID: 34473544 DOI: 10.1200/JCO.21.00334] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 11.5] [Reference Citation Analysis]
431 Pelka K, Hofree M, Chen JH, Sarkizova S, Pirl JD, Jorgji V, Bejnood A, Dionne D, Ge WH, Xu KH, Chao SX, Zollinger DR, Lieb DJ, Reeves JW, Fuhrman CA, Hoang ML, Delorey T, Nguyen LT, Waldman J, Klapholz M, Wakiro I, Cohen O, Albers J, Smillie CS, Cuoco MS, Wu J, Su MJ, Yeung J, Vijaykumar B, Magnuson AM, Asinovski N, Moll T, Goder-Reiser MN, Applebaum AS, Brais LK, DelloStritto LK, Denning SL, Phillips ST, Hill EK, Meehan JK, Frederick DT, Sharova T, Kanodia A, Todres EZ, Jané-Valbuena J, Biton M, Izar B, Lambden CD, Clancy TE, Bleday R, Melnitchouk N, Irani J, Kunitake H, Berger DL, Srivastava A, Hornick JL, Ogino S, Rotem A, Vigneau S, Johnson BE, Corcoran RB, Sharpe AH, Kuchroo VK, Ng K, Giannakis M, Nieman LT, Boland GM, Aguirre AJ, Anderson AC, Rozenblatt-Rosen O, Regev A, Hacohen N. Spatially organized multicellular immune hubs in human colorectal cancer. Cell 2021;184:4734-4752.e20. [PMID: 34450029 DOI: 10.1016/j.cell.2021.08.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 65] [Article Influence: 28.0] [Reference Citation Analysis]
432 Mazilu L, Suceveanu AI, Stanculeanu DL, Gheorghe AD, Fricatel G, Negru SM. Tumor microenvironment is not an 'innocent bystander' in the resistance to treatment of head and neck cancers (Review). Exp Ther Med 2021;22:1128. [PMID: 34466142 DOI: 10.3892/etm.2021.10562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
433 Bentham R, Litchfield K, Watkins TBK, Lim EL, Rosenthal R, Martínez-Ruiz C, Hiley CT, Bakir MA, Salgado R, Moore DA, Jamal-Hanjani M, Swanton C, McGranahan N; TRACERx Consortium. Using DNA sequencing data to quantify T cell fraction and therapy response. Nature 2021;597:555-60. [PMID: 34497419 DOI: 10.1038/s41586-021-03894-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
434 Merino DM, McShane LM, Fabrizio D, Funari V, Chen SJ, White JR, Wenz P, Baden J, Barrett JC, Chaudhary R, Chen L, Chen WS, Cheng JH, Cyanam D, Dickey JS, Gupta V, Hellmann M, Helman E, Li Y, Maas J, Papin A, Patidar R, Quinn KJ, Rizvi N, Tae H, Ward C, Xie M, Zehir A, Zhao C, Dietel M, Stenzinger A, Stewart M, Allen J; TMB Harmonization Consortium. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer 2020;8:e000147. [PMID: 32217756 DOI: 10.1136/jitc-2019-000147] [Cited by in Crossref: 164] [Cited by in F6Publishing: 178] [Article Influence: 82.0] [Reference Citation Analysis]
435 Nie RC, Chen GM, Wang Y, Yuan SQ, Zhou J, Duan JL, Liu WW, Chen S, Cai MY, Li YF. Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data. J Immunother 2021;44:371-5. [PMID: 34456293 DOI: 10.1097/CJI.0000000000000389] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
436 DiNatale RG, Hakimi AA, Chan TA. Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. Hum Mol Genet 2020;29:R214-25. [PMID: 33029628 DOI: 10.1093/hmg/ddaa203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
437 Roskoski R Jr. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. Pharmacol Res 2021;172:105806. [PMID: 34450320 DOI: 10.1016/j.phrs.2021.105806] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
438 Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Aleshin A, Haibe-Kains B, Brooks DG, McGaha TL, Butler MO, Bratman SV, Ohashi PS, Siu LL, Pugh TJ. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat Commun 2021;12:5137. [PMID: 34446728 DOI: 10.1038/s41467-021-25432-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
439 Westcott PMK, Muyas F, Smith O, Hauck H, Sacks NJ, Ely ZA, Jaeger AM, Rideout WM, Bhutkar A, Zhang D, Beytagh MC, Canner DA, Bronson RT, Naranjo S, Jin A, Patten J, Cruz AM, Cortes-ciriano I, Jacks T. Mismatch repair deficiency is not sufficient to increase tumor immunogenicity.. [DOI: 10.1101/2021.08.24.457572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
440 Erbe R, Wang Z, Wu S, Xiu J, Zaidi N, La J, Tuck D, Fillmore N, Giraldo NA, Topper M, Baylin S, Lippman M, Isaacs C, Basho R, Serebriiskii I, Lenz HJ, Astsaturov I, Marshall J, Taverna J, Lee J, Jaffee EM, Roussos Torres ET, Weeraratna A, Easwaran H, Fertig EJ. Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Rep 2021;36:109599. [PMID: 34433020 DOI: 10.1016/j.celrep.2021.109599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
441 Wang J, Tang C, Liu X. Development of an Individualized Immune Prognostic Signature for Clear Cell Renal Cell Carcinoma through the Identification of Differential Immune Genes. J Oncol 2021;2021:9587084. [PMID: 34422053 DOI: 10.1155/2021/9587084] [Reference Citation Analysis]
442 Tunali I, Tan Y, Gray JE, Katsoulakis E, Eschrich SA, Saller J, Aerts HJWL, Boyle T, Qi J, Guvenis A, Gillies RJ, Schabath MB. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. JNCI Cancer Spectr 2021;5:pkab048. [PMID: 34409252 DOI: 10.1093/jncics/pkab048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
443 Puccini A, Battaglin F, Iaia ML, Lenz HJ, Salem ME. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. J Immunother Cancer 2020;8:e000404. [PMID: 32393474 DOI: 10.1136/jitc-2019-000404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
444 Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021;27:1345-56. [PMID: 34385702 DOI: 10.1038/s41591-021-01450-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 36.5] [Reference Citation Analysis]
445 Zeng D, Wu J, Luo H, Li Y, Xiao J, Peng J, Ye Z, Zhou R, Yu Y, Wang G, Huang N, Wu J, Rong X, Sun L, Sun H, Qiu W, Xue Y, Bin J, Liao Y, Li N, Shi M, Kim KM, Liao W. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J Immunother Cancer 2021;9:e002467. [PMID: 34376552 DOI: 10.1136/jitc-2021-002467] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
446 Kim CG, Sang YB, Lee JH, Chon HJ. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. Int J Mol Sci 2021;22:8035. [PMID: 34360800 DOI: 10.3390/ijms22158035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
447 Wu D, Wei C, Li Y, Yang X, Zhou S. Pyroptosis, a New Breakthrough in Cancer Treatment. Front Oncol 2021;11:698811. [PMID: 34381721 DOI: 10.3389/fonc.2021.698811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
448 Lee Deak K, Jackson JB, Valkenburg KC, Keefer LA, Robinson Gerding KM, Angiuoli SV, Datto MB, McCall SJ. Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics, Inc., Elio Tissue Complete Kitted Solution. J Mol Diagn 2021:S1525-1578(21)00210-5. [PMID: 34314880 DOI: 10.1016/j.jmoldx.2021.07.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
449 Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N. Neutrophils in the era of immune checkpoint blockade. J Immunother Cancer 2021;9:e002242. [PMID: 34301813 DOI: 10.1136/jitc-2020-002242] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
450 You H, Xu-Monette ZY, Wei L, Nunns H, Nagy ML, Bhagat G, Fang X, Zhu F, Visco C, Tzankov A, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Hagemeister FB, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Van Krieken JH, Piris MA, Winter JN, Li Y, Au Q, Xu B, Albitar M, Young KH. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology 2021;10:1928365. [PMID: 34350060 DOI: 10.1080/2162402X.2021.1928365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
451 Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S. CD8+ T Cell Exhaustion in Cancer. Front Immunol 2021;12:715234. [PMID: 34354714 DOI: 10.3389/fimmu.2021.715234] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 13.5] [Reference Citation Analysis]
452 Feng Q, Song D, Wang X. Pan-cancer analysis reveals that neurotrophin signaling correlates positively with anti-tumor immunity, clinical outcomes, and response to targeted therapies and immunotherapies in cancer. Life Sci 2021;282:119848. [PMID: 34293398 DOI: 10.1016/j.lfs.2021.119848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
453 Kang BW, Chau I. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. ESMO Open 2020;5:e000791. [PMID: 32817133 DOI: 10.1136/esmoopen-2020-000791] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
454 Bao R, Spranger S, Hernandez K, Zha Y, Pytel P, Luke JJ, Gajewski TF, Volchenboum SL, Cohn SL, Desai AV. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer 2021;9:e002417. [PMID: 34272305 DOI: 10.1136/jitc-2021-002417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
455 Zhou D, Luan J, Huang C, Li J. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe? Gut Liver 2021;15:500-16. [PMID: 33087588 DOI: 10.5009/gnl20223] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
456 Dhainaut M, Rose SA, Akturk G, Wroblewska A, Park ES, Nielsen SR, Buckup M, Roudko V, Pia L, Le Berichel J, Bektesevic A, Lee BH, Baccarini A, Bhardwaj N, Rahman AH, Gnjatic S, Pe’er D, Merad M, Brown BD. Perturb-map enables CRISPR genomics with spatial resolution and identifies regulators of tumor immune composition.. [DOI: 10.1101/2021.07.13.451021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
457 Sarver M, Brown MC, Rhodin KE, Salama AKS, Beasley GM. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Hum Vaccin Immunother 2021;:1-9. [PMID: 34254900 DOI: 10.1080/21645515.2021.1943987] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
458 Slack JC, Church AJ. Molecular Alterations in Pediatric Solid Tumors. Surg Pathol Clin 2021;14:473-92. [PMID: 34373097 DOI: 10.1016/j.path.2021.05.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
459 Pabla S, Seager RJ, Van Roey E, Gao S, Hoefer C, Nesline MK, DePietro P, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Schoenborn M, Zhang S, Klein R, Glenn ST, Conroy JM. Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response. Biomark Res 2021;9:56. [PMID: 34233760 DOI: 10.1186/s40364-021-00308-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
460 Veeramachaneni R, Yu W, Newton JM, Kemnade JO, Skinner HD, Sikora AG, Sandulache VC. Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects. J Immunother Cancer 2021;9:e002773. [PMID: 34230113 DOI: 10.1136/jitc-2021-002773] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
461 Trivedi S, Sun L, Aggarwal C. Immunotherapy for Head and Neck Cancer. Hematol Oncol Clin North Am 2021:S0889-8588(21)00066-6. [PMID: 34244017 DOI: 10.1016/j.hoc.2021.05.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
462 Freeman SS, Sade-feldman M, Kim J, Stewart C, Gonye ALK, Ravi A, Arniella MB, Gushterova I, Lasalle TJ, Blaum EM, Yizhak K, Frederick DT, Sharova T, Leshchiner I, Elagina L, Spiro OG, Livitz D, Rosebrock D, Aguet F, Carrot-zhang J, Ha G, Lin Z, Chen JH, Barzily-rokni M, Hammond MR, Vitzthum von Eckstaedt HC, Blackmon SM, Jiao YJ, Gabriel S, Lawrence DP, Duncan LM, Stemmer-rachamimov AO, Wargo JA, Flaherty KT, Sullivan RJ, Boland GM, Meyerson M, Getz G, Hacohen N. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.. [DOI: 10.1101/2021.07.03.450733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
463 Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y, Zhou R, Qiu W, Huang N, Sun L, Li X, Bin J, Liao Y, Shi M, Liao W. IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures. Front Immunol 2021;12:687975. [PMID: 34276676 DOI: 10.3389/fimmu.2021.687975] [Cited by in Crossref: 63] [Cited by in F6Publishing: 80] [Article Influence: 31.5] [Reference Citation Analysis]
464 Kumari S, Advani D, Sharma S, Ambasta RK, Kumar P. Combinatorial therapy in tumor microenvironment: Where do we stand? Biochim Biophys Acta Rev Cancer 2021;1876:188585. [PMID: 34224836 DOI: 10.1016/j.bbcan.2021.188585] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 10.5] [Reference Citation Analysis]
465 Hsu CL, Ou DL, Bai LY, Chen CW, Lin L, Huang SF, Cheng AL, Jeng YM, Hsu C. Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Liver Cancer 2021;10:346-59. [PMID: 34414122 DOI: 10.1159/000515305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
466 Ascierto PA, Blank C, Dummer R, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Kalinski P, Krogsgaard M, Lo RS, Luke JJ, Neyns B, Postow MA, Quezada SA, Teng MWL, Trinchieri G, Testori A, Caracò C, Osman I, Puzanov I, Thurin M. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy). J Transl Med 2021;19:278. [PMID: 34193182 DOI: 10.1186/s12967-021-02951-x] [Reference Citation Analysis]
467 Szabo PM, Pant S, Ely S, Desai K, Anguiano E, Wang L, Edwards R, Green G, Zhang N. Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor Types. J Mol Diagn 2021;23:1159-73. [PMID: 34197924 DOI: 10.1016/j.jmoldx.2021.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
468 Kaiser M, Semeraro MD, Herrmann M, Absenger G, Gerger A, Renner W. Immune Aging and Immunotherapy in Cancer. Int J Mol Sci 2021;22:7016. [PMID: 34209842 DOI: 10.3390/ijms22137016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
469 Zhao Z, He B, Cai Q, Zhang P, Peng X, Zhang Y, Xie H, Wang X. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. Int Immunopharmacol 2021;98:107807. [PMID: 34175739 DOI: 10.1016/j.intimp.2021.107807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
470 Gide TN, Pires da Silva I, Quek C, Ferguson PM, Batten M, Shang P, Ahmed T, Menzies AM, Carlino MS, Saw RPM, Thompson JF, Scolyer RA, Long GV, Wilmott JS. Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers (Basel) 2021;13:3186. [PMID: 34202352 DOI: 10.3390/cancers13133186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
471 Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu LF, Kadel E 3rd, Baldwin N, Jhunjhunwala S, Nickles D, Assaf ZJ, Bower D, Patil N, McCleland M, Shames D, Molinero L, Huseni M, Sanjabi S, Cummings C, Mellman I, Mariathasan S, Hegde P, Powles T. Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun 2021;12:3969. [PMID: 34172722 DOI: 10.1038/s41467-021-24112-w] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 15.5] [Reference Citation Analysis]
472 Duerinck J, Schwarze JK, Awada G, Tijtgat J, Vaeyens F, Bertels C, Geens W, Klein S, Seynaeve L, Cras L, D'Haene N, Michotte A, Caljon B, Salmon I, Bruneau M, Kockx M, Van Dooren S, Vanbinst AM, Everaert H, Forsyth R, Neyns B. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. J Immunother Cancer 2021;9:e002296. [PMID: 34168003 DOI: 10.1136/jitc-2020-002296] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
473 Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, Sharma P. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med 2020;12:eabc4220. [PMID: 32554706 DOI: 10.1126/scitranslmed.abc4220] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 22.0] [Reference Citation Analysis]
474 Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, Sullivan AH, Viboch EJ, Patel T, Ibrahimova N, Warren SE, Arruda A, Liang Y, Smith TH, Foulds GA, Bailey MD, Gowen-MacDonald J, Muth J, Schmitz M, Cesano A, Pockley AG, Valk PJM, Löwenberg B, Bornhäuser M, Tasian SK, Rettig MP, Davidson-Moncada JK, DiPersio JF, Rutella S. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med 2020;12:eaaz0463. [PMID: 32493790 DOI: 10.1126/scitranslmed.aaz0463] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 33.5] [Reference Citation Analysis]
475 Shklovskaya E, Rizos H. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. Int J Mol Sci 2021;22:6741. [PMID: 34201655 DOI: 10.3390/ijms22136741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
476 Waite JC, Wang B, Haber L, Hermann A, Ullman E, Ye X, Dudgeon D, Slim R, Ajithdoss DK, Godin SJ, Ramos I, Wu Q, Oswald E, Poon P, Golubov J, Grote D, Stella J, Pawashe A, Finney J, Herlihy E, Ahmed H, Kamat V, Dorvilliers A, Navarro E, Xiao J, Kim J, Yang SN, Warsaw J, Lett C, Canova L, Schulenburg T, Foster R, Krueger P, Garnova E, Rafique A, Babb R, Chen G, Stokes Oristian N, Siao CJ, Daly C, Gurer C, Martin J, Macdonald L, MacDonald D, Poueymirou W, Smith E, Lowy I, Thurston G, Olson W, Lin JC, Sleeman MA, Yancopoulos GD, Murphy AJ, Skokos D. Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. Sci Transl Med 2020;12:eaba2325. [PMID: 32581132 DOI: 10.1126/scitranslmed.aba2325] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
477 Rinchai D, Verzoni E, Huber V, Cova A, Squarcina P, De Cecco L, de Braud F, Ratta R, Dugo M, Lalli L, Vallacchi V, Rodolfo M, Roelands J, Castelli C, Chaussabel D, Procopio G, Bedognetti D, Rivoltini L. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clin Transl Med 2021;11:e434. [PMID: 34185403 DOI: 10.1002/ctm2.434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
478 Bao J, Närhi K, Teodòsio A, Hemmes A, Linnavirta NM, Mäyränpää MI, Salmenkivi K, Le Quesne J, Verschuren EW. SOX9 has distinct roles in the formation and progression of different non-small cell lung cancer histotypes. J Pathol 2021;255:16-29. [PMID: 34021911 DOI: 10.1002/path.5733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
479 Ardighieri L, Missale F, Bugatti M, Gatta LB, Pezzali I, Monti M, Gottardi S, Zanotti L, Bignotti E, Ravaggi A, Tognon G, Odicino F, Calza S, Missolo-Koussou Y, Ries CH, Helft J, Vermi W. Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes. Front Immunol 2021;12:690201. [PMID: 34220848 DOI: 10.3389/fimmu.2021.690201] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
480 Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci 2021;22:6532. [PMID: 34207103 DOI: 10.3390/ijms22126532] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 8.5] [Reference Citation Analysis]
481 Hongo T, Kuga R, Miyazaki M, Komune N, Nakano T, Yamamoto H, Koike K, Sato K, Kogo R, Nabeshima K, Oda Y, Nakagawa T. Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma. Laryngoscope 2021. [PMID: 34143491 DOI: 10.1002/lary.29689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
482 Li K, Li T, Feng Z, Huang M, Wei L, Yan Z, Long M, Hu Q, Wang J, Liu S, Sgroi DC, Demehri S. CD8+ T cell immunity blocks the metastasis of carcinogen-exposed breast cancer. Sci Adv 2021;7:eabd8936. [PMID: 34144976 DOI: 10.1126/sciadv.abd8936] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
483 Zhou C, Lin A, Cao M, Ding W, Mou W, Guo N, Chen Z, Zhang J, Luo P. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma. Front Immunol 2021;12:634741. [PMID: 34220801 DOI: 10.3389/fimmu.2021.634741] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
484 Ma SC, Zhu HB, Wang J, Zhang YP, Guo XJ, Long LL, Guo ZQ, Wu DH, Dong ZY, Bai X. De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma. Front Oncol 2021;11:666145. [PMID: 34221982 DOI: 10.3389/fonc.2021.666145] [Reference Citation Analysis]
485 Liu R, Yang F, Yin JY, Liu YZ, Zhang W, Zhou HH. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study. Front Immunol 2021;12:685370. [PMID: 34220837 DOI: 10.3389/fimmu.2021.685370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
486 Kim YJ, Sheu KM, Tsoi J, Abril-Rodriguez G, Medina E, Grasso CS, Torrejon DY, Champhekar AS, Litchfield K, Swanton C, Speiser DE, Scumpia PO, Hoffmann A, Graeber TG, Puig-Saus C, Ribas A. Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapy. J Clin Invest 2021;131:145859. [PMID: 33914706 DOI: 10.1172/JCI145859] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
487 Liu F, Yang Z, Zheng L, Shao W, Cui X, Wang Y, Jia J, Fu Y. A Tumor Progression Related 7-Gene Signature Indicates Prognosis and Tumor Immune Characteristics of Gastric Cancer. Front Oncol 2021;11:690129. [PMID: 34195091 DOI: 10.3389/fonc.2021.690129] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
488 Elyashiv O, Wong YNS, Ledermann JA. Frontline Maintenance Treatment for Ovarian Cancer. Curr Oncol Rep 2021;23:97. [PMID: 34125335 DOI: 10.1007/s11912-021-01088-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
489 Davis AP, Cooper WA, Boyer M, Lee JH, Pavlakis N, Kao SC. Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy 2021;13:941-52. [PMID: 34114474 DOI: 10.2217/imt-2021-0090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
490 Sahu A, Tembo T, Kose K, Santella A, Alfonso A, Li M, Cordova M, Gill M, Fox C, Gonzalez S, Wang AW, Kurtansky N, Chandrani P, Kumar P, Yin S, Jilani H, Mehta P, Navarrete-dechent C, Peterson G, King K, Dusza S, Yang N, Li S, Phillips W, Rossi A, Halpern A, Deng L, Pulitzer M, Marghoob A, Chen CJ, Rajadhyaksha M. Cellular-level phenotyping of tumor-immune microenvironment (TiME) in patients in vivo reveals distinct inflammation and endothelial anergy signatures.. [DOI: 10.1101/2021.06.10.447835] [Reference Citation Analysis]
491 Miller RE, Lewis AJ, Powell ME. PARP inhibitors and immunotherapy in ovarian and endometrial cancers. Br J Radiol 2021;:20210002. [PMID: 33882241 DOI: 10.1259/bjr.20210002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
492 Shi S, Ma T, Xi Y. Characterization of the immune cell infiltration landscape in bladder cancer to aid immunotherapy. Arch Biochem Biophys 2021;708:108950. [PMID: 34118215 DOI: 10.1016/j.abb.2021.108950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
493 Park R, Park JC. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer. Immunotherapy 2021;13:931-40. [PMID: 34100301 DOI: 10.2217/imt-2021-0048] [Reference Citation Analysis]
494 Zhang Y, Narayanan SP, Mannan R, Raskind G, Wang X, Vats P, Su F, Hosseini N, Cao X, Kumar-Sinha C, Ellison SJ, Giordano TJ, Morgan TM, Pitchiaya S, Alva A, Mehra R, Cieslik M, Dhanasekaran SM, Chinnaiyan AM. Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. Proc Natl Acad Sci U S A 2021;118:e2103240118. [PMID: 34099557 DOI: 10.1073/pnas.2103240118] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 18.5] [Reference Citation Analysis]
495 Wang Y, Tong Z, Zhang W, Zhang W, Buzdin A, Mu X, Yan Q, Zhao X, Chang HH, Duhon M, Zhou X, Zhao G, Chen H, Li X. FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. Front Oncol 2021;11:683419. [PMID: 34164344 DOI: 10.3389/fonc.2021.683419] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
496 Agarwal P, Le DT, Boland PM. Immunotherapy in colorectal cancer. Adv Cancer Res 2021;151:137-96. [PMID: 34148613 DOI: 10.1016/bs.acr.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
497 Karabajakian A, Bouaoud J, Michon L, Kamal M, Crozes C, Zrounba P, Auclair-Perossier J, Gadot N, Attignon V, Le Tourneau C, Benzerdjeb N, Fayette J, Saintigny P. Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncol 2021;119:105368. [PMID: 34111704 DOI: 10.1016/j.oraloncology.2021.105368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
498 Lussier DM, Alspach E, Ward JP, Miceli AP, Runci D, White JM, Mpoy C, Arthur CD, Kohlmiller HN, Jacks T, Artyomov MN, Rogers BE, Schreiber RD. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A 2021;118:e2102611118. [PMID: 34099555 DOI: 10.1073/pnas.2102611118] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
499 Li L, Wang X. Identification of gastric cancer subtypes based on pathway clustering. NPJ Precis Oncol 2021;5:46. [PMID: 34079012 DOI: 10.1038/s41698-021-00186-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
500 Bindal P, Gray JE, Boyle TA, Florou V, Puri S. Biomarkers of therapeutic response with immune checkpoint inhibitors. Ann Transl Med 2021;9:1040. [PMID: 34277840 DOI: 10.21037/atm-20-6396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
501 Murakami R, Hamanishi J, Brown JB, Abiko K, Yamanoi K, Taki M, Hosoe Y, Yamaguchi K, Baba T, Matsumura N, Konishi I, Mandai M. Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. Sci Rep 2021;11:11427. [PMID: 34075161 DOI: 10.1038/s41598-021-91012-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
502 Shimada Y, Okuda S, Watanabe Y, Tajima Y, Nagahashi M, Ichikawa H, Nakano M, Sakata J, Takii Y, Kawasaki T, Homma KI, Kamori T, Oki E, Ling Y, Takeuchi S, Wakai T. Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. J Gastroenterol 2021;56:547-59. [PMID: 33909150 DOI: 10.1007/s00535-021-01789-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
503 Mai J, Li Z, Xia X, Zhang J, Li J, Liu H, Shen J, Ramirez M, Li F, Li Z, Yokoi K, Liu X, Mittendorf EA, Ferrari M, Shen H. Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine. Adv Sci (Weinh) 2021;8:2100166. [PMID: 34194942 DOI: 10.1002/advs.202100166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
504 Pingili AK, Chaib M, Sipe LM, Miller EJ, Teng B, Sharma R, Yarbro JR, Asemota S, Al Abdallah Q, Mims TS, Marion TN, Daria D, Sekhri R, Hamilton AM, Troester MA, Jo H, Choi HY, Hayes DN, Cook KL, Narayanan R, Pierre JF, Makowski L. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. Cell Rep 2021;35:109285. [PMID: 34161764 DOI: 10.1016/j.celrep.2021.109285] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
505 Li G, Jiang Y, Li G, Qiao Q. Comprehensive analysis of radiosensitivity in head and neck squamous cell carcinoma. Radiotherapy and Oncology 2021;159:126-35. [DOI: 10.1016/j.radonc.2021.03.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
506 Bi C, Zhou S, Liu X, Zhu Y, Yu J, Zhang X, Shi M, Wu R, He H, Zhan C, Lin Y, Shen B. NDDRF: A risk factor knowledgebase for personalized prevention of neurodegenerative diseases. Journal of Advanced Research 2021. [DOI: 10.1016/j.jare.2021.06.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
507 Kumar A, Watkins R, Vilgelm AE. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. Front Immunol 2021;12:690499. [PMID: 34140957 DOI: 10.3389/fimmu.2021.690499] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
508 Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Caglevic C, Chung HC, Muro K, Van Cutsem E, Kobie J, Cristescu R, Aurora-Garg D, Lu J, Shih CS, Adelberg D, Cao ZA, Fuchs CS. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol 2021;32:1127-36. [PMID: 34082019 DOI: 10.1016/j.annonc.2021.05.803] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
509 Vathiotis IA, Yang Z, Reeves J, Toki M, Aung TN, Wong PF, Kluger H, Syrigos KN, Warren S, Rimm DL. Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. NPJ Precis Oncol 2021;5:45. [PMID: 34050252 DOI: 10.1038/s41698-021-00184-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
510 Pereira B, Chen CT, Goyal L, Walmsley C, Pinto CJ, Baiev I, Allen R, Henderson L, Saha S, Reyes S, Taylor MS, Fitzgerald DM, Broudo MW, Sahu A, Gao X, Winckler W, Brannon AR, Engelman JA, Leary R, Stone JR, Campbell CD, Juric D. Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. Nat Commun 2021;12:3199. [PMID: 34045463 DOI: 10.1038/s41467-021-23394-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
511 Kamori T, Oki E, Shimada Y, Hu Q, Hisamatsu Y, Ando K, Shimokawa M, Wakai T, Oda Y, Mori M. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells. Cancer Rep (Hoboken) 2021;:e1420. [PMID: 34042312 DOI: 10.1002/cnr2.1420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
512 Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, Han JY, Majem M, Forster MD, Monnet I, Novello S, Gubens MA, Boyer M, Su WC, Samkari A, Jensen EH, Kobie J, Piperdi B, Baas P. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. J Thorac Oncol 2021:S1556-0864(21)02172-9. [PMID: 34048946 DOI: 10.1016/j.jtho.2021.05.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 21.5] [Reference Citation Analysis]
513 To KKW, Fong W, Cho WCS. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. Front Oncol 2021;11:635007. [PMID: 34113560 DOI: 10.3389/fonc.2021.635007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 14.5] [Reference Citation Analysis]
514 Shi Z, Shen J, Qiu J, Zhao Q, Hua K, Wang H. CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors. Theranostics 2021;11:7175-87. [PMID: 34158843 DOI: 10.7150/thno.59056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
515 Fenizia F, Pasquale R, Abate RE, Lambiase M, Roma C, Bergantino F, Chaudhury R, Hyland F, Allen C, Normanno N. Challenges in bioinformatics approaches to tumor mutation burden analysis. Oncol Lett 2021;22:555. [PMID: 34084222 DOI: 10.3892/ol.2021.12816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
516 Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, Osokin N, Kozlov I, Frenkel F, Gancharova O, Almog N, Tsiper M, Ataullakhanov R, Fowler N. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 2021;39:845-865.e7. [PMID: 34019806 DOI: 10.1016/j.ccell.2021.04.014] [Cited by in Crossref: 142] [Cited by in F6Publishing: 165] [Article Influence: 71.0] [Reference Citation Analysis]
517 Bi WL, Nayak L, Meredith DM, Driver J, Du Z, Hoffman S, Li Y, Lee EQ, Beroukhim R, Rinne M, McFaline-Figueroa R, Chukwueke U, McCluskey C, Gaffey S, Cherniack AD, Stefanik J, Doherty L, Taubert C, Cifrino M, LaFrankie D, Graillon T, Wen PY, Ligon KL, Al-Mefty O, Huang RY, Muzikansky A, Chiocca EA, Santagata S, Dunn IF, Reardon DA. Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. Neuro Oncol 2021:noab118. [PMID: 34015129 DOI: 10.1093/neuonc/noab118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
518 Song Y, Sun Y, Sun T, Tang R. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer. Comb Chem High Throughput Screen 2020;23:381-91. [PMID: 32264809 DOI: 10.2174/1386207323666200407075004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
519 Bai RL, Chen NF, Li LY, Cui JW. A brand new era of cancer immunotherapy: breakthroughs and challenges. Chin Med J (Engl) 2021;134:1267-75. [PMID: 34039862 DOI: 10.1097/CM9.0000000000001490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
520 Yang J, Zhao S, Wang J, Sheng Q, Liu Q, Shyr Y. Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma. J Genet Genomics 2021;48:361-8. [PMID: 34127402 DOI: 10.1016/j.jgg.2021.03.016] [Reference Citation Analysis]
521 Mall R, Saad M, Roelands J, Rinchai D, Kunji K, Almeer H, Hendrickx W, M Marincola F, Ceccarelli M, Bedognetti D. Network-based identification of key master regulators associated with an immune-silent cancer phenotype. Brief Bioinform 2021:bbab168. [PMID: 33979427 DOI: 10.1093/bib/bbab168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
522 Kim JC, Heo YJ, Kang SY, Lee J, Kim KM. Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer. Cancers (Basel) 2021;13:2316. [PMID: 34065963 DOI: 10.3390/cancers13102316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
523 Richard G, De Groot AS, Steinberg GD, Garcia TI, Kacew A, Ardito M, Martin WD, Berdugo G, Princiotta MF, Balar AV, Sweis RF. Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival. Sci Rep 2021;11:9983. [PMID: 33976291 DOI: 10.1038/s41598-021-89016-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
524 Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity 2021;54:859-74. [PMID: 33838745 DOI: 10.1016/j.immuni.2021.01.012] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 49.5] [Reference Citation Analysis]
525 Yeong J, Suteja L, Simoni Y, Lau KW, Tan AC, Li HH, Lim S, Loh JH, Wee FYT, Nerurkar SN, Takano A, Tan EH, Lim TKH, Newell EW, Tan DSW. Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC. J Thorac Oncol 2021;16:1349-58. [PMID: 33975004 DOI: 10.1016/j.jtho.2021.04.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
526 Magnes T, Wagner S, Kiem D, Weiss L, Rinnerthaler G, Greil R, Melchardt T. Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 2021;22:4981. [PMID: 34067112 DOI: 10.3390/ijms22094981] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
527 Schildhaus HU, Weichert W. [Predictive diagnostics for checkpoint inhibitors]. Pathologe 2021;42:380-90. [PMID: 33956171 DOI: 10.1007/s00292-021-00939-4] [Reference Citation Analysis]
528 Fenizia F, Alborelli I, Costa JL, Vollbrecht C, Bellosillo B, Dinjens W, Endris V, Heydt C, Leonards K, Merkelback-Bruse S, Pfarr N, van Marion R, Allen C, Chaudhary R, Gottimukkala R, Hyland F, Wong-Ho E, Jermann P, Machado JC, Hummel M, Stenzinger A, Normanno N. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium. J Mol Diagn 2021;23:882-93. [PMID: 33964449 DOI: 10.1016/j.jmoldx.2021.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
529 Yan W, Jin H, Zhang X, Long S, Xia Q, Meng D, Ding B, Li D, Ma J, Cao J, Wang S. Identification of an immune signature to predict poor clinical outcome in cervical cancer. Epigenomics 2021;13:891-907. [PMID: 33955785 DOI: 10.2217/epi-2020-0437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
530 William WN Jr, Zhao X, Bianchi JJ, Lin HY, Cheng P, Lee JJ, Carter H, Alexandrov LB, Abraham JP, Spetzler DB, Dubinett SM, Cleveland DW, Cavenee W, Davoli T, Lippman SM. Immune evasion in HPV- head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss. Proc Natl Acad Sci U S A 2021;118:e2022655118. [PMID: 33952700 DOI: 10.1073/pnas.2022655118] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
531 Gutting T, Hauber V, Pahl J, Klapproth K, Wu W, Dobrota I, Herweck F, Reichling J, Helm L, Schroeder T, Li B, Weidner P, Zhan T, Eckardt M, Betge J, Belle S, Sticht C, Gaiser T, Boutros M, Ebert MPA, Cerwenka A, Burgermeister E. PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells. Oncoimmunology 2021;10:1906500. [PMID: 34026331 DOI: 10.1080/2162402X.2021.1906500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
532 Toedebusch R, Grodzki AC, Dickinson PJ, Woolard K, Vinson N, Sturges B, Snyder J, Li CF, Nagasaka O, Consales B, Vernau K, Knipe M, Murthy V, Lein PJ, Toedebusch CM. Glioma-associated microglia/macrophages augment tumorigenicity in canine astrocytoma, a naturally occurring model of human glioma. Neurooncol Adv 2021;3:vdab062. [PMID: 34131649 DOI: 10.1093/noajnl/vdab062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
533 Jiao X, Wei X, Li S, Liu C, Chen H, Gong J, Li J, Zhang X, Wang X, Peng Z, Qi C, Wang Z, Wang Y, Wang Y, Zhuo N, Zhang H, Lu Z, Shen L. A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. NPJ Precis Oncol 2021;5:36. [PMID: 33947957 DOI: 10.1038/s41698-021-00172-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
534 Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol 2021;39:2647-55. [PMID: 33945288 DOI: 10.1200/JCO.21.00079] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 16.5] [Reference Citation Analysis]
535 Lim JU, Kang HS. A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer. Ann Transl Med 2021;9:809. [PMID: 34268422 DOI: 10.21037/atm-21-68] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
536 Xu JY, Liu AR, Wu ZS, Xie JF, Qu XX, Li CH, Meng SS, Liu SQ, Yang CS, Liu L, Huang YZ, Guo FM, Yang Y, Qiu HB. Nucleotide polymorphism in ARDS outcome: a whole exome sequencing association study. Ann Transl Med 2021;9:780. [PMID: 34268393 DOI: 10.21037/atm-20-5728] [Reference Citation Analysis]
537 Lah Turnšek T, Jiao X, Novak M, Jammula S, Cicero G, Ashton AW, Joyce D, Pestell RG. An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5. Int J Mol Sci 2021;22:4464. [PMID: 33923334 DOI: 10.3390/ijms22094464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
538 Fu Z, Mowday AM, Smaill JB, Hermans IF, Patterson AV. Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. Cells 2021;10:1006. [PMID: 33923305 DOI: 10.3390/cells10051006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
539 Chen Y, Meng Z, Zhang L, Liu F. CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment. Front Immunol 2021;12:664845. [PMID: 33968066 DOI: 10.3389/fimmu.2021.664845] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
540 Yuan H, Ji J, Shi M, Shi Y, Liu J, Wu J, Yang C, Xi W, Li Q, Zhu W, Li J, Gong X, Zhang J. Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden. Front Oncol 2021;11:682017. [PMID: 33968789 DOI: 10.3389/fonc.2021.682017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
541 Vo DH, Mcgleave G, Overton IM. Immune cell networks uncover candidate biomarkers of cancer immunotherapy response.. [DOI: 10.1101/2021.04.22.440902] [Reference Citation Analysis]
542 Manzano RG, Catalan-Latorre A, Brugarolas A. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. BMC Cancer 2021;21:432. [PMID: 33879103 DOI: 10.1186/s12885-021-08078-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
543 Cai Y, Wang X, Wang N, Wu J, Ma L, Xie X, Zhang H, Dang C, Kang H, Zhang S, Zhou Z. Correlations between tumor mutation burden and immune infiltrates and their prognostic value in pancreatic cancer by bioinformatic analysis. Life Sci 2021;277:119505. [PMID: 33872662 DOI: 10.1016/j.lfs.2021.119505] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
544 Lim KP, Zainal NS. Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines. Front Mol Biosci 2021;8:623475. [PMID: 33937323 DOI: 10.3389/fmolb.2021.623475] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
545 Lahman MC, Paulson KG, Nghiem PT, Chapuis AG. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma. J Invest Dermatol 2021;141:1897-905. [PMID: 33863500 DOI: 10.1016/j.jid.2020.12.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
546 Martínez-Pérez E, Molina-Vila MA, Marino-Buslje C. Panels and models for accurate prediction of tumor mutation burden in tumor samples. NPJ Precis Oncol 2021;5:31. [PMID: 33850256 DOI: 10.1038/s41698-021-00169-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
547 Garutti M, Bonin S, Buriolla S, Bertoli E, Pizzichetta MA, Zalaudek I, Puglisi F. Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. Cancers (Basel) 2021;13:1819. [PMID: 33920288 DOI: 10.3390/cancers13081819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
548 Wang L, Chen F, Liu R, Shi L, Zhao G, Yan Z. Gene expression and immune infiltration in melanoma patients with different mutation burden. BMC Cancer 2021;21:379. [PMID: 33836680 DOI: 10.1186/s12885-021-08083-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
549 Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky MD. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clin Cancer Res 2021;27:4287-300. [PMID: 33837006 DOI: 10.1158/1078-0432.CCR-20-4574] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
550 Vara BA, Levi SM, Achab A, Candito DA, Fradera X, Lesburg CA, Kawamura S, Lacey BM, Lim J, Methot JL, Xu Z, Xu H, Smith DM, Piesvaux JA, Miller JR, Bittinger M, Ranganath SH, Bennett DJ, DiMauro EF, Pasternak A. Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds. ACS Med Chem Lett 2021;12:653-61. [PMID: 33859804 DOI: 10.1021/acsmedchemlett.1c00096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
551 Shum B, Larkin J, Turajlic S. Predictive biomarkers for response to immune checkpoint inhibition. Semin Cancer Biol 2021:S1044-579X(21)00097-3. [PMID: 33819567 DOI: 10.1016/j.semcancer.2021.03.036] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
552 Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov 2021;11:1368-97. [PMID: 33811048 DOI: 10.1158/2159-8290.CD-20-1209] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 19.5] [Reference Citation Analysis]
553 Uzhachenko RV, Bharti V, Ouyang Z, Blevins A, Mont S, Saleh N, Lawrence HA, Shen C, Chen SC, Ayers GD, DeNardo DG, Arteaga C, Richmond A, Vilgelm AE. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep 2021;35:108944. [PMID: 33826903 DOI: 10.1016/j.celrep.2021.108944] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
554 Bian C, Wang Y, Lu Z, An Y, Wang H, Kong L, Du Y, Tian J. ImmunoAIzer: A Deep Learning-Based Computational Framework to Characterize Cell Distribution and Gene Mutation in Tumor Microenvironment. Cancers (Basel) 2021;13:1659. [PMID: 33916145 DOI: 10.3390/cancers13071659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
555 Kim HD, Jeong S, Park S, Lee YJ, Ju YS, Kim D, Song GW, Lee JH, Kim SY, Shin J, Shin EC, Hwang S, Yoo C, Park SH. Implication of CD69(+) CD103(+) tissue-resident-like CD8(+) T cells as a potential immunotherapeutic target for cholangiocarcinoma. Liver Int 2021;41:764-76. [PMID: 33548061 DOI: 10.1111/liv.14814] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
556 Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res 2021;27:3050-60. [PMID: 33771853 DOI: 10.1158/1078-0432.CCR-20-4118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
557 Ahn SG, Kim SK, Shepherd JH, Cha YJ, Bae SJ, Kim C, Jeong J, Perou CM. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer. Breast Cancer Res Treat 2021;188:165-78. [PMID: 33770313 DOI: 10.1007/s10549-021-06193-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
558 Apollonio B, Ioannou N, Papazoglou D, Ramsay AG. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Front Oncol 2021;11:626818. [PMID: 33842331 DOI: 10.3389/fonc.2021.626818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
559 Wahle BM, Zolkind P, Ramirez R, Skidmore ZL, Mazul A, Hayes DN, Sandulache VC, Thorstad WL, Adkins D, Griffith OL, Griffith M, Zevallos JP. Comparative Multiomic Analysis Reveals Low T Cell Infiltration as the Primary Feature of Tobacco Use in HPV(+) Oropharyngeal Cancer.. [DOI: 10.1101/2021.03.23.436478] [Reference Citation Analysis]
560 Zhou L, Huang L, Xu Q, Lv Y, Wang Z, Zhan P, Han H, Shao Y, Lin D, Lv T, Song Y. Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer. Front Oncol 2021;11:596542. [PMID: 33828970 DOI: 10.3389/fonc.2021.596542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
561 Goodman AE, Karapetyan L, Pugliano-Mauro M, Levenson JE, Luke JJ. Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac Allograft. Front Immunol 2021;12:660795. [PMID: 33828564 DOI: 10.3389/fimmu.2021.660795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
562 Isaacs J, Anders C, McArthur H, Force J. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Curr Treat Options Oncol 2021;22:38. [PMID: 33743085 DOI: 10.1007/s11864-021-00833-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
563 Wisdom AJ, Kirsch DG. Dissecting the Functional Significance of DNA Polymerase Mutations in Cancer. Cancer Res 2020;80:5459-61. [PMID: 33323408 DOI: 10.1158/0008-5472.CAN-20-3241] [Reference Citation Analysis]
564 Fattore L, Ruggiero CF, Liguoro D, Castaldo V, Catizone A, Ciliberto G, Mancini R. The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma. Front Oncol 2021;11:645069. [PMID: 33816298 DOI: 10.3389/fonc.2021.645069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
565 Li P, Hao S, Ye Y, Wei J, Tang Y, Tan L, Liao Z, Zhang M, Li J, Gui C, Xiao J, Huang Y, Chen X, Cao J, Luo J, Chen W. Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer. Front Cell Dev Biol 2021;9:646982. [PMID: 33816497 DOI: 10.3389/fcell.2021.646982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
566 Ma X, Huang R, Wu X, Zhang P. Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy. BMC Bioinformatics 2021;22:127. [PMID: 33731020 DOI: 10.1186/s12859-021-04050-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
567 McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 2021;32:661-72. [PMID: 33736924 DOI: 10.1016/j.annonc.2021.02.006] [Cited by in Crossref: 259] [Cited by in F6Publishing: 296] [Article Influence: 129.5] [Reference Citation Analysis]
568 Chan JJ, Tan TJY, Dent RA. Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer. Curr Opin Oncol 2020;32:575-84. [PMID: 32852307 DOI: 10.1097/CCO.0000000000000675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
569 Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. J Cancer 2021;12:2933-51. [PMID: 33854594 DOI: 10.7150/jca.52187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
570 Younis RH, Ghita I, Elnaggar M, Chaisuparat R, Theofilou VI, Dyalram D, Ord RA, Davila E, Tallon LJ, Papadimitriou JC, Webb TJ, Bentzen SM, Lubek JE. Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile. Front Immunol 2021;12:596646. [PMID: 33776991 DOI: 10.3389/fimmu.2021.596646] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
571 Jing Y, Zhang Y, Wang J, Li K, Chen X, Heng J, Gao Q, Ye Y, Zhang Z, Liu Y, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. J Natl Cancer Inst 2021:djab035. [PMID: 33705549 DOI: 10.1093/jnci/djab035] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
572 Kamal Y, Dwan D, Hoehn HJ, Sanz-Pamplona R, Alonso MH, Moreno V, Cheng C, Schell MJ, Kim Y, Felder SI, Rennert HS, Melas M, Lazaris C, Bonner JD, Siegel EM, Shibata D, Rennert G, Gruber SB, Frost HR, Amos CI, Schmit SL. Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse. Oncoimmunology 2021;10:1862529. [PMID: 33763292 DOI: 10.1080/2162402X.2020.1862529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
573 Feng B, Hess J. Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer. Cancers (Basel) 2021;13:1162. [PMID: 33800421 DOI: 10.3390/cancers13051162] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
574 Almangush A, Leivo I, Mäkitie AA. Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. Front Oncol 2021;11:616629. [PMID: 33763354 DOI: 10.3389/fonc.2021.616629] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
575 Dos Santos LV, Abrahão CM, William WN Jr. Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas. Front Oncol 2021;11:596290. [PMID: 33747915 DOI: 10.3389/fonc.2021.596290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
576 Jin Y, Wang Z, He D, Zhu Y, Hu X, Gong L, Xiao M, Chen X, Cheng Y, Cao K. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma. Front Immunol 2021;12:637933. [PMID: 33746977 DOI: 10.3389/fimmu.2021.637933] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
577 Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr Opin Immunol 2021;69:47-55. [PMID: 33676271 DOI: 10.1016/j.coi.2021.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
578 Ross-Macdonald P, Walsh AM, Chasalow SD, Ammar R, Papillon-Cavanagh S, Szabo PM, Choueiri TK, Sznol M, Wind-Rotolo M. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. J Immunother Cancer 2021;9:e001506. [PMID: 33658305 DOI: 10.1136/jitc-2020-001506] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
579 Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, Zhao S, Dong X, Yao M, Wang K, Zhou Q. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Med 2021;10:2216-31. [PMID: 33655698 DOI: 10.1002/cam4.3649] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
580 O'Meara TA, Tolaney SM. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget 2021;12:394-400. [PMID: 33747355 DOI: 10.18632/oncotarget.27877] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
581 Veigas F, Mahmoud YD, Merlo J, Rinflerch A, Rabinovich GA, Girotti MR. Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:1018. [PMID: 33804419 DOI: 10.3390/cancers13051018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
582 Kumagai S, Koyama S, Nishikawa H. Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer 2021;21:181-97. [PMID: 33462501 DOI: 10.1038/s41568-020-00322-0] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 37.5] [Reference Citation Analysis]
583 Lhuillier C, Rudqvist NP, Yamazaki T, Zhang T, Charpentier M, Galluzzi L, Dephoure N, Clement CC, Santambrogio L, Zhou XK, Formenti SC, Demaria S. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J Clin Invest 2021;131:138740. [PMID: 33476307 DOI: 10.1172/JCI138740] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 22.5] [Reference Citation Analysis]
584 Yang Q, Shen R, Xu H, Shi X, Xu L, Zhang L, Fan X, Jin X. Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates. Ann Transl Med 2021;9:465. [PMID: 33850862 DOI: 10.21037/atm-21-289] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
585 Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Kim ST. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Ther Adv Med Oncol 2021;13:1758835921992992. [PMID: 33717226 DOI: 10.1177/1758835921992992] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
586 Wang S, Fang Y, Jiang N, Xing S, Li Q, Chen R, Yi X, Zhang Z, Li N. Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy. Front Immunol 2021;12:631483. [PMID: 33732253 DOI: 10.3389/fimmu.2021.631483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
587 Thomas R, Al-Khadairi G, Decock J. Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. Front Oncol 2020;10:600573. [PMID: 33718107 DOI: 10.3389/fonc.2020.600573] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 16.5] [Reference Citation Analysis]
588 Cejalvo JM, Gambardella V, Fleitas T, Cervantes A. In the literature: February 2021. ESMO Open 2021;6:100061. [PMID: 33639602 DOI: 10.1016/j.esmoop.2021.100061] [Reference Citation Analysis]
589 Zhao C, Wu L, Liang D, Chen H, Ji S, Zhang G, Yang K, Hu Y, Mao B, Liu T, Yu Y, Zhang H, Xu J. Identification of immune checkpoint and cytokine signatures associated with the response to immune checkpoint blockade in gastrointestinal cancers. Cancer Immunol Immunother 2021;70:2669-79. [PMID: 33624146 DOI: 10.1007/s00262-021-02878-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
590 Li H, Wang J. [Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:131-40. [PMID: 33508897 DOI: 10.3779/j.issn.1009-3419.2021.102.06] [Reference Citation Analysis]
591 Meierjohann S. Effect of stress-induced polyploidy on melanoma reprogramming and therapy resistance. Semin Cancer Biol 2021:S1044-579X(21)00028-6. [PMID: 33610722 DOI: 10.1016/j.semcancer.2021.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
592 Donia M, Jönsson G. Midkine-A potential therapeutic target in melanoma. Pigment Cell Melanoma Res 2021;34:834-5. [PMID: 33599989 DOI: 10.1111/pcmr.12967] [Reference Citation Analysis]
593 Angerilli V, Galuppini F, Pagni F, Fusco N, Malapelle U, Fassan M. The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. Diagnostics (Basel) 2021;11:339. [PMID: 33670699 DOI: 10.3390/diagnostics11020339] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
594 Paderi A, Giorgione R, Giommoni E, Mela MM, Rossi V, Doni L, Minervini A, Carini M, Pillozzi S, Antonuzzo L. Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:860. [PMID: 33670634 DOI: 10.3390/cancers13040860] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
595 Shang X, Li Z, Sun J, Zhao C, Lin J, Wang H. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab. Lung Cancer 2021;154:105-12. [PMID: 33640623 DOI: 10.1016/j.lungcan.2021.02.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
596 Chan JY, Lim JQ, Yeong J, Ravi V, Guan P, Boot A, Tay TKY, Selvarajan S, Md Nasir ND, Loh JH, Ong CK, Huang D, Tan J, Li Z, Ng CC, Tan TT, Masuzawa M, Sung KW, Farid M, Quek RHH, Tan NC, Teo MCC, Rozen SG, Tan P, Futreal A, Teh BT, Soo KC. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. J Clin Invest 2020;130:5833-46. [PMID: 33016928 DOI: 10.1172/JCI139080] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
597 Golkaram M, Salmans ML, Kaplan S, Vijayaraghavan R, Martins M, Khan N, Garbutt C, Wise A, Yao J, Casimiro S, Abreu C, Macedo D, Costa AL, Alvim C, Mansinho A, Filipe P, Marques da Costa P, Fernandes A, Borralho P, Ferreira C, Aldeia F, Malaquias J, Godsey J, So A, Pawlowski T, Costa L, Zhang S, Liu L. HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome. NPJ Genom Med 2021;6:13. [PMID: 33589643 DOI: 10.1038/s41525-021-00177-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
598 Zhong J, Liu Z, Cai C, Duan X, Deng T, Zeng G. m6A modification patterns and tumor immune landscape in clear cell renal carcinoma. J Immunother Cancer 2021;9:e001646. [PMID: 33574053 DOI: 10.1136/jitc-2020-001646] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
599 How JA, Jazaeri AA, Soliman PT, Fleming ND, Gong J, Piha-Paul SA, Janku F, Stephen B, Naing A. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep 2021;11:3667. [PMID: 33574401 DOI: 10.1038/s41598-021-83317-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
600 Curran T, Sun Z, Gerry B, Findlay VJ, Wallace K, Li Z, Paulos C, Ford M, Rubinstein MP, Chung D, Camp ER. Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Med 2021;10:1805-14. [PMID: 33560598 DOI: 10.1002/cam4.3753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
601 Huang J, Liu H, Zhao Y, Luo T, Liu J, Liu J, Pan X, Tang W. MicroRNAs Expression Patterns Predict Tumor Mutational Burden in Colorectal Cancer. Front Oncol 2020;10:550986. [PMID: 33634010 DOI: 10.3389/fonc.2020.550986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
602 Haanen JB, Blank CU. Prognostic and predictive role of the tumor immune landscape. Q J Nucl Med Mol Imaging 2020;64:143-51. [PMID: 32421286 DOI: 10.23736/S1824-4785.20.03255-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
603 Terry RL, Meyran D, Ziegler DS, Haber M, Ekert PG, Trapani JA, Neeson PJ. Immune profiling of pediatric solid tumors. J Clin Invest 2020;130:3391-402. [PMID: 32538896 DOI: 10.1172/JCI137181] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
604 Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, Sweis RF, Bathe OF, Heimann C, Campbell MJ, Stretch C, Huntsman S, Graff RE, Syed N, Radvanyi L, Shelley S, Wolf D, Marincola FM, Ceccarelli M, Galon J, Ziv E, Bedognetti D. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021;54:367-386.e8. [PMID: 33567262 DOI: 10.1016/j.immuni.2021.01.011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 21.5] [Reference Citation Analysis]
605 Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, Ariyan CE, Shoushtari AN, Balachandran VP, Hakimi AA, Crago AM, Long Roche KC, Smith JJ, Ganly I, Wong RJ, Patel SG, Shah JP, Lee NY, Riaz N, Wang J, Zehir A, Berger MF, Chan TA, Seshan VE, Morris LGT. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun 2021;12:729. [PMID: 33526794 DOI: 10.1038/s41467-021-20935-9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 39.0] [Reference Citation Analysis]
606 Kim SI, Cassella CR, Byrne KT. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Front Immunol 2020;11:629722. [PMID: 33597954 DOI: 10.3389/fimmu.2020.629722] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 13.0] [Reference Citation Analysis]
607 Haddad AF, Young JS, Aghi MK. Using viral vectors to deliver local immunotherapy to glioblastoma. Neurosurg Focus 2021;50:E4. [PMID: 33524947 DOI: 10.3171/2020.11.FOCUS20859] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
608 Pelka K, Hofree M, Chen J, Sarkizova S, Pirl JD, Jorgji V, Bejnood A, Dionne D, Ge WH, Xu KH, Chao SX, Zollinger DR, Lieb DJ, Reeves JW, Fuhrman CA, Hoang ML, Delorey T, Nguyen LT, Waldman J, Klapholz M, Wakiro I, Cohen O, Smillie CS, Cuoco MS, Wu J, Su M, Yeung J, Vijaykumar B, Magnuson AM, Asinovski N, Moll T, Goder-reiser MN, Applebaum AS, Brais LK, Dellostritto LK, Denning SL, Phillips ST, Hill EK, Meehan JK, Frederick DT, Sharova T, Kanodia A, Todres EZ, Jané-valbuena J, Biton M, Izar B, Lambden CD, Clancy TE, Bleday R, Melnitchouk N, Irani J, Kunitake H, Berger DL, Srivastava A, Hornick JL, Ogino S, Rotem A, Vigneau S, Johnson BE, Corcoran R, Sharpe AH, Kuchroo VK, Ng K, Giannakis M, Nieman LT, Boland GM, Aguirre AJ, Anderson AC, Rozenblatt-rosen O, Regev A, Hacohen N. Multicellular immune hubs and their organization in MMRd and MMRp colorectal cancer.. [DOI: 10.1101/2021.01.30.426796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
609 Wei XL, Xu JY, Wang DS, Chen DL, Ren C, Li JN, Wang F, Wang FH, Xu RH. Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. Ther Adv Med Oncol 2021;13:1758835921988996. [PMID: 33613701 DOI: 10.1177/1758835921988996] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
610 Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Kissick H, Signoretti S, Sowalsky AG, Balk SP, Einstein DJ. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.. [DOI: 10.1101/2021.01.27.21250464] [Reference Citation Analysis]
611 Schmiechen ZC, Stromnes IM. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Front Immunol 2020;11:613815. [PMID: 33584701 DOI: 10.3389/fimmu.2020.613815] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
612 Ooki A, Shinozaki E, Yamaguchi K. Immunotherapy in Colorectal Cancer: Current and Future Strategies. J Anus Rectum Colon 2021;5:11-24. [PMID: 33537496 DOI: 10.23922/jarc.2020-064] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
613 Wolpaw AJ, Grossmann LD, Dong MM, Dessau JL, Brafford PA, Volgina D, Rodriguez-garcia A, Uzun Y, Powell DJ, Tan K, Hogarty MD, Maris JM, Dang CV. Epigenetic state determines inflammatory sensing in neuroblastoma.. [DOI: 10.1101/2021.01.27.428523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
614 Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TBK, Rosenthal R, Biswas D, Rowan A, Lim E, Al Bakir M, Turati V, Guerra-Assunção JA, Conde L, Furness AJS, Saini SK, Hadrup SR, Herrero J, Lee SH, Van Loo P, Enver T, Larkin J, Hellmann MD, Turajlic S, Quezada SA, McGranahan N, Swanton C. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 2021;184:596-614.e14. [PMID: 33508232 DOI: 10.1016/j.cell.2021.01.002] [Cited by in Crossref: 216] [Cited by in F6Publishing: 237] [Article Influence: 108.0] [Reference Citation Analysis]
615 Ma HH, Chen DS, Li S, Xiao MZ, Qi C. The value and inadequacy of tumor mutation burden on efficacy of immune checkpoint inhibitors in head and neck cancers. Oral Oncol 2021;117:105179. [PMID: 33514453 DOI: 10.1016/j.oraloncology.2021.105179] [Reference Citation Analysis]
616 Alame M, Cornillot E, Cacheux V, Rigau V, Costes-Martineau V, Lacheretz-Szablewski V, Colinge J. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling. Theranostics 2021;11:3565-79. [PMID: 33664848 DOI: 10.7150/thno.54343] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
617 Hu-Lieskovan S, Malouf GG, Jacobs I, Chou J, Liu L, Johnson ML. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need. Future Oncol 2021;17:1401-39. [PMID: 33475012 DOI: 10.2217/fon-2020-0967] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
618 Sakimura S, Nagayama S, Fukunaga M, Hu Q, Kitagawa A, Kobayashi Y, Hasegawa T, Noda M, Kouyama Y, Shimizu D, Saito T, Niida A, Tsuruda Y, Otsu H, Matsumoto Y, Uchida H, Masuda T, Sugimachi K, Sasaki S, Yamada K, Takahashi K, Innan H, Suzuki Y, Nakamura H, Totoki Y, Mizuno S, Ohshima M, Shibata T, Mimori K. Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases. PLoS Genet 2021;17:e1009113. [PMID: 33476333 DOI: 10.1371/journal.pgen.1009113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
619 Koumarianou A, Duran-Moreno J. The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches. Cancers (Basel) 2021;13:363. [PMID: 33498238 DOI: 10.3390/cancers13030363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
620 Mints M, Landin D, Näsman A, Mirzaie L, Ursu RG, Zupancic M, Marklund L, Dalianis T, Munck-Wikland E, Ramqvist T. Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer. Sci Rep 2021;11:1782. [PMID: 33469045 DOI: 10.1038/s41598-020-80226-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
621 Muzaffar J, Bari S, Kirtane K, Chung CH. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:338. [PMID: 33477635 DOI: 10.3390/cancers13020338] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 15.0] [Reference Citation Analysis]
622 Jeong AR, Ball ED, Goodman AM. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? Clin Med Insights Oncol 2020;14:1179554920976366. [PMID: 33447123 DOI: 10.1177/1179554920976366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
623 Nie W, Gan L, Wang X, Gu K, Qian FF, Hu MJ, Zhang D, Chen SQ, Lu J, Cao SH, Li JW, Wang Y, Zhang B, Wang SY, Li CH, Yang P, Xu MD, Zhang XY, Zhong H, Han BH. Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation. Oncoimmunology 2021;10:1865670. [PMID: 33537171 DOI: 10.1080/2162402X.2020.1865670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
624 Bowling EA, Wang JH, Gong F, Wu W, Neill NJ, Kim IS, Tyagi S, Orellana M, Kurley SJ, Dominguez-Vidaña R, Chung HC, Hsu TY, Dubrulle J, Saltzman AB, Li H, Meena JK, Canlas GM, Chamakuri S, Singh S, Simon LM, Olson CM, Dobrolecki LE, Lewis MT, Zhang B, Golding I, Rosen JM, Young DW, Malovannaya A, Stossi F, Miles G, Ellis MJ, Yu L, Buonamici S, Lin CY, Karlin KL, Zhang XH, Westbrook TF. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell 2021;184:384-403.e21. [PMID: 33450205 DOI: 10.1016/j.cell.2020.12.031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 20.0] [Reference Citation Analysis]
625 Gromeier M, Brown MC, Zhang G, Lin X, Chen Y, Wei Z, Beaubier N, Yan H, He Y, Desjardins A, Herndon JE 2nd, Varn FS, Verhaak RG, Zhao J, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Lipp ES, Nair SK, Khasraw M, Peters KB, Randazzo D, Sampson JH, McLendon RE, Bigner DD, Ashley DM. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat Commun 2021;12:352. [PMID: 33441554 DOI: 10.1038/s41467-020-20469-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 21.5] [Reference Citation Analysis]
626 Natoli M, Gallon J, Lu H, Amgheib A, Pinato DJ, Mauri FA, Marafioti T, Akarca AU, Ullmo I, Ip J, Aboagye EO, Brown R, Karadimitris A, Ghaem-Maghami S. Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression. J Immunother Cancer 2021;9:e001519. [PMID: 33436485 DOI: 10.1136/jitc-2020-001519] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
627 Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N, Martinez D, Jimenez J, Sansano I, Mancuso FM, Nuciforo P, Montuenga LM, Sánchez-Cespedes M, Prat A, Vivancos A, Felip E, Amat R. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Mol Oncol 2021;15:887-900. [PMID: 33342055 DOI: 10.1002/1878-0261.12891] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
628 Cui Y, Li Q, Li W, Wang Y, Lv F, Shi X, Tang Z, Shen Z, Hou Y, Zhang H, Mao B, Liu T. NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer. Front Oncol 2020;10:574937. [PMID: 33479597 DOI: 10.3389/fonc.2020.574937] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
629 Chantharasamee J, Adashek JJ, Wong K, Eckardt MA, Chmielowski B, Dry S, Eilber FC, Singh AS. Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies. Curr Treat Options Oncol 2021;22:9. [PMID: 33400014 DOI: 10.1007/s11864-020-00806-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
630 Mpakali A, Stratikos E. The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. Cancers (Basel) 2021;13:E134. [PMID: 33406696 DOI: 10.3390/cancers13010134] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
631 Haddad AF, Young JS, Mummaneni NV, Kasahara N, Aghi MK. Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies. J Neurooncol 2021;152:1-13. [PMID: 33389564 DOI: 10.1007/s11060-020-03684-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
632 Chen Z, Liu G, Liu G, Bolkov MA, Shinwari K, Tuzankina IA, Chereshnev VA, Wang Z. Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes. Hereditas 2021;158:1. [PMID: 33388091 DOI: 10.1186/s41065-020-00165-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
633 Anichini A, Mortarini R. Mechanisms of Resistance to Immunotherapy in Cutaneous Melanoma. New Therapies in Advanced Cutaneous Malignancies 2021. [DOI: 10.1007/978-3-030-64009-5_19] [Reference Citation Analysis]
634 Wong CN, Fessas P, Dominy K, Mauri FA, Kaneko T, Parcq PD, Khorashad J, Toniutto P, Goldin RD, Avellini C, Pinato DJ. Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. Liver Int 2021;41:192-203. [PMID: 33098208 DOI: 10.1111/liv.14706] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
635 Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:525-43. [PMID: 33850328 DOI: 10.1038/s41575-021-00438-0] [Cited by in Crossref: 264] [Cited by in F6Publishing: 261] [Article Influence: 132.0] [Reference Citation Analysis]
636 Raaby Gammelgaard K, Sandfeld-Paulsen B, Godsk SH, Demuth C, Meldgaard P, Sorensen BS, Jakobsen MR. cGAS-STING pathway expression as a prognostic tool in NSCLC. Transl Lung Cancer Res 2021;10:340-54. [PMID: 33569317 DOI: 10.21037/tlcr-20-524] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
637 Rivoltini L, Cova A, Squarcina P. Immunological Features of Melanoma: Clinical Implications in the Era of New Therapies. New Therapies in Advanced Cutaneous Malignancies 2021. [DOI: 10.1007/978-3-030-64009-5_4] [Reference Citation Analysis]
638 Pavan A, Bragadin AB, Calvetti L, Ferro A, Zulato E, Attili I, Nardo G, Dal Maso A, Frega S, Menin AG, Fassan M, Calabrese F, Pasello G, Guarneri V, Aprile G, Conte P, Rosell R, Indraccolo S, Bonanno L. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. Transl Lung Cancer Res 2021;10:202-20. [PMID: 33569305 DOI: 10.21037/tlcr-20-674] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
639 Vokes NI, Awad MM. Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail? Lung Cancer 2021. [DOI: 10.1007/978-3-030-74028-3_2] [Reference Citation Analysis]
640 Rischin D. Biomarkers for Immune Modulatory Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC). Critical Issues in Head and Neck Oncology 2021. [DOI: 10.1007/978-3-030-63234-2_6] [Reference Citation Analysis]
641 Levesque MP. Multi-Dimensional Biomarkers for the Personalized Treatment of Melanoma. Systems Medicine 2021. [DOI: 10.1016/b978-0-12-801238-3.11671-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
642 Sheehan K, Schalper KA. Tumor Microenvironment: Immune Effector and Suppressor Imbalance. Lung Cancer 2021. [DOI: 10.1007/978-3-030-74028-3_1] [Reference Citation Analysis]
643 De Leo A, Ugolini A, Veglia F. Myeloid Cells in Glioblastoma Microenvironment. Cells 2020;10:E18. [PMID: 33374253 DOI: 10.3390/cells10010018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 11.7] [Reference Citation Analysis]
644 Sung WWY, Chow JCH, Cho WCS. Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy. Expert Rev Clin Pharmacol 2021;14:141-3. [PMID: 33322961 DOI: 10.1080/17512433.2021.1865797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
645 Guan J, Lu C, Jin Q, Lu H, Chen X, Tian L, Zhang Y, Ortega J, Zhang J, Siteni S, Chen M, Gu L, Shay JW, Davis AJ, Chen ZJ, Fu YX, Li GM. MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway. Cancer Cell 2021;39:109-121.e5. [PMID: 33338427 DOI: 10.1016/j.ccell.2020.11.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 17.3] [Reference Citation Analysis]
646 Green SE, McCusker MG, Mehra R. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. Expert Opin Emerg Drugs 2020;25:501-14. [PMID: 33196319 DOI: 10.1080/14728214.2020.1852215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
647 Lu C, Guan J, Lu S, Jin Q, Rousseau B, Lu T, Stephens D, Zhang H, Zhu J, Yang M, Ren Z, Liang Y, Liu Z, Han C, Liu L, Cao X, Zhang A, Qiao J, Batten K, Chen M, Castrillon DH, Wang T, Li B, Diaz LA Jr, Li GM, Fu YX. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell 2021;39:96-108.e6. [PMID: 33338425 DOI: 10.1016/j.ccell.2020.11.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 19.0] [Reference Citation Analysis]
648 Toki MI, Syrigos N, Syrigos K. Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. Int J Cancer 2021;149:277-86. [PMID: 33300601 DOI: 10.1002/ijc.33429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
649 Chen XJ, Yuan SQ, Duan JL, Chen YM, Chen S, Wang Y, Li YF. The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. Dis Markers 2020;2020:6717912. [PMID: 33488843 DOI: 10.1155/2020/6717912] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
650 Ng S, Lim S, Sim ACN, Mangadu R, Lau A, Zhang C, Martinez SB, Chandramohan A, Lim U, Ho SSW, Chang SC, Gopal P, Hong LZ, Schwaid A, Fernandis AZ, Loboda A, Li C, Phan U, Henry B, Partridge AW. STUB1 is an intracellular checkpoint for interferon gamma sensing.. [DOI: 10.1101/2020.12.14.420539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
651 Shen L, Chen Q, Yang C, Wu Y, Yuan H, Chen S, Ou S, Jiang Y, Huang T, Ke L, Mo J, Feng Z, Zhou P, Fan W. Role of PRDM1 in Tumor Immunity and Drug Response: A Pan-Cancer Analysis. Front Pharmacol 2020;11:593195. [PMID: 33384601 DOI: 10.3389/fphar.2020.593195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
652 Lagos GG, Izar B, Rizvi NA. Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. Am Soc Clin Oncol Educ Book 2020;40:1-11. [PMID: 32315237 DOI: 10.1200/EDBK_289967] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
653 Mac QD, Xu C, Bowen JR, Sivakumar A, Phuengkham H, Su F, Stentz SZ, Sim H, Harris AM, Li TT, Qiu P, Kwong GA. Activity-based urinary biomarkers of response and resistance to checkpoint blockade immunotherapy.. [DOI: 10.1101/2020.12.10.420265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
654 Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol 2021;32:384-94. [PMID: 33309774 DOI: 10.1016/j.annonc.2020.12.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 9.7] [Reference Citation Analysis]
655 He K, Liu S, Xia Y, Xu J, Liu F, Xiao J, Li Y, Ding Q, Lu L, Xiang G, Zhan M. CXCL12 and IL7R as Novel Therapeutic Targets for Liver Hepatocellular Carcinoma Are Correlated With Somatic Mutations and the Tumor Immunological Microenvironment. Front Oncol 2020;10:574853. [PMID: 33344233 DOI: 10.3389/fonc.2020.574853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
656 Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker HT. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. J Immunother Cancer 2020;8:e000705. [PMID: 33268350 DOI: 10.1136/jitc-2020-000705] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
657 Alvarado-Cruz I, Mahmoud M, Khan M, Zhao S, Oeck S, Meas R, Clairmont K, Quintana V, Zhu Y, Porciuncula A, Wyatt H, Ma S, Shyr Y, Kong Y, LoRusso PM, Laverty D, Nagel ZD, Schalper KA, Krauthammer M, Sweasy JB. Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells. Biochem Pharmacol 2021;184:114359. [PMID: 33285109 DOI: 10.1016/j.bcp.2020.114359] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
658 Zheng Q, Li J, Zhang H, Wang Y, Zhang S. Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review. Front Oncol 2020;10:602705. [PMID: 33344255 DOI: 10.3389/fonc.2020.602705] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
659 Wang Y, Zhang K, Georgiev P, Wells S, Xu H, Lacey BM, Xu Z, Laskey J, Mcleod R, Methot JL, Bittinger M, Pasternak A, Ranganath S. Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function. PLoS One 2020;15:e0243145. [PMID: 33270695 DOI: 10.1371/journal.pone.0243145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
660 Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer 2021;21:104-21. [PMID: 33268841 DOI: 10.1038/s41568-020-00313-1] [Cited by in Crossref: 125] [Cited by in F6Publishing: 141] [Article Influence: 41.7] [Reference Citation Analysis]
661 Friedmann Angeli JP, Meierjohann S. NRF2-dependent stress defense in tumor antioxidant control and immune evasion. Pigment Cell Melanoma Res 2021;34:268-79. [PMID: 33205526 DOI: 10.1111/pcmr.12946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
662 Xu Y, Li H, Huang Z, Chen K, Yu X, Sheng J, Zhang HH, Fan Y. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy. Transl Lung Cancer Res 2020;9:2367-79. [PMID: 33489799 DOI: 10.21037/tlcr-20-1130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
663 Zuazo M, Arasanz H, Bocanegra A, Fernandez G, Chocarro L, Vera R, Kochan G, Escors D. Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. Front Immunol 2020;11:586907. [PMID: 33329566 DOI: 10.3389/fimmu.2020.586907] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
664 Khasraw M, Walsh KM, Heimberger AB, Ashley DM. What is the Burden of Proof for Tumor Mutational Burden in gliomas? Neuro Oncol 2020:noaa256. [PMID: 33252666 DOI: 10.1093/neuonc/noaa256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
665 Xu Z, Zhu B, Park Y. Design for immuno-oncology clinical trials enrolling both responders and nonresponders. Stat Med 2020;39:3914-36. [PMID: 32944979 DOI: 10.1002/sim.8694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
666 Qi Y, Liu B, Sun Q, Xiong X, Chen Q. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. Front Immunol 2020;11:578877. [PMID: 33329549 DOI: 10.3389/fimmu.2020.578877] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
667 Eddy K, Chen S. Overcoming Immune Evasion in Melanoma. Int J Mol Sci 2020;21:E8984. [PMID: 33256089 DOI: 10.3390/ijms21238984] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
668 Lu M, Wu KH, Trudeau S, Jiang M, Zhao J, Fan E. A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy. Sci Rep 2020;10:20575. [PMID: 33239757 DOI: 10.1038/s41598-020-77653-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
669 Wang Q, Huang J, Zhang H, Liu H, Yu M. Identification and analysis of immune-related subtypes of hepatocellular carcinoma. Exp Biol Med (Maywood) 2021;246:667-77. [PMID: 33231514 DOI: 10.1177/1535370220970130] [Reference Citation Analysis]
670 Imazeki H, Kato K. Development of chemotherapeutics for unresectable advanced esophageal cancer. Expert Rev Anticancer Ther 2020;20:1083-92. [PMID: 32820965 DOI: 10.1080/14737140.2020.1814149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
671 Sutherland KD, Vissers JHA. Balancing the Count: Harmonizing Panel-Based Tumor Mutational Burden Assessment. J Thorac Oncol 2020;15:1106-9. [PMID: 32593443 DOI: 10.1016/j.jtho.2020.03.012] [Reference Citation Analysis]
672 Wang J, Zhang X, Li J, Ma X, Feng F, Liu L, Wu J, Sun C. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration. Aging (Albany NY) 2020;13:351-63. [PMID: 33234738 DOI: 10.18632/aging.104204] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
673 Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, Mensurado S, Moeini A, Flanagan E, Bell CR, Chiang SC, Chikkanna-Gowda CP, Rogers N, Silva-Santos B, Jaillon S, Mantovani A, Reis e Sousa C, Guerra N, Davis DM, Zelenay S. Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. Immunity 2020;53:1215-1229.e8. [PMID: 33220234 DOI: 10.1016/j.immuni.2020.10.020] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 21.7] [Reference Citation Analysis]
674 Pilla L, Alberti A, Di Mauro P, Gemelli M, Cogliati V, Cazzaniga ME, Bidoli P, Maccalli C. Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. Cancers (Basel) 2020;12:E3456. [PMID: 33233603 DOI: 10.3390/cancers12113456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
675 Mukherjee G, Bag S, Chakraborty P, Dey D, Roy S, Jain P, Roy P, Soong R, Majumder PP, Dutt S. Density of CD3+ and CD8+ cells in gingivo-buccal oral squamous cell carcinoma is associated with lymph node metastases and survival. PLoS One 2020;15:e0242058. [PMID: 33211709 DOI: 10.1371/journal.pone.0242058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
676 Richter C, Mayhew D, Rennhack JP, So J, Stover EH, Hwang JH, Szczesna-Cordary D. Genomic Amplification and Functional Dependency of the Gamma Actin Gene ACTG1 in Uterine Cancer. Int J Mol Sci 2020;21:E8690. [PMID: 33217970 DOI: 10.3390/ijms21228690] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
677 Leong A, Kim M. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. Int J Mol Sci 2020;21:E8689. [PMID: 33217955 DOI: 10.3390/ijms21228689] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
678 Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW, Stein J, Tsai HL, Wang H, Belcaid Z, Murray J, Balan A, Ferreira L, Ross-Macdonald P, Wind-Rotolo M, Baras AS, Taube J, Karchin R, Scharpf RB, Grasso C, Ribas A, Pardoll DM, Topalian SL, Velculescu VE. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Rep Med 2020;1:100139. [PMID: 33294860 DOI: 10.1016/j.xcrm.2020.100139] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
679 Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL. Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci 2021;1489:30-47. [PMID: 33184911 DOI: 10.1111/nyas.14526] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
680 Gokuldass A, Draghi A, Papp K, Borch TH, Nielsen M, Westergaard MCW, Andersen R, Schina A, Bol KF, Chamberlain CA, Presti M, Met Ö, Harbst K, Lauss M, Soraggi S, Csabai I, Szállási Z, Jönsson G, Svane IM, Donia M. Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma. Cancers (Basel) 2020;12:E3344. [PMID: 33198174 DOI: 10.3390/cancers12113344] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
681 Zhu Z, Lan Y, Wang L, Ge J, Wang J, Liu F, He Z, Zhang H, Luo M, Lin D, Tan Y, Xu Y, Luo T. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. BMC Cancer 2020;20:1072. [PMID: 33167941 DOI: 10.1186/s12885-020-07552-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
682 Qi X, Qi C, Wu T, Hu Y. CSF1R and HCST: Novel Candidate Biomarkers Predicting the Response to Immunotherapy in Non-Small Cell Lung Cancer. Technol Cancer Res Treat 2020;19:1533033820970663. [PMID: 33153411 DOI: 10.1177/1533033820970663] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
683 Zhang Z, Zhang F, Yuan F, Li Y, Ma J, Ou Q, Liu Z, Yang B, Wang L, Tao H, Zhang S, Li X, Zhi X, Ge X, Bao H, Wu X, Hu Y, Wang J. Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol 2020;12:1758835920970049. [PMID: 33224276 DOI: 10.1177/1758835920970049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
684 Orellana VP, Tittarelli A, Retamal MA. Connexins in melanoma: Potential role of Cx46 in its aggressiveness. Pigment Cell Melanoma Res 2021;34:853-68. [PMID: 33140904 DOI: 10.1111/pcmr.12945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
685 Taha T, Reiss A, Amit A, Perets R. Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet? BioDrugs 2020;34:749-62. [PMID: 33141420 DOI: 10.1007/s40259-020-00450-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
686 Li L, Zhu X, Qian Y, Yuan X, Ding Y, Hu D, He X, Wu Y. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future. Front Immunol 2020;11:594271. [PMID: 33224149 DOI: 10.3389/fimmu.2020.594271] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
687 Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell 2020;37:443-55. [PMID: 32289269 DOI: 10.1016/j.ccell.2020.03.017] [Cited by in Crossref: 191] [Cited by in F6Publishing: 215] [Article Influence: 63.7] [Reference Citation Analysis]
688 Sanmamed MF, Eguren-Santamaria I, Schalper KA. Overview of Lung Cancer Immunotherapy. Cancer J 2020;26:473-84. [PMID: 33298718 DOI: 10.1097/PPO.0000000000000488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
689 Williams JB, Kupper TS. Resident Memory T Cells in the Tumor Microenvironment. Adv Exp Med Biol 2020;1273:39-68. [PMID: 33119875 DOI: 10.1007/978-3-030-49270-0_3] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
690 Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell 2021;39:154-73. [PMID: 33125859 DOI: 10.1016/j.ccell.2020.10.001] [Cited by in Crossref: 141] [Cited by in F6Publishing: 174] [Article Influence: 47.0] [Reference Citation Analysis]
691 Liu W, Tong H, Zhang C, Zhuang R, Guo H, Lv C, Yang H, Lin Q, Guo X, Wang Z, Wang Y, Shen F, Wang S, Dai C, Wang G, Liu J, Lu W, Zhang Y, Zhou Y. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma. BMC Cancer 2020;20:1035. [PMID: 33115433 DOI: 10.1186/s12885-020-07456-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
692 Hu J, Cui C, Yang W, Huang L, Yu R, Liu S, Kong Y. Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images. Transl Oncol 2021;14:100921. [PMID: 33129113 DOI: 10.1016/j.tranon.2020.100921] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
693 Chong W, Wang Z, Shang L, Jia S, Liu J, Fang Z, Du F, Wu H, Liu Y, Chen Y, Chen H. Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC. Mol Ther Nucleic Acids 2021;23:89-100. [PMID: 33335795 DOI: 10.1016/j.omtn.2020.10.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
694 Bao R, Stapor D, Luke JJ. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med 2020;12:90. [PMID: 33106165 DOI: 10.1186/s13073-020-00787-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
695 Jia M, Chi T. Sex-specific predictive values of biomarkers for immunotherapy efficacy in lung adenocarcinoma.. [DOI: 10.1101/2020.10.26.356220] [Reference Citation Analysis]
696 Nisticò P, Ciliberto G. Biological mechanisms linked to inflammation in cancer: Discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. Int J Biol Markers 2020;35:8-11. [PMID: 32079468 DOI: 10.1177/1724600820906155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
697 Teterycz P, Czarnecka AM, Indini A, Spałek MJ, Labianca A, Rogala P, Cybulska-Stopa B, Quaglino P, Ricardi U, Badellino S, Szumera-Ciećkiewicz A, Falkowski S, Mandala M, Rutkowski P. Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. Cancers (Basel) 2020;12:E3131. [PMID: 33114734 DOI: 10.3390/cancers12113131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
698 Aoude LG, Bonazzi VF, Brosda S, Patel K, Koufariotis LT, Oey H, Nones K, Wood S, Pearson JV, Lonie JM, Arneil M, Atkinson V, Smithers BM, Waddell N, Barbour AP. Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Sci Rep 2020;10:17687. [PMID: 33077847 DOI: 10.1038/s41598-020-74956-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
699 Cerezo-Wallis D, Contreras-Alcalde M, Troulé K, Catena X, Mucientes C, Calvo TG, Cañón E, Tejedo C, Pennacchi PC, Hogan S, Kölblinger P, Tejero H, Chen AX, Ibarz N, Graña-Castro O, Martinez L, Muñoz J, Ortiz-Romero P, Rodriguez-Peralto JL, Gómez-López G, Al-Shahrour F, Rabadán R, Levesque MP, Olmeda D, Soengas MS. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nat Med 2020;26:1865-77. [PMID: 33077955 DOI: 10.1038/s41591-020-1073-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
700 Todorovic E, Truong T, Eskander A, Lin V, Swanson D, Dickson BC, Weinreb I. Middle Ear and Temporal Bone Nonkeratinizing Squamous Cell Carcinomas With DEK-AFF2 Fusion: An Emerging Entity. Am J Surg Pathol 2020;44:1244-50. [PMID: 32366754 DOI: 10.1097/PAS.0000000000001498] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
701 Tokunaga R, Xiu J, Goldberg RM, Philip PA, Seeber A, Battaglin F, Arai H, Lo JH, Naseem M, Puccini A, Berger MD, Soni S, Zhang W, Chen S, Hwang JJ, Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ. The impact of ARID1A mutation on molecular characteristics in colorectal cancer. Eur J Cancer 2020;140:119-29. [PMID: 33080474 DOI: 10.1016/j.ejca.2020.09.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
702 Qi Z, Xu Z, Zhang L, Zou Y, Yan W, Li C, Liu N, Wu H. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by sequential intermittent anti-PI3Kα/β/δ and anti-PD-1 treatment.. [DOI: 10.1101/2020.10.17.343608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
703 Newell F, Wilmott JS, Johansson PA, Nones K, Addala V, Mukhopadhyay P, Broit N, Amato CM, Van Gulick R, Kazakoff SH, Patch AM, Koufariotis LT, Lakis V, Leonard C, Wood S, Holmes O, Xu Q, Lewis K, Medina T, Gonzalez R, Saw RPM, Spillane AJ, Stretch JR, Rawson RV, Ferguson PM, Dodds TJ, Thompson JF, Long GV, Levesque MP, Robinson WA, Pearson JV, Mann GJ, Scolyer RA, Waddell N, Hayward NK. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun 2020;11:5259. [PMID: 33067454 DOI: 10.1038/s41467-020-18988-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 16.3] [Reference Citation Analysis]
704 Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell 2020;183:347-362.e24. [PMID: 33064988 DOI: 10.1016/j.cell.2020.08.053] [Cited by in Crossref: 214] [Cited by in F6Publishing: 214] [Article Influence: 71.3] [Reference Citation Analysis]
705 Wang HC, Yeh TJ, Chan LP, Hsu CM, Cho SF. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. Int J Mol Sci 2020;21:E7621. [PMID: 33076306 DOI: 10.3390/ijms21207621] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
706 Gjoerup O, Brown CA, Ross JS, Huang RSP, Schrock A, Creeden J, Fabrizio D, Tolba K. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. AAPS J 2020;22:132. [PMID: 33057937 DOI: 10.1208/s12248-020-00514-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
707 Caruso FP, Garofano L, D'Angelo F, Yu K, Tang F, Yuan J, Zhang J, Cerulo L, Pagnotta SM, Bedognetti D, Sims PA, Suvà M, Su XD, Lasorella A, Iavarone A, Ceccarelli M. A map of tumor-host interactions in glioma at single-cell resolution. Gigascience 2020;9:giaa109. [PMID: 33155039 DOI: 10.1093/gigascience/giaa109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
708 Bilusic M, Einstein DJ, Karzai FH, Dahut WL, Gulley JL, Aragon-Ching JB, Madan RA. The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. Urol Clin North Am 2020;47:457-67. [PMID: 33008496 DOI: 10.1016/j.ucl.2020.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
709 Sage AP, Ng KW, Marshall EA, Stewart GL, Minatel BC, Enfield KSS, Martin SD, Brown CJ, Abraham N, Lam WL. Assessment of long non-coding RNA expression reveals novel mediators of the lung tumour immune response. Sci Rep 2020;10:16945. [PMID: 33037279 DOI: 10.1038/s41598-020-73787-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
710 Karapetyan L, Luke JJ, Davar D. Toll-Like Receptor 9 Agonists in Cancer. Onco Targets Ther 2020;13:10039-60. [PMID: 33116588 DOI: 10.2147/OTT.S247050] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
711 Thompson JC, Davis C, Deshpande C, Hwang WT, Jeffries S, Huang A, Mitchell TC, Langer CJ, Albelda SM. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. J Immunother Cancer 2020;8:e000974. [PMID: 33028693 DOI: 10.1136/jitc-2020-000974] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
712 Yang Z, Wei S, Deng Y, Wang Z, Liu L. Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis. Jpn J Clin Oncol 2020;50:1023-31. [PMID: 32542383 DOI: 10.1093/jjco/hyaa076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
713 Nie RC, Duan JL, Liang Y, Chen XJ, Chen YM, Luo TQ, Chen GM, Wang Y, Li YF. Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. Immunotherapy 2020;12:1313-24. [PMID: 33012209 DOI: 10.2217/imt-2020-0007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
714 Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, Almanza D, Stehr H, Gojenola L, Bonilla RF, Jin MC, Jeon YJ, Tseng D, Liu C, Merghoub T, Neal JW, Wakelee HA, Padda SK, Ramchandran KJ, Das M, Plodkowski AJ, Yoo C, Chen EL, Ko RB, Newman AM, Hellmann MD, Alizadeh AA, Diehn M. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell 2020;183:363-376.e13. [PMID: 33007267 DOI: 10.1016/j.cell.2020.09.001] [Cited by in Crossref: 109] [Cited by in F6Publishing: 120] [Article Influence: 36.3] [Reference Citation Analysis]
715 Chai AWY, Yee PS, Price S, Yee SM, Lee HM, Tiong VK, Gonçalves E, Behan FM, Bateson J, Gilbert J, Tan AC, McDermott U, Garnett MJ, Cheong SC. Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. Elife 2020;9:e57761. [PMID: 32990596 DOI: 10.7554/eLife.57761] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
716 Shklovskaya E, Rizos H. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. Int J Mol Sci 2020;21:E7139. [PMID: 32992658 DOI: 10.3390/ijms21197139] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
717 Jiang J, Ding Y, Wu M, Chen Y, Lyu X, Lu J, Wang H, Teng L. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma. Cancer Med 2020;9:8498-518. [PMID: 32969604 DOI: 10.1002/cam4.3481] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
718 Sharma A, Merritt E, Hu X, Cruz A, Jiang C, Sarkodie H, Zhou Z, Malhotra J, Riedlinger GM, De S. Non-Genetic Intra-Tumor Heterogeneity Is a Major Predictor of Phenotypic Heterogeneity and Ongoing Evolutionary Dynamics in Lung Tumors. Cell Rep 2019;29:2164-2174.e5. [PMID: 31747591 DOI: 10.1016/j.celrep.2019.10.045] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 19.7] [Reference Citation Analysis]
719 Borel C, Jung AC, Burgy M. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2020;12:E2691. [PMID: 32967162 DOI: 10.3390/cancers12092691] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
720 Kang N, Eccleston M, Clermont PL, Latarani M, Male DK, Wang Y, Crea F. EZH2 inhibition: a promising strategy to prevent cancer immune editing. Epigenomics 2020;12:1457-76. [PMID: 32938196 DOI: 10.2217/epi-2020-0186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
721 Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra R, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo P, Wind-rotolo M, Unsal-kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky MD. Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing.. [DOI: 10.1101/2020.09.16.300111] [Reference Citation Analysis]
722 Fumet JD, Limagne E, Thibaudin M, Ghiringhelli F. Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy. Cancers (Basel) 2020;12:E2637. [PMID: 32947882 DOI: 10.3390/cancers12092637] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
723 Dienstmann R, Garralda E, Aguilar S, Sala G, Viaplana C, Ruiz-Pace F, González-Zorelle J, Grazia LoGiacco D, Ogbah Z, Ramos Masdeu L, Mancuso F, Fasani R, Jimenez J, Martinez P, Oaknin A, Saura C, Oliveira M, Balmaña J, Carles J, Macarulla T, Elez E, Alsina M, Braña I, Felip E, Tabernero J, Rodon J, Nuciforo P, Vivancos A. Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. JCO Precis Oncol 2020;4:PO. [PMID: 32923891 DOI: 10.1200/PO.19.00398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
724 Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res 2020;26:6362-73. [PMID: 32928797 DOI: 10.1158/1078-0432.CCR-20-1762] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
725 Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL Jr, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell 2020;38:500-515.e3. [PMID: 32916126 DOI: 10.1016/j.ccell.2020.08.005] [Cited by in Crossref: 104] [Cited by in F6Publishing: 114] [Article Influence: 34.7] [Reference Citation Analysis]
726 Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020;21:1353-1365. [PMID: 32919526 DOI: 10.1016/S1470-2045(20)30445-9] [Cited by in Crossref: 672] [Cited by in F6Publishing: 526] [Article Influence: 224.0] [Reference Citation Analysis]
727 Zhang L, Li B, Peng Y, Wu F, Li Q, Lin Z, Xie S, Xiao L, Lin X, Ou Z, Cai T, Rong H, Fan S, Li J. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study. Oral Oncol 2020;110:104943. [PMID: 32919362 DOI: 10.1016/j.oraloncology.2020.104943] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
728 Wang L, Gao Y, Zhang G, Li D, Wang Z, Zhang J, Hermida LC, He L, Wang Z, Si J, Geng S, Ai R, Ning F, Cheng C, Deng H, Dimitrov DS, Sun Y, Huang Y, Wang D, Hu X, Wei Z, Wang W, Liao X. Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Sci Transl Med 2020;12:eaax2282. [DOI: 10.1126/scitranslmed.aax2282] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
729 Chen IX, Newcomer K, Pauken KE, Juneja VR, Naxerova K, Wu MW, Pinter M, Sen DR, Singer M, Sharpe AH, Jain RK. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proc Natl Acad Sci U S A 2020;117:23684-94. [PMID: 32907939 DOI: 10.1073/pnas.2002806117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
730 Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Caracò C, Thurin M. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med 2020;18:346. [PMID: 32894202 DOI: 10.1186/s12967-020-02482-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
731 Alborelli I, Bratic Hench I, Chijioke O, Prince SS, Bubendorf L, Leuenberger LP, Tolnay M, Leonards K, Quagliata L, Jermann P, Matter MS. Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients. Lung Cancer 2020;149:84-9. [PMID: 32980613 DOI: 10.1016/j.lungcan.2020.08.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
732 Gurjao C, Tsukrov D, Imakaev M, Luquette LJ, Mirny LA. Limited evidence of tumour mutational burden as a biomarker of response to immunotherapy.. [DOI: 10.1101/2020.09.03.260265] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
733 Li X, Wen D, Li X, Yao C, Chong W, Chen H. Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer. Front Immunol 2020;11:1678. [PMID: 33013820 DOI: 10.3389/fimmu.2020.01678] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
734 Heinrich S, Castven D, Galle PR, Marquardt JU. Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2495. [PMID: 32899197 DOI: 10.3390/cancers12092495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
735 Riccò B, Salati M, Reggiani Bonetti L, Dominici M, Luppi G. PD-1 blockade in deficient mismatch repair mixed adenoneuroendocrine carcinoma of the stomach: new hope for an orphan disease. Tumori 2020;106:NP57-62. [PMID: 32878569 DOI: 10.1177/0300891620952845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
736 Hanna GJ, Ruiz ES, LeBoeuf NR, Thakuria M, Schmults CD, Decaprio JA, Silk AW. Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). Br J Cancer 2020;123:1535-42. [PMID: 32868898 DOI: 10.1038/s41416-020-01044-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
737 Wan L, Wang Z, Xue J, Yang H, Zhu Y. Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis. Transl Cancer Res 2020;9:5437-49. [PMID: 35117909 DOI: 10.21037/tcr-20-1131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
738 Zhang W, Wang P, Pang Q. Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. Ann Transl Med 2020;8:1193. [PMID: 33241042 DOI: 10.21037/atm-20-4625] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
739 Effern M, Glodde N, Braun M, Liebing J, Boll HN, Yong M, Bawden E, Hinze D, van den Boorn-konijnenberg D, Daoud M, Aymans P, Landsberg J, Smyth MJ, Flatz L, Tüting T, Bald T, Gebhardt T, Hölzel M. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity 2020;53:564-580.e9. [DOI: 10.1016/j.immuni.2020.07.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
740 Burrack AL, Spartz EJ, Raynor JF, Wang I, Olson M, Stromnes IM. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. Cell Rep 2019;28:2140-2155.e6. [PMID: 31433988 DOI: 10.1016/j.celrep.2019.07.059] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 15.3] [Reference Citation Analysis]
741 Theocharis S, Tasoulas J, Masaoutis C, Kokkali S, Klijanienko J. Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment? Expert Opin Ther Targets 2020;24:1047-59. [PMID: 32744127 DOI: 10.1080/14728222.2020.1804863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
742 Zhang X, Shi M, Chen T, Zhang B. Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Mol Ther Nucleic Acids 2020;22:298-309. [PMID: 33230435 DOI: 10.1016/j.omtn.2020.08.030] [Cited by in Crossref: 98] [Cited by in F6Publishing: 109] [Article Influence: 32.7] [Reference Citation Analysis]
743 Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 2020;8:34. [PMID: 32864131 DOI: 10.1186/s40364-020-00209-0] [Cited by in Crossref: 123] [Cited by in F6Publishing: 138] [Article Influence: 41.0] [Reference Citation Analysis]
744 Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2020;8. [PMID: 32847986 DOI: 10.1136/jitc-2020-000987] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
745 Ballot E, Ladoire S, Routy B, Truntzer C, Ghiringhelli F. Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy. Cancers (Basel) 2020;12:E2418. [PMID: 32858956 DOI: 10.3390/cancers12092418] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
746 Zhang QF, Li J, Jiang K, Wang R, Ge JL, Yang H, Liu SJ, Jia LT, Wang L, Chen BL. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Theranostics 2020;10:10619-33. [PMID: 32929370 DOI: 10.7150/thno.44871] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
747 Hegde S. Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine. Indian J Surg Oncol 2021;12:118-27. [PMID: 33994737 DOI: 10.1007/s13193-020-01192-6] [Reference Citation Analysis]
748 Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Front Immunol 2020;11:1956. [PMID: 32983126 DOI: 10.3389/fimmu.2020.01956] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 22.7] [Reference Citation Analysis]
749 French JD. Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies. Nat Rev Endocrinol 2020;16:629-41. [PMID: 32839578 DOI: 10.1038/s41574-020-0398-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
750 Gambardella V, Cejalvo JM, Tarazona N, Cervantes A. In the literature: August 2020. ESMO Open 2020;5:e000909. [PMID: 32817070 DOI: 10.1136/esmoopen-2020-000909] [Reference Citation Analysis]
751 Alame M, Cornillot E, Cacheux V, Rigau V, Costes-martineau V, Lacheretz-szablewski V, Colinge J. The immune landscape of primary central nervous system diffuse large B cell lymphoma.. [DOI: 10.1101/2020.08.17.254284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
752 Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, Abdullah SE, Higgs BW, Dennis PA, van der Heijden MS, Segal NH, Chaft JE, Hembrough T, Barrett JC, Hellmann MD. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov 2020;10:1842-53. [PMID: 32816849 DOI: 10.1158/2159-8290.CD-20-0047] [Cited by in Crossref: 79] [Cited by in F6Publishing: 87] [Article Influence: 26.3] [Reference Citation Analysis]
753 Niu Y, Lin A, Luo P, Zhu W, Wei T, Tang R, Guo L, Zhang J. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors. Front Pharmacol 2020;11:1213. [PMID: 32903385 DOI: 10.3389/fphar.2020.01213] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
754 Raimondi A, Sepe P, Zattarin E, Mennitto A, Stellato M, Claps M, Guadalupi V, Verzoni E, de Braud F, Procopio G. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. Front Oncol 2020;10:1644. [PMID: 32903369 DOI: 10.3389/fonc.2020.01644] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
755 Chen Y, Huang Y, Gao X, Li Y, Lin J, Chen L, Chang L, Chen G, Guan Y, Pan LK, Xia X, Guo Z, Pan J, Xu Y, Yi X, Chen C. CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors. Front Immunol 2020;11:1620. [PMID: 32903763 DOI: 10.3389/fimmu.2020.01620] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
756 Hegde S, Krisnawan VE, Herzog BH, Zuo C, Breden MA, Knolhoff BL, Hogg GD, Tang JP, Baer JM, Mpoy C, Lee KB, Alexander KA, Rogers BE, Murphy KM, Hawkins WG, Fields RC, DeSelm CJ, Schwarz JK, DeNardo DG. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Cancer Cell 2020;37:289-307.e9. [PMID: 32183949 DOI: 10.1016/j.ccell.2020.02.008] [Cited by in Crossref: 145] [Cited by in F6Publishing: 154] [Article Influence: 48.3] [Reference Citation Analysis]
757 Lu Z, Peng Z, Liu C, Wang Z, Wang Y, Jiao X, Li J, Shen L. Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers. Innovation (N Y) 2020;1:100041. [PMID: 34557714 DOI: 10.1016/j.xinn.2020.100041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
758 Hatakeyama K, Nagashima T, Ohshima K, Ohnami S, Ohnami S, Shimoda Y, Naruoka A, Maruyama K, Iizuka A, Ashizawa T, Mochizuki T, Urakami K, Akiyama Y, Yamaguchi K. Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients. Cancer Sci 2020;111:3893-901. [PMID: 32662546 DOI: 10.1111/cas.14572] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
759 Strudel M, Festino L, Vanella V, Beretta M, Marincola FM, Ascierto PA. Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. Curr Med Chem 2020;27:2792-813. [PMID: 31804158 DOI: 10.2174/0929867326666191205160007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
760 Borch TH, Andersen R, Ellebaek E, Met Ö, Donia M, Marie Svane I. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. J Immunother Cancer 2020;8:e000668. [PMID: 32747469 DOI: 10.1136/jitc-2020-000668] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
761 Pérez-Romero K, Rodríguez RM, Amedei A, Barceló-Coblijn G, Lopez DH. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy. Int J Mol Sci 2020;21:E5521. [PMID: 32752264 DOI: 10.3390/ijms21155521] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
762 Bao R, Hernandez K, Huang L, Luke JJ. ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. J Immunother Cancer. 2020;8. [PMID: 32675312 DOI: 10.1136/jitc-2020-001020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
763 Chen Y, Hu R, Li X, Shi Z, Tian H, Feng J, Yu S. B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma. Pathol Res Pract 2020;216:153134. [PMID: 32853956 DOI: 10.1016/j.prp.2020.153134] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
764 Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol 2019;30:1572-9. [PMID: 31268133 DOI: 10.1093/annonc/mdz206] [Cited by in Crossref: 93] [Cited by in F6Publishing: 100] [Article Influence: 31.0] [Reference Citation Analysis]
765 Crosby EJ, Acharya CR, Haddad AF, Rabiola CA, Lei G, Wei JP, Yang XY, Wang T, Liu CX, Wagner KU, Muller WJ, Chodosh LA, Broadwater G, Hyslop T, Shepherd JH, Hollern DP, He X, Perou CM, Chai S, Ashby BK, Vincent BG, Snyder JC, Force J, Morse MA, Lyerly HK, Hartman ZC. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clin Cancer Res 2020;26:4670-81. [PMID: 32732224 DOI: 10.1158/1078-0432.CCR-20-0389] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
766 Litchfield K, Reading JL, Lim EL, Xu H, Liu P, Al-Bakir M, Wong YNS, Rowan A, Funt SA, Merghoub T, Perkins D, Lauss M, Svane IM, Jönsson G, Herrero J, Larkin J, Quezada SA, Hellmann MD, Turajlic S, Swanton C. Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nat Commun 2020;11:3800. [PMID: 32733040 DOI: 10.1038/s41467-020-17526-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
767 Wang Y, Chen L, Ju L, Xiao Y, Wang X. Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma. Int Immunopharmacol 2020;87:106818. [PMID: 32738594 DOI: 10.1016/j.intimp.2020.106818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
768 Karlovich CA, Williams PM. Clinical Applications of Next-Generation Sequencing in Precision Oncology. Cancer J 2019;25:264-71. [PMID: 31335390 DOI: 10.1097/PPO.0000000000000385] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
769 Linette GP, Carreno BM. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era. Curr Hematol Malig Rep 2019;14:286-91. [PMID: 31187421 DOI: 10.1007/s11899-019-00523-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
770 McNamara MG, Jacobs T, Lamarca A, Hubner RA, Valle JW, Amir E. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treat Rev 2020;89:102084. [PMID: 32738738 DOI: 10.1016/j.ctrv.2020.102084] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
771 Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Front Cell Dev Biol 2020;8:672. [PMID: 32793604 DOI: 10.3389/fcell.2020.00672] [Cited by in Crossref: 69] [Cited by in F6Publishing: 76] [Article Influence: 23.0] [Reference Citation Analysis]
772 Wu L, Yu Y, Zhou J, Wang X, Li J, Wang Y. Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature. Immunotherapy 2020;12:957-64. [PMID: 32686549 DOI: 10.2217/imt-2020-0038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
773 Dosset M, Joseph EL, Rivera Vargas T, Apetoh L. Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells 2020;9:E1727. [PMID: 32707692 DOI: 10.3390/cells9071727] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
774 Garutti M, Buriolla S, Bertoli E, Vitale MG, Rossi E, Schinzari G, Minisini AM, Puglisi F. "To Anticipate": Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers. Cancers (Basel) 2020;12:E1941. [PMID: 32708968 DOI: 10.3390/cancers12071941] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4]